INVACARE (IVCRQ) 10-K 14 Apr 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Apr. 12, 2023	Jun. 30, 2022
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	1-15103
Entity Registrant Name	INVACARE CORPORATION
Entity Incorporation, State or Country Code	OH
Entity Tax Identification Number	95-2680965
Entity Address, Address Line One	One Invacare Way
Entity Address, City or Town	Elyria
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44035
City Area Code	440
Local Phone Number	329-6000
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Documents Incorporated by Reference	Except as otherwise stated, the information contained in this Annual Report on Form 10-K is as of December 31, 2022.
Entity Central Index Key	0000742112
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Public Float			$ 42,073,756
Document Information [Line Items]
Entity Public Float			$ 42,073,756
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	Cleveland, Ohio
Share Price			$ 1.28
Common Stock
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		37,982,425
Entity Public Float			$ 42,069,062
Document Information [Line Items]
Entity Public Float			42,069,062
Entity Common Stock, Shares Outstanding		37,982,425
Class B Common Shares
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		3,667
Entity Public Float			4,694
Document Information [Line Items]
Entity Public Float			$ 4,694
Entity Common Stock, Shares Outstanding		3,667

Consolidated Statement Of Compr

Consolidated Statement Of Comprehensive Income (Loss) - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues	$ 741,733,000	$ 872,457,000	$ 850,689,000
Cost of products sold	566,340,000	633,351,000	605,437,000
Gross Profit	175,393,000	239,106,000	245,252,000
Selling, general and administrative expenses	226,780,000	232,242,000	236,357,000
Gain on sale of business	0	0	(9,790,000)
Charges related to restructuring activities	25,820,000	2,534,000	7,358,000
Impairment of goodwill	0	28,564,000	0
Impairment of intangible assets	3,259,000	0	0
Operating Income (Loss)	(80,466,000)	(24,234,000)	11,327,000
Net gain on convertible debt derivatives	(1,510,000)	0	0
Gain (Loss) on Extinguishment of Debt	(9,419,000)	(9,422,000)	7,360,000
Interest expense	28,520,000	24,307,000	28,499,000
Interest income	(56,000)	(1,000)	(93,000)
Loss Before Income Taxes	(98,001,000)	(39,118,000)	(24,439,000)
Income tax provision	3,070,000	6,445,000	3,841,000
Net Loss	$ (101,071,000)	$ (45,563,000)	$ (28,280,000)
Net Earnings (Loss) per Share—Basic:
Net Earnings (loss) per Share - Basic (in dollars per share)	$ (2.77)	$ (1.31)	$ (0.83)
Weighted Average Shares Outstanding - Basic (in shares)	36,517	34,875	34,266
Net Earnings (Loss) per Share—Assuming Dilution:
Net Earnings (loss) per Share - Assuming Dilution (in dollars per share)	$ (2.77)	$ (1.31)	$ (0.83)
Weighted Average Shares Outstanding - Assuming Dilution (in shares)	36,629	35,274	34,375
Other comprehensive income (loss):
Foreign currency translation adjustments	$ (48,197,000)	$ (28,724,000)	$ 43,405,000
Defined benefit plans:
Amortization of prior service costs and unrecognized losses	6,487,000	(427,000)	(375,000)
Deferred tax adjustment resulting from defined benefit plan activity	(197,000)	(39,000)	55,000
Valuation reserve associated with defined benefit plan activity	197,000	39,000	(55,000)
Current period gain (loss) on cash flow hedges	(1,000)	815,000	(825,000)
Deferred tax benefit (expense) related to gain (loss) on cash flow hedges	0	(112,000)	103,000
Other Comprehensive Income (Loss)	(41,711,000)	(28,448,000)	42,308,000
Comprehensive Income (Loss)	$ (142,782,000)	$ (74,011,000)	$ 14,028,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 58,792	$ 83,745
Trade receivables, net	87,952	117,115
Installment receivables, net	311	218
Inventories, net	112,561	144,274
Other current assets	39,702	40,036
Total Current Assets	299,318	385,388
Other Assets	5,159	5,362
Intangibles	21,669	26,356
Property and Equipment, net	51,533	60,921
Finance Lease Assets, net	56,272	63,029
Operating Lease Assets, net	10,737	12,600
Goodwill	326,281	355,875	$ 402,461
Assets	770,969	909,531	945,981
Current Liabilities
Accounts payable	104,590	130,036
Accrued expenses	106,091	102,971
Current taxes payable	2,774	3,914
Current portion of long-term debt	154	3,107
Current portion of finance lease obligations	3,106	3,009
Current portion of operating lease obligations	3,420	4,217
Total Current Liabilities	220,135	247,254
Long-Term Debt	354,087	305,022
Long-Term Obligations - Finance Leases	57,994
Long-Term Obligations - Operating Leases	7,259	8,234
Other Long-Term Obligations	$ 50,402	$ 66,796
Preferred Stock, Shares Outstanding	0	0
Preferred Stock, Shares Authorized	300	300
Shareholders' Equity
Preferred Shares (Authorized 300 shares; none outstanding)	$ 0	$ 0
Additional paid-in-capital	281,366	276,665
Retained earnings (accumulated deficit)	(78,426)	22,645
Accumulated other comprehensive income (loss)	(24,723)	16,988	45,436
Treasury Shares (4,536 and 4,397 shares at December 31, 2022 and December 31, 2021, respectively)	(107,939)	(107,788)
Total Shareholders' Equity	81,092	218,489	$ 333,846	$ 308,516
Total Liabilities and Shareholders' Equity	770,969	909,531
Common Shares (Authorized 150,000 shares; 42,540 and 39,416 issued and outstanding at December 31, 2022 and December 31, 2021, respectively)—no par
Shareholders' Equity
Common shares	10,812	9,977
Class B Common Shares (Authorized 12,000 shares; 4 and 4 issued and outstanding at December 31, 2022 and December 31, 2021, respectively)—no par
Shareholders' Equity
Common shares	$ 2	$ 2

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Preferred Stock, Shares Authorized	300	300
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Common, Shares	4,536	4,397
Finance Lease, Liability, Noncurrent	$ 57,994	$ 63,736
Cash and cash equivalents	58,792	83,745
Long-Term Obligations - Operating Leases	7,259	8,234
Other Long-Term Obligations	50,402	66,796
Trade receivables, net	87,952	117,115
Installment receivables, net	311	218
Liabilities, Current	220,135	247,254
Liabilities and Equity	770,969	909,531
Inventories, net	112,561	144,274
Other current assets	39,702	40,036
Total Current Assets	299,318	385,388
Other Assets	5,159	5,362
Intangibles	21,669	26,356
Property and Equipment, net	51,533	60,921
Finance Lease Assets, net	56,272	63,029
Operating Lease Assets, net	10,737	12,600
Goodwill	326,281	355,875
Total Assets	770,969	909,531
Accounts payable	104,590	130,036
Accrued expenses	106,091	102,971
Current taxes payable	2,774	3,914
Current portion of long-term debt	154	3,107
Current portion of finance lease obligations	3,106	3,009
Current portion of operating lease obligations	3,420	4,217
Total Shareholders' Equity	81,092	218,489
Long-Term Debt	354,087	305,022
Preferred Shares (Authorized 300 shares; none outstanding)	0	0
Additional paid-in-capital	281,366	276,665
Retained earnings (accumulated deficit)	(78,426)	22,645
Accumulated other comprehensive income (loss)	(24,723)	16,988
Treasury Stock, Value	$ 107,939	$ 107,788
Common Stock
Common Stock, Shares Authorized	150,000
Common Stock, Shares, Issued	42,540	39,416
Common shares	$ 10,812	$ 9,977
Class B Common Shares
Common Stock, Shares Authorized	12,000
Common Stock, Shares, Issued	4	4
Common shares	$ 2	$ 2

Consolidated Statement Of Cash

Consolidated Statement Of Cash Flows	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Purchases of capped calls	$ 0	$ (18,787,000)	$ 0
Impairment of intangible assets	3,259,000	0	0
Impairment of goodwill	0	28,564,000	0
Inventory Write-down		0	0
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	(3,706,000)	(2,315,000)	6,606,000
Other Noncash Income	573,000	0	0
Depreciation and amortization	15,491,000	16,821,000	14,317,000
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	58,792,000	83,745,000	105,298,000
Operating Activities
Net loss	(101,071,000)	(45,563,000)	(28,280,000)
Adjustments to reconcile net earnings to net cash used by operating activities:
Gain on sale of business	0	0	(9,790,000)
Depreciation and amortization	15,491,000	16,821,000	14,317,000
Amortization operating lease right of use assets	4,862,000	6,273,000	6,951,000
Provision (benefit) for losses on trade and installment receivables	(862,000)	(16,000)	(427,000)
Benefit for deferred income taxes	(241,000)	(224,000)	(2,192,000)
Provision for other deferred liabilities	(1,431,000)	(160,000)	(971,000)
Provision for equity compensation	2,080,000	4,323,000	8,645,000
Loss (gain) on disposals of property and equipment	126,000	(278,000)	(1,046,000)
Loss (gain) on debt extinguishment including debt finance charges and associated fees	9,419,000	9,422,000	(7,360,000)
Impairment of intangible assets	3,259,000	0	0
Impairment of goodwill	0	28,564,000	0
Amortization of convertible debt discount, term loan original issuance discount and accretion of convertible debt	3,891,000	3,534,000	11,487,000
Amortization of debt fees	2,684,000	2,236,000	1,690,000
Net gain on convertible debt derivatives	(1,510,000)	0	0
Changes in operating assets and liabilities:
Trade receivables	23,178,000	(11,028,000)	7,692,000
Installment sales contracts, net	317,000	388,000	(481,000)
Inventories, net	17,108,000	(33,129,000)	8,955,000
Other current assets	3,209,000	2,755,000	(5,313,000)
Accounts payable	(19,156,000)	47,101,000	(2,359,000)
Accrued expenses	(3,970,000)	(26,868,000)	1,713,000
Other long-term liabilities	(4,744,000)	64,000	1,170,000
Net Cash Provided by (Used in) Operating Activities	(55,251,000)	(14,309,000)	21,917,000
Investing Activities
Purchases of property and equipment	(3,778,000)	(17,698,000)	(22,304,000)
Proceeds from sale of property and equipment	5,000	33,000	396,000
Proceeds from sale of business	0	0	14,563,000
Change in other long-term assets	(7,000)	(252,000)	(27,000)
Other	(540,000)	115,000	(2,175,000)
Net Cash Used by Investing Activities	(4,320,000)	(17,802,000)	(9,547,000)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	110,512,000	155,033,000	86,081,000
Repurchases of convertible debt, payments on revolving lines of credit and finance leases	(61,000,000)	(116,250,000)	(70,603,000)
Payment of financing costs	(11,037,000)	(5,369,000)	(1,505,000)
Payment of dividends	0	0	(414,000)
Purchases of capped calls	0	(18,787,000)	0
Payments to debt holders	0	0	(5,593,000)
Purchases of treasury shares	(151,000)	(1,754,000)	(1,707,000)
Net Cash Provided by Financing Activities	38,324,000	12,873,000	6,259,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(24,953,000)	(21,553,000)	$ 25,235,000
Cash and cash equivalents at beginning of year	83,745,000
Cash and cash equivalents at end of year	$ 58,792,000	$ 83,745,000

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in- Capital	Retained Earnings	Accumulated Other Comprehensive Earnings	Treasury Stock, Common	Class B Common Shares Common Stock
Beginning Balance at Dec. 31, 2019	$ 308,516	$ 9,588	$ 312,650	$ 87,475	$ 3,128	$ (104,327)	$ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	2,190	91	3,222			(1,123)
Restricted stock awards	4,748	137	5,195			(584)
Net loss	(28,280)			(28,280)
Foreign currency translation adjustments	43,405
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	43,405
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	(722)				(722)
Defined benefit plans:
Amortization of prior service costs and unrecognized losses and credits	(375)				(375)
Comprehensive Income (Loss)	14,028
Dividends	(414)
Purchases of capped calls	0
Adoption of Credit Loss Standard	(243)
Ending Balance at Dec. 31, 2020	333,846	9,816	326,088	58,538	45,436	(106,034)	2
Defined benefit plans:
Exchange of Convertible Notes	5,021		5,021
Payments of Ordinary Dividends, Common Stock	414
Stock-based compensation expense	(1,795)	52	(1,179)			(668)
Restricted stock awards	4,364	109	5,341			(1,086)
Net loss	(45,563)			(45,563)
Foreign currency translation adjustments	(28,724)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	(28,724)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	703				703
Amortization of prior service costs and unrecognized losses and credits	(427)				(427)
Comprehensive Income (Loss)	(74,011)
Adoption of ASU 2020-06			(34,798)	9,670
Purchases of capped calls	(18,787)
Adoption of Credit Loss Standard	(25,128)			9,670
Ending Balance at Dec. 31, 2021	218,489	9,977	276,665	22,645	16,988	(107,788)	2
Defined benefit plans:
Payments of Ordinary Dividends, Common Stock	0
Stock-based compensation expense	(844)	0	(844)			0
Restricted stock awards	2,773	160	2,764			(151)
Net loss	(101,071)			(101,071)
Foreign currency translation adjustments	(48,197)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	(48,197)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	(1)				(1)
Amortization of prior service costs and unrecognized losses and credits	6,487				6,487
Comprehensive Income (Loss)	(142,782)
Purchases of capped calls	0
Ending Balance at Dec. 31, 2022	81,092	10,812	281,366	$ (78,426)	$ (24,723)	$ (107,939)	$ 2
Defined benefit plans:
Payments of Ordinary Dividends, Common Stock	0
Stock Issued During Period, Value, New Issues	$ 3,456	$ 675	$ 2,781

Accounting Policies

Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Accounting Policies	Accounting Policies Nature of Operations: Invacare Corporation is a leading manufacturer and distributor of medical equipment used in the home based upon the company's distribution channels, breadth of product line and net sales. The company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and continuing care markets. Principles of Consolidation: The consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of December 31, 2022 and the results of its operations and its cash flow for the years ended December 31, 2022, 2021 and 2020, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a November 30 fiscal year end to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated. Going Concern: The company's financial statements have been prepared under the assumption that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the normal course of business. In connection with the preparation of the consolidated financial statements, the company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, that raised substantial doubt as to the company's ability to continue as a going concern. On January 31, 2023, the company and two of its U.S. subsidiaries filed voluntary petitions under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). The Debtors obtained joint administration of their chapter 11 cases under the caption In re Invacare Corporation, et al. , Case No. 23-90068 (CML) (the “Chapter 11 Cases”). In light of the company's Chapter 11 Cases, the company's ability to continue as a going concern is contingent upon, among other things, the company's ability to, subject to approval by the Bankruptcy Court, implement a business plan of reorganization, emerge from the Chapter 11 proceedings and generate sufficient liquidity following the reorganization to meet contractual obligations and operating needs. The Chapter 11 Cases create certain risks and uncertainties related to, among other things, (i) the company's ability to obtain requisite support for the business plan of reorganization from various stakeholders, and (iii) the disruptive effects of the Chapter 11 Cases on the company's business making it potentially more difficult to maintain business, financing and operational relationships. Although the company believes the reorganization upon the outcome of the Chapter 11 Cases will position the company for liquidity and profitable growth, the Chapter 11 filing caused an event of default under certain instruments governing the company's indebtedness, which is stayed during the pendency of the bankruptcy proceeding. Further, there are several risks and uncertainties associated with the company's bankruptcy, including, among others (a) the company's chapter 11 plan of reorganization may never be confirmed or become effective, (b) the Restructuring Support Agreement may be terminated by one or more of the parties thereto, (c) the Bankruptcy Court may grant or deny motions in a manner that is adverse to the company and its subsidiaries, and (d) the company's Chapter 11 Cases may be converted into a Chapter 7 liquidation. These factors, together with the company's recurring losses and accumulated deficit, create substantial doubt regarding the company's ability to continue as a going concern. Refer to those risk factors discussed under “Risk Factors” in Part II, Item 1A of this Report. Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates. Cash and Cash Equivalents : The company's policy is to treat investments that are readily convertible to cash and with maturities so near that there is little risk of changes in value due to changes in interest rates as cash and cash equivalents. Cash and cash equivalents are carried at cost, which approximates fair value. Accounts Receivable: The company records accounts receivable when control of the product or service transfers to its unaffiliated customers, risk of loss is passed and title is transferred. The estimated allowance for uncollectible amounts is based primarily on management's evaluation of the financial condition of specific customers. The company records accounts receivable reserves for amounts that may become uncollectible in the future. The company writes off accounts receivable when it becomes apparent, based upon customer circumstances, that such amounts will not be collected and legal remedies are exhausted. Reserves for customer bonus and cash discounts are recorded as a reduction in revenue and netted against gross accounts receivable. Customer rebates in excess of a given customer's accounts receivable balance are classified in Accrued Expenses. Customer rebates and cash discounts are estimated based on the most likely amount principal as well as historical experience and anticipated performance. In addition, customers have the right to return product within the company's normal terms policy, and as such, the company estimates the expected returns based on an analysis of historical experience and adjusts revenue accordingly. Inventories: Inventories are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Finished goods and work in process inventories include material, labor and manufacturing overhead costs. Inventories have been reduced by an allowance for excess and obsolete inventories. The estimated allowance is based on management's review of inventories on hand compared to estimated future usage and sales. Property and Equipment: Property and equipment are stated based on cost. The company principally uses the straight-line method of depreciation for financial reporting purposes based on annual rates sufficient to amortize the cost of the assets over their estimated useful lives. Machinery and equipment, internal use software as well as furniture and fixtures are generally depreciated using lives of 3 to 10 years, while buildings and improvements are depreciated using lives of 5 to 40 years. Accelerated methods of depreciation are used for federal income tax purposes. Expenditures for maintenance and repairs are charged to expense as incurred. Amortization of assets under finance leases is included in depreciation expense. Long-lived assets are assessed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An asset would be considered impaired when the future net undiscounted cash flows generated by the asset or asset group are less than its carrying value. An impairment loss would be recognized based on the amount by which the carrying value of the asset exceeds its fair value. Goodwill and Other Intangibles: In accordance with Intangibles—Goodwill and Other , ASC 350, goodwill and indefinite lived intangibles are subject impairment. The company completes its annual impairment assessment in the fourth quarter of each year or whenever events or changes in circumstances indicate the carrying value could be below a reporting unit's fair value. For purposes of the goodwill impairment assessment, the fair value of each reporting unit is estimated using an income approach by forecasting cash flows and discounting those cash flows using an appropriate weighted average cost of capital (WACC) as well as considering market and cost approaches, as appropriate. The fair values are then compared to the carrying value of the net assets of each reporting unit. Intangible assets are also assessed for impairment by estimating forecasted cash flows and discounting those cash flows as needed to calculate impairment amounts. The fair value of trademarks were calculated using a relief from royalty payment methodology which requires applying an estimated market royalty rate to forecasted net sales and discounting the resulting cash flows to determine fair value. Accrued Warranty Cost: Generally, the company's products are covered by assurance-type warranties against defects in material and workmanship for various periods depending on the product from the date of sale to the customer. Certain components carry a lifetime warranty. In addition, the company has sold extended warranties that, while immaterial, require the company to defer the revenue associated with those warranties until earned. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments, as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted, as needed. However, the company does consider other events, such as a product recall, which could necessitate additional warranty reserve provisions. Refer to Accrued Expenses in the Notes to the Consolidated Financial Statements for a reconciliation of the changes in the warranty accrual. Product Liability Cost: The company was self-insured in North America for product liability exposures for losses up to $10,000,000 per occurrence and $13,000,000 in the aggregate. The company also has additional layers of external insurance coverage, related to all lines of insurance coverage, insuring up to $75,000,000 in aggregate losses per policy year arising from individual claims anywhere in the world that exceed the captive insurance company policy limits or the limits of the company's per country foreign liability limits, as applicable. There can be no assurance that Invacare's current insurance levels will continue to be adequate or available at affordable rates. Product liability reserves are recorded for individual claims based upon historical experience, industry expertise and other indicators. Additional reserves, in excess of the specific individual case reserves, are provided for incurred but not reported claims based upon actuarial valuations at the time such valuations are conducted. Historical claims experience and other assumptions are taken into consideration by the company in estimating the ultimate reserves. For example, the actuarial analysis assumes that historical loss experience is an indicator of future experience, that the distribution of exposures by geographic area and nature of operations for ongoing operations is expected to be very similar to historical operations with no dramatic changes and that the government indices used to trend losses and exposures are appropriate. Estimates made are adjusted on a regular basis and can be impacted by actual loss awards and settlements on claims. While actuarial analysis is used to help determine adequate reserves, the company is responsible for the determination and recording of adequate reserves in accordance with accepted loss reserving standards and practices. Revenue Recognition: The company recognizes revenues when control of the product or service is transferred to unaffiliated customers. Revenues from Contracts with Customers , ASC 606, provides guidance on the application of generally accepted accounting principles to revenue recognition issues. The company has concluded that its revenue recognition policy is appropriate and in accordance with GAAP under ASC 606. All of the company's product-related contracts, and a portion related to services, have a single performance obligation, which is the promise to transfer an individual good or service, with revenue recognized at a point in time. Certain service-related contracts contain multiple performance obligations that require the company to allocate the transaction price to each performance obligation. For such contracts, the company allocates revenue to each performance obligation based on its relative standalone selling price at inception of the contract. The company determined the standalone selling price based on the expected cost-plus margin methodology. Revenue related to the service contracts with multiple performance obligations is recognized over time. To the extent performance obligations are satisfied over time, the company defers revenue recognition until the performance obligations are satisfied. The determination of when and how much revenue to recognize can require the use of significant judgment. Revenue is recognized when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the company's products and services to the customer. Revenue is measured as the amount of consideration expected to be received in exchange for transferring the product or providing services. The amount of consideration received and recognized as revenue by the company can vary as a result of variable consideration terms included in the contracts such as customer rebates, cash discounts and return policies. Customer rebates and cash discounts are estimated based on the most likely amount principle and these estimates are based on historical experience and anticipated performance. Customers have the right to return product within the company's normal terms policy, and as such, the company estimates the expected returns based on an analysis of historical experience. The company adjusts its estimate of revenue at the earlier of when the most likely amount of consideration the company expects to receive changes or when the consideration becomes fixed. The company generally does not expect that there will be significant changes to its estimates of variable consideration (refer to Receivables in the Notes to the Consolidated Financial Statements include elsewhere in this report). Depending on the terms of the contract, the company may defer recognizing a portion of the revenue at the end of a given period as the result of title transfer terms that are based upon delivery and or acceptance which align with transfer of control of the company's products to its customers. Sales are made only to customers with whom the company believes collection is probable based upon a credit analysis, which may include obtaining a credit application, a signed security agreement, personal guarantee and/or a cross corporate guarantee depending on the credit history of the customer. Credit lines are established for new customers after an evaluation of their credit report and/or other relevant financial information. Existing credit lines are regularly reviewed and adjusted with consideration given to any outstanding past due amounts. The company records distributed product sales gross as a principal since the company takes title to the products and has the risks of loss for collections, delivery and returns. The company's payment terms are for relatively short periods and thus do not contain any element of financing. Additionally, no contract costs are incurred that would require capitalization and amortization. Sales, value added, and other taxes the company collects concurrent with revenue producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense. Shipping and handling costs are included in cost of products sold. The majority of the company's warranties are considered assurance-type warranties and continue to be recognized as expense when the products are sold (refer to Current Liabilities in the Notes to the Consolidated Financial Statements include elsewhere in this report). These warranties cover against defects in material and workmanship for various periods depending on the product from the date of sale to the customer. Certain components carry a lifetime warranty. In addition, the company has sold extended warranties that, while immaterial, require the company to defer the revenue associated with those warranties until earned. The company has established procedures to appropriately defer such revenue. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The company continuously assesses the adequacy of its product warranty accruals and makes adjustments as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product recall, which could require additional warranty reserve provisions. Refer to Accrued Expenses in the Notes to the Consolidated Financial Statements for a reconciliation of the changes in the warranty accrual. Research and Development: Research and development costs are expensed as incurred and included in cost of products sold. The company's annual expenditures for product development and engineering were approximately $3,492,000, $8,656,000 and $12,275,000 for 2022, 2021 and 2020, respectively. Advertising: Advertising costs are expensed as incurred and included in selling, general an d administrative expenses. Advertising expenses amounted to $4,511,000, $5,062,000 and $5,107,000 for 2022, 2021 and 2020, respectively, the majority of which is in curred for advertising in the United States and Europe. Income Taxes: The company uses the liability method in measuring the provision for income taxes and recognizing deferred tax assets and liabilities on the balance sheet. The liability method requires that deferred income taxes reflect the tax consequences of currently enacted rates for differences between the tax and financial reporting bases of assets and liabilities. Taxes related to Global Intangible Low-Taxes Income (GILTI) are treated as current period expense when incurred. Value Added Taxes: The company operates internationally and is required to comply with value added tax (VAT) or goods and service tax (GST) regulations, particularly in Europe and Asia Pacific. VAT and GST are taxes on consumption in which the company pays tax on its purchases of goods and services and charges customers on the sale of product. The difference between billings to customers and payments on purchases is then remitted or received from the government as filings are due. The company records tax assets and liabilities related to these taxes and the balances in these accounts can vary significantly from period to period based on the timing of the underlying transactions. Derivative Instruments: Derivatives and Hedging, ASC 815, requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. A majority of the company's derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change. During the third and fourth quarter of 2022, the company entered into privately negotiated Secured Convertible 2026 Notes of $41,475,000 in aggregate principal amount. Convertible debt conversion liabilities of $1,595,000 were recorded based on initial fair values and these fair values are updated each reporting period with the offset to the income statement. Foreign Currency Translation: The functional currency of the company's subsidiaries outside the United States is the applicable local currency. The assets and liabilities of the company's foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Revenues and expenses are translated at monthly average exchange rates. Gains and losses resulting from translation of balance sheet items are included in accumulated other comprehensive earnings. Net Earnings Per Share: Basic earnings per share are computed based on the weighted-average number of common shares and Class B common shares outstanding during the year. Diluted earnings per share are computed based on the weighted-average number of common shares and Class B common shares outstanding plus the effects of dilutive stock options and awards outstanding during the year. For periods in which there was a net loss, loss per share assuming dilution utilized weighted average shares-basic. Defined Benefit Plans: The company's benefit plans are accounted for in accordance with Compensation-Retirement Benefits , ASC 715 which requires plan sponsors to recognize the funded status of their defined benefit postretirement benefit plans in the consolidated balance sheet, measure the fair value of plan assets and benefit obligations as of the balance sheet date and to recognize changes in that funded status in the year in which the changes occur through comprehensive income. Recent Accounting Pronouncements (Already Adopted): In August 2020, the FASB issued ASU 2020-06 “Debt with Conversion and Other Options” (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40)”, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU 2020-06 removes from U.S. GAAP the separation models for (1) convertible debt with a cash conversion feature (CCF) and (2) convertible instrument with a beneficial conversion feature (BCF). As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (2) a convertible debt instrument was issued at a substantial premium. The guidance may be early adopted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The company adopted ASU 2020-06 effective January 1, 2021, using the modified retrospective method, which resulted in the removal of convertible debt discounts of $25,218,000, adjustment of $34,798,000 to additional paid-in-capital and $9,670,000 adjustment to retained earnings. Convertible debt discounts prior to adoption of ASU 2020-06 were amortized over the convertible debt term through interest expense. Subsequent to adoption, convertible debt discounts are not applicable when accounting for debt as a single unit of account. Interest expense for 2020 related to debt discount amortization (which was not recognized in 2021 or 2022 due to adoption) was $9,673,000 or $0.28 per basic and diluted share. There was no impact of adoption on performance metrics used for short-term or long-term incentive compensation. Accretion specific to the Series II 2024 Notes was unaffected by adoption. Due to the valuation allowance, there was no net impact to income taxes for the adoption. Subsequent to adoption weighted average shares when calculating diluted earnings per share requires the application of the if-converted method for all convertible instruments. In March 2020, the FASB issued ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting,” which is intended to provide temporary optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burden related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates if certain criteria are met. The guidance may be adopted in any period prior to the guidance expiration on December 31, 2022.

Operations Held for Sale (Notes

Operations Held for Sale (Notes)	12 Months Ended
	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Mergers, Acquisitions and Dispositions Disclosures	On March 7, 2020, the company completed the sale (the “DCL Transaction”) of its subsidiary, Dynamic Controls, a New Zealand incorporated unlimited company (“Dynamic Controls”), to Allied Motion Christchurch Limited, a New Zealand limited company (the “DCL Purchaser”), pursuant to a Securities Purchase Agreement among the company, Invacare Holdings New Zealand, a New Zealand incorporated unlimited company, and the Purchaser, dated March 6, 2020 (the “DCL Purchase Agreement”). Dynamic Controls was a producer of electronic control systems for powered medical mobility devices, including systems incorporating the LiNX™ technology platform. LiNX™ is a registered trademark owned by Dynamic Controls. Dynamic Controls was a component of the All Other Segment. Dynamic Controls was a supplier of power mobility products and respiratory components to the company as well as supplying power mobility products to external customers. Sales in 2020 through the date of disposition were $5,331,000, including intercompany sales of $2,532,000. Income before income taxes was approximately $445,000 in 2020, through the date of disposition. The transaction was the result of considering options for the products sold by Dynamic Controls which resulted in selling the business to a third-party which can provide access to further technological innovations to further differentiate the company’s power mobility products. The gross proceeds from the DCL Transaction were $14,563,000, net of taxes and expenses. The company realized a pre-tax gain of $9,790,000. The Purchase Agreement contained customary indemnification obligations of each party with respect to breaches of their respective representations, warranties and covenants, and certain other specified matters, which were subject to certain exceptions, terms and limitations described further in the DCL Purchase Agreement. At the closing of the DCL Transaction, the parties entered into a supply agreement pursuant to which Dynamic Controls will supply certain electronic components as required by the company for the five-year period following the DCL Transaction, including ongoing supply and support of the LiNX™ electronic control system with informatics technology, continued contract manufacturing of certain electronic components for the company’s respiratory products and continued infrastructure and applications support for the informatics solution for the company’s respiratory products. The estimated continued inflows and outflows following the disposal with the DCL Purchaser are not expected to be material to the company. The assets and liabilities of Dynamic Controls as of March 7, 2020 consisted of the following (in thousands): March 7, 2020 Trade receivables, net $ 4,129 Inventories, net 3,082 Other assets 855 Property and equipment, net 600 Operating lease assets, net 2,127 Total assets $ 10,793 Accounts payable $ 4,692 Accrued expenses 2,473 Current taxes payable 41 Current portion of operating lease obligations 366 Long-term obligations 1,019 Total liabilities $ 8,591 Trade receivables as of March 7, 2020 included receivables previously classified as intercompany related to product sold by Dynamic Controls to other Invacare entities. On January 30, 2023 the company completed the sale of its respiratory business assets to Ventec Life Systems, Inc, a Delaware corporation and subsidiary of React Health, LLC (the “Purchaser”), pursuant to an Asset Purchase Agreement dated as of January 30, 2023 (the “Purchase Agreement”). The purchase price paid by the Purchaser was $11,925,644 in cash payable at closing. The Purchase Agreement contains customary indemnification obligations of each party with respect to breaches of their respective representations, warranties and covenants, and certain other specified matters, which are subject to certain exceptions, terms and limitations described further in the Purchase Agreement. The company agreed to non-competition obligations with respect to respiratory products for a five-year period following the Transaction, which are more fully described in the Purchase Agreement. In addition, the company entered into a supply agreement and a transition services agreement with the Purchaser to provide for, among other matters, the ongoing parts and service and support for the warranty and non-warranty service of respiratory products in the field. The foregoing description of the Purchase Agreement is a summary, does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement. On January 27, 2023, the company completed the sale of its Top End™ ® sports and recreational wheelchair and handcycle business net assets to Top End Sports, LLC. Cash proceeds on the sale were not material to the company.

Receivables

Receivables	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Receivables	Receivables Receivables as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Accounts receivable, gross $ 112,659 $ 142,806 Customer rebate reserve (11,569) (12,267) Allowance for doubtful accounts (3,279) (3,642) Cash discount reserves (8,756) (9,179) Other, principally returns and allowances reserves (1,103) (603) Accounts receivable, net $ 87,952 $ 117,115 Reserves for customer rebates and cash discounts are recorded as a reduction in revenue and netted against gross accounts receivable. Customer rebates in excess of a given customer's accounts receivable balance are classified in Accrued Expenses. Customer rebates and cash discounts are estimated based on the most likely amount principle as well as historical experience and anticipated performance. In addition, customers have the right to return product within the company’s normal terms policy, and as such, the company estimates the expected returns based on an analysis of historical experience and adjusts revenue accordingly. During the third quarter of 2021, the company entered into an agreement with a bank to sell certain trade receivables with governmental entity customers in the Nordic region without recourse. Under ASC 860, the sale of the receivables qualify as a true sale and not a secured borrowing. No gain or loss was recorded on the sale of the receivables. Bank charges, which are recorded as interest expense, attributable to the program were immaterial for the years ended December 31, 2022 and 2021. Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all the company’s receivables are due from health care, medical equipment providers and long-term care facilities predominantly located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to providers, both foreign and domestic, are ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The company adopted ASU 2016-13, “Measurement of Credit Losses on Financial Statements” on January 1, 2020. Accordingly, the company is now applying an "expected loss” model that will generally require earlier recognition of allowances for losses for trade receivables. In addition, the company expects more variability in its allowance for doubtful accounts as it previously provided for bad debts based on a specific reserve methodology while the new expected loss methodology requires companies to provide for estimated losses beginning at the time of sale. The adoption of the new standard resulted in an increase in credit losses and adjustment to retained earnings of $243,000 which is reflected in the Consolidated Statement of Shareholders' Equity. The company's approach is to separate its receivables into good-standing and collection receivables. Good-standing receivables are assigned to risk pools of high, medium and low. The risk pools are driven by the specifics associated with the geography of origination. Expected loss percentages are calculated and assigned to each risk pool, driven primarily by historical experience. The historical loss percentages are calculated for each risk pool and then judgmentally revised to consider current risk factors as well as consideration of the impact of forecasted events, as applicable. The expected loss percentages are then applied to receivables balances each period to determine the allowance for doubtful accounts. In North America, excluding Canada, good-standing receivables are assigned to the low risk pool and assigned an expected loss percentage of 1.0% as these receivables are deemed to share the same risk profile and collections efforts are the same. Installment receivables in North America are characterized as collection receivables and thus reserves are based on specific analysis of each customer. In Canada, good-standing receivables are deemed low risk and assigned a loss percentage of 0.1%. In Europe, expected losses are determined by each location in each country. Most locations have a majority of their receivables assigned to the low risk pool, which has an average expected loss percentage of 0.3%. About half of the locations have a portion of their receivables assigned as medium risk with an average expected loss percentage of 0.8%. Only a few locations have any receivables characterized as high risk and the average credit loss percentage for those locations is 2.7%. Collection risk is generally low as payment terms in certain key markets, such as Germany, are immediate and in many locations the ultimate customer is the government. In the Asia Pacific region, receivables are characterized as low risk, which have an average expected loss percentage of 1.0%. Historical losses are low in this region where the use of credit insurance is often customary. The movement in the trade receivables allowance for doubtful accounts was as follows (in thousands): 2022 Balance as of beginning of period $ 3,642 Current period provision 862 Recoveries (direct write-offs), net (1,225) Balance as of end of period $ 3,279 The company did not make any material changes to the assignment of receivables to the different risk pools or to the expected loss reserves in the year. For collections receivables, the estimated allowance for uncollectible amounts is based primarily on management’s evaluation of the financial condition of each customer. In addition, as a result of the company's financing arrangement with DLL, a third-party financing company which the company has worked with since 2000, management monitors the collection status of these contracts in accordance with the company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishes reserves for specific customers as needed. The company writes off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. Refer to Concentration of Credit Risk in the Notes to the Consolidated Financial Statements for a description of the financing arrangement. Long-term installment receivables are included in “Other Assets” on the consolidated balance sheet. The company has recorded a contingent liability in the amount of $333,000 related to the contingent aspect of the company's guarantee associated with its arrangement with DLL. The contingent liability is recorded applying the same expected loss model used for the trade and installment receivables recorded on the company's books. Specifically, historical loss history is used to determine the expected loss percentage, which is then adjusted judgmentally to consider other factors, as needed. The company’s U.S. customers electing to finance their purchases can do so using DLL. Repurchased DLL receivables recorded on the books of the company represent a single portfolio segment of receivables to the independent provider channel and long-term care customers. The portfolio segment of these receivables are distinguished by geography and credit quality. These receivables were repurchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by three payments. The estimated allowance for uncollectible amounts and evaluation for both classes of installment receivables is based on the company’s quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed. The company assesses the bad debt reserve levels based upon the status of the customer’s adherence to a legally negotiated payment schedule and the company’s ability to enforce judgments, liens, etc. For purposes of granting or extending credit, the company utilizes a scoring model to generate a composite score that considers each customer’s consumer credit score and/or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for most customers desiring credit greater than $250,000, which generally includes a detailed review of the customer’s financial statements as well as consideration of other factors such as exposure to changing reimbursement laws. Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the company goes through a legal process for pursuing collection of outstanding amounts, the length of which typically approximates eighteen months. Any write-offs are made after the legal process has been completed. Installment receivables as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Current Long- Total Current Long- Total Installment receivables $ 311 $ 266 $ 577 $ 218 $ 734 $ 952 Less: Unearned interest — — — — — — 311 266 577 218 734 952 Allowance for doubtful accounts — — — — — — Installment receivables, net $ 311 $ 266 $ 577 $ 218 $ 734 $ 952 No sales of installment receivables were made by the company during the year. The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands): 2022 2021 Balance as of beginning of period $ — $ 487 Current period provision (benefit) — (75) Direct write-offs charged against the allowance — (412) Balance as of end of period $ — $ — Installment receivables by class as of December 31, 2022 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 577 577 — — Total Non-impaired installment receivables with no related allowance recorded 577 577 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 577 $ 577 $ — $ — Installment receivables by class as of December 31, 2021 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 952 952 — — Total Non-impaired installment receivables with no related allowance recorded 952 952 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 952 $ 952 $ — $ — Installment receivables with a related allowance recorded as noted in the table above represent those installment receivables on a non-accrual basis. As of December 31, 2022, the company had no U.S. installment receivables past due of 90 days or more for which the company is still accruing interest. Individually, all U.S. installment receivables are assigned a specific allowance for doubtful accounts based on management's review when the company does not expect to receive both the contractual principal and interest payments as specified in the loan agreement. The aging of the company's installment receivables was as follows as of December 31, 2022 and 2021 (in thousands): December 31, 2022 December 31, 2021 Total U.S. Asia Pacific Total U.S. Canada Current $ 533 $ — $ 533 $ 952 $ — $ 952 0-30 days past due 44 — 44 — — — 31-60 days past due — — — — — — 61-90 days past due — — — — — — 90+ days past due — — — — — — $ 577 $ — $ 577 $ 952 $ — $ 952

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories, Net Inventories, net as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Raw materials $ 57,174 $ 69,371 Finished goods 45,476 62,124 Work in process 9,911 12,779 Inventories, net $ 112,561 $ 144,274 In the third quarter of 2022, with the decision to exit the respiratory products business, the company recorded a charge to gross margin totaling $8,651,000, with $5,387,000 increasing the inventory reserve and $3,264,000 for purchase obligations. No significant adjustments were recorded to adjust this estimate in the fourth quarter of 2022.

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other Current Assets Other current assets as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Tax receivables principally value added taxes $ 22,946 $ 21,943 Prepaid insurance 1,223 4,462 Prepaid inventory and freight 3,077 2,394 Recoverable income taxes 1,990 2,301 Service contracts 1,366 304 Derivatives (foreign currency forward contracts) 1,117 386 Receivable due from information technology provider 934 612 Prepaid debt fees 339 379 Prepaid and other current assets 6,710 7,255 Other Current Assets $ 39,702 $ 40,036

Other Long-Term Assets

Other Long-Term Assets	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Long-Term Assets	Other Long-Term Assets Other long-term assets as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Cash surrender value of life insurance policies 2,686 2,481 Deferred income taxes 1,102 1,540 Deferred financing fees 733 409 Installment receivables 266 734 Investments 85 86 Other 287 112 Other Long-Term Assets $ 5,159 $ 5,362

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property And Equipment	Property and Equipment Property and equipment as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Machinery and equipment $ 269,835 $ 278,347 Capitalized software 30,923 30,448 Land, buildings and improvements 25,095 27,299 Furniture and fixtures 8,053 8,943 Leasehold improvements 4,802 6,782 Property and Equipment, gross 338,708 351,819 Accumulated depreciation (287,175) (290,898) Property and Equipment, net $ 51,533 $ 60,921 Machinery and equipment includes demonstration units placed in provider locations which are depreciated to their estimated recoverable values over their estimated useful lives. In 2019, the company initiated the first stage of an Enterprise Resource Planning (“ERP”) software implementation. Related to the ERP project, the company capitalized certain costs in accordance with ASC 350 as shown in capitalized software above . The net book value of capitalized software was $26,015,000 and $28,715,000 at December 31, 2022 and 2021 , respectively. Depreciation expense related to capitalized software started in 2021, subsequent to the first stage implementation of the ERP and was $3,176,000 and $1,733,000 for the year ended December 31, 2022 and 2021 , respectively. Unpaid purchases of property and equipment at December 31, 2022 and 2021 were $0 and $1,090,000, respectively and are excluded from purchases of property and equipment on the consolidated statements of cash flows for those periods ending and are included in subsequent periods when paid.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The carrying amount of goodwill by reporting unit is as follows (in thousands): North America Europe Consolidated Balance at December 31, 2020 $ 28,485 $ 373,976 $ 402,461 Foreign currency translation adjustments 79 (18,101) (18,022) Impairment of goodwill (28,564) — (28,564) Balance at December 31, 2021 — 355,875 355,875 Foreign currency translation adjustments — (29,594) (29,594) Balance at December 31, 2022 $ — $ 326,281 $ 326,281 In accordance with Intangibles—Goodwill and Other , ASC 350, goodwill is assessed for impairment. The company first estimates the fair value of each reporting unit and compares the calculated fair value to the carrying value of each reporting unit. A reporting unit is defined as an operating segment or one level below. The company had determined that its reporting units are North America, Europe and Asia Pacific. During the third quarter of 2021, the company's reporting units of North America / HME and Institutional Products Group merged into one reporting unit of North America, consistent with the operating segment. Developments in 2021 and the conclusion of the reporting units merger were tied mostly to actions of the company to implement components of a new ERP system which changed both the level of discrete financial information readily available and the go-forward manner in which the company assesses performance and allocates resources to the North America operating segment. The reporting unit change within the North America operating segment in the third quarter of 2021 was a triggering event and required the company to perform an interim goodwill impairment assessment. Based on the interim goodwill impairment assessment, the company concluded that the carrying value of the North America reporting unit was above its fair value. That conclusion resulted in the recording of impairment of goodwill in the third quarter of 2021 of $28,564,000. The company completed the interim test in the third quarter of 2021 consistent with the process of its annual impairment assessment in the fourth quarter of each year. During the third quarter of 2022, a continued decline in the share price of the company's common shares caused the company's market capitalization to fall below the carrying value of shareholders' equity. Further, inputs used in estimating the weighted average cost of capital (“WACC”) had moved unfavorably to increase the WACC used in a discounted cash flows model. The combination of these and other developments were identified as a triggering event and the company proceeded with a quantitative goodwill impairment assessment of its Europe reporting unit (the only reporting unit with goodwill). An interim quantitative goodwill impairment assessment was performed as of September 30, 2022, utilizing a discounted cash flows methodology. Key assumptions used in the discounted cash flow analysis included, but were not limited to, a WACC of approximately 14.51%, terminal growth rates and financial projections of performance and cash flows. Components of the WACC include quoted rates for 20-year debt of potential acquirer companies with similar credit risk and the cost of equity based on the 20-year treasury rate for the risk free rate, a market risk premium, an industry average beta and a small cap stock adjustment. The assumptions are based on a market participant's point of view and thus these inputs are deemed Level III inputs in regard to the fair value hierarchy. The WACC used in the 2021 annual assessment was 11.19% and was 11.27% in 2020. The WACC used has a significant impact in the outcome of the discounted cash flow methodology utilized in the company's impairment assessment as a higher WACC would decrease fair value estimates. The company also utilized an Enterprise Value (“EV”) to Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) method to compute the fair value of reporting units which considers potential acquirers and their EV to EBITDA multiples adjusted by an estimated premium. The EV method is used to corroborate fair values but more weight is placed on the discounted cash flow method results. The company concluded based on the results of the interim quantitative goodwill impairment assessment performed as of September 30, 2022 that goodwill was not impaired in Europe. The company typically completes an annual impairment assessment in the fourth quarter of each year or whenever events or changes in circumstances indicate the carrying value could be below a reporting unit's fair value. The assessment results as of September 30, 2022 were not materially different from the company's historic valuation fourth quarter valuation date as of October 1 st. Through the fourth quarter of 2022, the company monitored for triggers which could negatively impact components to calculations from the interim impairment assessment and could suggest additional risk of impairment as of December 31, 2022. Inputs to the WACC and other factors in the quantitative assessment did not move materially unfavorably to warrant an update to the quantitative assessment as of December 31, 2022. While there was no impairment in 2022 related to goodwill for the Europe reporting unit, a future potential impairment is possible for Europe should actual results differ materially from forecasted results used in the valuation analysis. The valuation of goodwill can differ materially if financial projections or market inputs used to determine the WACC change significantly. For instance, higher interest rates or greater stock price volatility would increase the WACC and thus increase the chance of impairment. Assumptions used in the quantitative assessment require significant judgements and estimates which are inherently uncertain. If actual results are materially lower than estimates, it could result in a material impact on the consolidated financial statements in future periods. In addition, business changes impacting the company's assessment of reporting units could also have a material impact on impairment assessment results. There is no goodwill in the North America or Asia Pacific reporting units at December 31, 2022. As part of the company's assessment of goodwill for impairment, the company also considers the potential for impairment of any intangible assets and other long-lived assets. Refer to Other Long-Term Assets, Property and Equipment and Intangibles in the Notes to the Consolidated Financial Statements.

Intangibles

Intangibles	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles	Intangibles The company's intangibles consist of the following (in thousands): December 31, 2022 December 31, 2021 Historical Accumulated Historical Accumulated Customer lists $ 48,515 $ 48,515 $ 52,447 $ 52,447 Trademarks 18,867 — 24,137 — Developed technology 7,154 6,859 7,652 7,149 Patents 4,092 4,092 5,543 5,543 License agreements 3,981 1,480 2,905 1,196 Other 1,148 1,142 1,147 1,140 Intangibles $ 83,757 $ 62,088 $ 93,831 $ 67,475 All of the company's intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for trademarks shown above, which have indefinite lives. The changes in intangible asset balances reflected on the balance sheet from December 31, 2021 to December 31, 2022 were the result of foreign currency translation on historical cost and accumulated amortization as well as impairment of certain trademarks discussed below. The company evaluates the carrying value of definite-lived assets annually in the fourth quarter and whenever events or circumstances indicate possible impairment. Definite-lived assets are determined to be impaired if the future undiscounted cash flows expected to be generated by the asset are less than the carrying value. Actual impairment amounts for definite-lived assets are then calculated using a discounted cash flow calculation. Any impairment for indefinite-lived intangible assets is calculated as the difference between the future discounted cash flows expected to be generated by the asset less than the carrying value for the asset. Amortization expense related to intangible assets was $507,000, $404,000 and $377,000 for 2022, 2021 and 2020, respectively. Estimated amortization expense for each of the next five years is expected to be $611,000 for 2023, $562,000 in 2024, $439,000 in 2025, $437,000 in 2026 and $311,000 in 2027. Amortized intangible assets are being amortized on a straight-line basis over remaining lives of 2 to 7 years with a weighted average remaining life of approximately 5.6 years. During the third quarter of 2022, the company recognized an intangible impairment charge in the North America segment of $1,012,000 related to a trademark with an indefinite life the company determined it would no longer use. During the fourth quarter of 2022, the company recognized intangible assets impairment charges in the Europe segment of $2,247,000 related to trademarks with an indefinite life the company determined had reduced future use due to product rationalization.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Expenses Accrued expenses as of December 31, 2022 and 2021 consisted of accruals for the following (in thousands): 2022 2021 Taxes other than income taxes, primarily value added taxes $ 27,106 $ 24,012 Salaries and wages 19,307 23,217 Professional 11,267 8,697 Warranty 7,981 11,198 Interest 6,900 3,297 IT service contracts 5,581 4,013 Rebates 4,923 6,569 Freight 4,542 5,460 Product line exit obligations 3,743 — Severance 3,472 400 Deferred revenue 2,279 4,156 Product liability, current portion 2,125 2,362 Insurance 951 625 Supplemental Executive Retirement Program liability Plan (SERP) 391 391 Derivatives (foreign currency forward exchange contracts) 137 1,938 Other items, principally trade accruals 5,386 6,636 Accrued Expenses $ 106,091 $ 102,971 Generally, the company's products are covered by warranties against defects in material and workmanship for various periods depending on the product from the date of sales to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. In addition, the company has sold extended warranties that, while immaterial, require the company to defer the revenue associated with those warranties until earned. The company has established procedures to appropriately defer such revenue. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product field action and recalls, which could require additional warranty reserve provision. Accrued rebates relate to several volume incentive programs the company offers its customers. The company accounts for these rebates as a reduction of revenue when the products are sold. Rebates are netted against gross accounts receivables. If rebates are in excess of such receivables, they are then classified as accrued expenses. The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands): 2022 2021 Balance as of January 1 $ 11,198 $ 10,991 Warranties provided during the period 2,202 6,361 Settlements made during the period (5,577) (6,718) Changes in liability for pre-existing warranties during the period, including expirations 158 564 Balance as of December 31 $ 7,981 $ 11,198

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Debt as of December 31, 2022 and 2021 consisted of the following (in thousands): 2022 2021 Convertible senior notes at 4.50%, due in June 2022 $ — $ 2,642 Convertible senior notes Series I at 5.00%, due in November 2024 72,408 72,140 Convertible senior notes Series II at 5.00%, due in November 2024 76,719 78,251 Convertible senior notes at 4.25%, due in March 2026 67,665 119,036 Secured convertible senior notes at 5.68%, due in July 2026 37,240 — Term loan, due in July 2026 82,808 — Other obligations 17,401 36,060 354,241 308,129 Less current maturities of long-term debt (154) (3,107) Long-Term Debt $ 354,087 $ 305,022 On September 30, 2015, the company entered into an Amended and Restated Revolving Credit and Security Agreement, which was subsequently amended (the “Prior Credit Agreement”) and which was to mature on January 16, 2024. The Prior Credit Agreement was entered into by and among the company, certain of the company’s direct and indirect U.S. and Canadian subsidiaries and certain of the company’s European subsidiaries, certain other of the company’s direct and indirect U.S., Canadian and European subsidiaries, and PNC Bank, National Association (“PNC”), JPMorgan Chase Bank, N.A., J.P. Morgan Europe Limited, KeyBank National Association, and Citizens Bank, National Association. PNC is the administrative agent (the “Prior Credit Agreement Administrative Agent”) and J.P. Morgan Europe Limited is the European agent (the “European Agent”) under the Prior Credit Agreement. As discussed further below, the Prior Credit Agreement was amended and restated (the “ABL Credit Agreement”) on July 26, 2022. The company had outstanding letters of credit of $4,229,000 and $3,450,000 as of December 31, 2022 and 2021, respectively. Outstanding letters of credit and other reserves impacting borrowing capacity were $3,654,000 and $2,585,000 as of December 31, 2022 and 2021, respectively. The company had outstanding borrowings of $15,220,000 under its ABL Credit Agreement as of December 31, 2022. The company had outstanding borrowings of $22,150,000 under its North America Credit Facility under the Prior Credit Agreement as of December 31, 2021. The company had outstanding borrowings of $7,366,000 (€6,500,000) under its French Credit Facility and $5,986,000 (£4,500,000) under its UK Credit Facility under its Prior Credit Agreement as of December 31, 2021, together referred to as the European Credit Facility. No borrowings were outstanding under the European Credit Facility as of December 31, 2022 as it was terminated in July 2022. North America Borrowers Credit Facility For the company's North America Borrowers, the Prior Credit Agreement provided for an asset-based-lending senior secured revolving credit facility which was secured by substantially all the company's U.S. and Canadian assets, other than real estate. The Prior Credit Agreement provided the company and the other Borrowers with a credit facility in an aggregate principal amount of $60,000,000, subject to availability based on a borrowing base formula, under a senior secured revolving credit, letter of credit and swing line loan facility (the “North America Credit Facility”). Up to $20,000,000 of the North America Credit Facility was available for issuance of letters of credit. The aggregate principal amount of the North America Credit Facility could have been increased by up to $25,000,000 to the extent requested by the company and agreed to by any Lender or new financial institution approved by the Prior Credit Agreement Administrative Agent. The aggregate borrowing availability under the North America Credit Facility was determined based on a borrowing base formula. The aggregate usage under the North America Credit Facility could not exceed an amount equal to the sum of (a) 85% of eligible U.S. accounts receivable plus (b) the lesser of (i) 70% of eligible U.S. inventory and eligible foreign in-transit inventory and (ii) 85% of the net orderly liquidation value of eligible U.S. inventory and eligible foreign in-transit inventory (not to exceed $4,000,000), plus (c) the lesser of (i) 80% of the net orderly liquidation value of U.S. eligible machinery and equipment and (ii) $0 as of December 31, 2022 (subject to reduction as provided in the Prior Credit Agreement), plus (d) 85% of eligible Canadian accounts receivable, plus (e) the lesser of (i) 70% of eligible Canadian inventory and (ii) 85% of the net orderly liquidation value of eligible Canadian inventory, less (f) swing loans outstanding under the North America Credit Facility, less (g) letters of credit issued and undrawn under the North America Credit Facility, less (h) a $3,000,000 minimum availability reserve, less (i) other reserves required by the Prior Credit Administrative Agent, and in each case subject to the definitions and limitations in the Prior Credit Agreement. Interest accrued on outstanding indebtedness under the Prior Credit Agreement at the SOFR rate, plus a margin ranging from 2.25% to 2.75%, or at the alternate base rate, plus a margin ranging from 1.25% to 1.75%, as selected by the company. Borrowings under the North American Credit Facility were subject to commitment fees of 0.25% or 0.375% per year, depending on utilization. The Prior Credit Agreement contained customary representations, warranties and covenants. Exceptions to the operating covenants in the Prior Credit Agreement provide the company with flexibility to, among other things, enter into or undertake certain sale and leaseback transactions, dispositions of assets, additional credit facilities, sales of receivables, additional indebtedness and intercompany indebtedness, all subject to limitations set forth in the Prior Credit Agreement, as amended. The Prior Credit Agreement also contained a covenant requiring the company to maintain minimum availability under the North America Credit Facility of not less than (i) 12.5% of the maximum amount that may be drawn under the North America Credit Facility for five (5) consecutive business days, or (ii) 11.25% of the maximum amount that may be drawn under the North America Credit Facility on any business day. The company also was subject to dominion triggers under the North America Credit Facility requiring the company to maintain borrowing capacity of not less than $7,500,000 on any business day or any five consecutive days in order to avoid triggering full control by an agent for the lenders of the company's cash receipts for application to the company's obligations under the agreement. The Prior Credit Agreement contained customary default provisions, with certain grace periods and exceptions, which provide for events of default that include, among other things, failure to pay amounts due, breach of covenants, representations or warranties, bankruptcy, the occurrence of a material adverse effect, exclusion from any medical reimbursement program, and an interruption of any material manufacturing facilities for more than 10 consecutive days. The North American Credit Facility was terminated on July 26, 2022. European Credit Facility The Prior Credit Agreement also provided for a revolving credit, letter of credit and swing line loan facility which gives the company and the European Borrowers the ability to borrow up to an aggregate principal amount of $30,000,000, with a $5,000,000 sublimit for letters of credit and a $2,000,000 sublimit for swing line loans (the “European Credit Facility”). Up to $15,000,000 of the European Credit Facility will be available to each of Invacare Limited (the “UK Borrower”) and Invacare Poirier SAS (the “French Borrower” and, together with the UK Borrower, the “European Borrowers”). The European Credit Facility was terminated on July 26, 2022. The aggregate borrowing availability for each European Borrower under the European Credit Facility is determined based on a borrowing base formula. The aggregate borrowings of each of the European Borrowers under the European Credit Facility may not exceed an amount equal to (a) 85% of the European Borrower's eligible accounts receivable, less (b) the European Borrower's borrowings and swing line loans outstanding under the European Credit Facility, less (c) the European Borrower's letters of credit issued and undrawn under the European Credit Facility, less (d) a $3,000,000 minimum availability reserve, less (e) other reserves required by the European Agent, and in each case subject to the definitions and limitations in the Prior Credit Agreement. Interest accrued on outstanding indebtedness under the European Credit Facility at the SOFR rate, plus a margin ranging from 2.50% to 3.00%, or for swing line loans, at the overnight SOFR rate, plus a margin ranging from 2.50% to 3.00%, as selected by the company. The margin was adjusted quarterly based on utilization. Borrowings under the European Credit Facility were subject to commitment fees of 0.25% or 0.375% per year, depending on utilization. The European Credit Facility was secured by substantially all the personal property assets of the UK Borrower and its in-country subsidiaries, and all the receivables of the French Borrower and its in-country subsidiaries. The UK and French facilities (which comprise the European Credit Facility) were cross collateralized, and the US personal property assets previously pledged under the North America Credit Facility also served as collateral for the European Credit Facility. The European Credit Facility was subject to customary representations, warranties and covenants generally consistent with those applicable to the North America Credit Facility. Exceptions to the operating covenants in the Prior Credit Agreement provided the company with flexibility to, among other things, enter into or undertake certain sale/leaseback transactions, dispositions of assets, additional credit facilities, sales of receivables, additional indebtedness and intercompany indebtedness, all subject to limitations set forth in the Prior Credit Agreement. The Prior Credit Agreement also contained a covenant requiring the European Borrowers to maintain undrawn availability under the European Credit Facility of not less than (i) 12.5% of the maximum amount that may be drawn under the European Credit Facility for five (5) consecutive business days, or (ii) 11.25% of the maximum amount that may be drawn under the European Credit Facility on any business day. The European Borrowers also were subject to cash dominion triggers under the European Credit Facility requiring the European Borrower to maintain borrowing capacity of not less than $3,750,000 on any business day or $3,750,000 for five consecutive business days in order to avoid triggering full control by an agent for the Lenders of the European Borrower's cash receipts for application to its obligations under the European Credit Facility. The European Credit Facility was subject to customary default provisions, with certain grace periods and exceptions, consistent with those applicable to the North America Credit Facility, which provide that events of default include, among other things, failure to pay amounts due, breach of covenants, representations or warranties, cross-default, bankruptcy, the occurrence of a material adverse effect, exclusion from any medical reimbursement program, and an interruption in the operations of any material manufacturing facility for more than 10 consecutive days. The proceeds of the European Credit Facility were used to finance the working capital and other business needs of the company. The company had outstanding borrowings of $7,366,000 (€6,500,000) under its French Credit Facility and $5,986,000 (£4,500,000) under its UK Credit Facility as of December 31, 2021. In January 2021, the Prior Credit Agreement was amended to provide for, among other things, the addition of the company's Netherlands subsidiary as a guarantor under the European Credit Facility, amendments to the restrictive covenants in the Prior Credit Agreement to (1) increase the maximum amount of permitted miscellaneous indebtedness to $30,000,000 from $10,000,000 and (2) permit up to $9,000,000 of financing based on certain European public and government receivables, and terms that, upon the occurrence of certain events related to a transition from the use of LIBOR, permit the agent for the lenders to amend the Prior Credit Agreement to replace the LIBOR rate and/or the Euro rate with a benchmark replacement rate. In March 2021, the Prior Credit Agreement was further amended to permit the issuance of the 2026 Notes and the capped call transactions entered into by the company in connection with the issuance of the 2026 Notes, as further discussed in the sections below. On December 29, 2021, the Prior Credit Agreement was further amended with the primary provisions to replace the references to the LIBOR rate or Euro rate to a term secured overnight finance rate (“SOFR”). ABL Credit Agreement On July 26, 2022, the company entered into a Second Amended and Restated Revolving Credit and Security Agreement (the “ABL Credit Agreement”), amending and restating the company’s existing Revolving Credit and Security Agreement, as amended (the “Prior Credit Agreement”). The ABL Credit Agreement was entered into by and among the company, certain of the company’s direct and indirect domestic and Canadian subsidiaries (together with the company, the “Borrowers”), certain other of the company’s direct and indirect domestic and Canadian subsidiaries (the “Guarantors”), and PNC Bank, National Association (“PNC”) and JPMorgan Chase Bank, N.A. (the “ABL Lenders”). PNC is the administrative agent (the “Administrative Agent”) under the ABL Credit Agreement. The ABL Credit Agreement retained the existing asset-based lending senior secured revolving credit facility provided for the company and the domestic and Canadian Borrowers under the Prior Credit Agreement but extended the maturity date to January 16, 2026, reduced the maximum aggregate principal amount the company and the domestic and Canadian Borrowers could borrow to $35,000,000, limited the borrowing base thereunder to eligible domestic and Canadian accounts receivable and included a minimum availability reserve of $3,000,000. Borrowings under the ABL Credit Agreement were subject to a springing maturity date of 191 days prior to the maturity dates of certain convertible notes due 2024 and 2026, and 100 days prior to the maturity date of the Secured Term Loan under the Highbridge Loan Agreement, if such notes or such term loan remain outstanding as of such respective dates. The ABL Credit Agreement also permitted the loans made under the Highbridge Loan Agreement and terminated the European Credit Facility under the Prior Credit Agreement. In connection with the ABL Credit Agreement and the Highbridge Loan Agreement, the European Credit Facility under the Prior Credit Agreement was repaid in full and the liens securing the European Credit Facility under the Prior Credit Agreement were terminated and released. The aggregate borrowing availability under the ABL Credit Agreement was determined based on a borrowing base formula. As of December 31, 2022, the company had gross borrowing base of $29,817,000 and net borrowing availability of $15,288,000 under the ABL Credit Agreement, considering the minimum availability reserve, then-outstanding letters of credit, other reserves and the $4,375,000 dominion trigger amount. Interest accrued on outstanding indebtedness under the ABL Credit Agreement at an adjusted Term SOFR rate, plus a margin of 3.25%, or for swing line loans and prime rate revolving loans, at the overnight Prime rate, plus a margin of 2.25%. The ABL Credit Agreement contained customary terms and covenants and negative covenants, such as limitations on indebtedness, liens, fundamental changes, asset sales, investments and other matters customarily restricted in such agreements. Most of these restrictions were subject to certain minimum thresholds and exceptions. The ABL Credit Agreement also contained customary events of default, after which the revolving loan may be due and payable immediately, including, without limitation, payment defaults, material inaccuracy of representations and warranties, covenant defaults, bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against the company and its subsidiaries, change in control and lien priority. Proceeds from the Secured Term Loan under the Highbridge Loan Agreement were used to repay in full outstanding borrowings under the Prior Credit Agreement. Refer to the Term Loan due 2026 section below. In connection with entering into the company's Prior Credit Agreement and the ABL Credit Agreement, the company incurred fees which were capitalized and were being amortized as interest expense. As of December 31, 2022, debt fees yet to be amortized totaled $1,011,000. The company was in compliance with the ABL Credit Agreement covenants at December 31, 2022. Convertible senior notes due 2022 In the second quarter of 2017, the company issued $120,000,000 aggregate principal amount of 4.50% Convertible Senior Notes due 2022 (the “2022 Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2022 Notes bear interest at a rate of 4.50% per year payable semi-annually in arrears on June 1 and December 1 of each year, beginning December 1, 2017. The 2022 Notes matured on June 1, 2022. At maturity, $2,650,000 principal amount of the 2022 Notes remained outstanding, which the company repaid in cash. In connection with the offering of the 2022 Notes, the company entered into privately negotiated convertible note hedge transactions with one financial institution (the “option counterparty”). These transactions cover, subject to customary anti-dilution adjustments, the number of the company's common shares that will initially underlie the 2022 Notes, and are expected generally to reduce the potential equity dilution, and/or offset any cash payments in excess of the principal amount due, as the case may be, upon conversion of the 2022 Notes. The company evaluated the note hedges under the applicable accounting literature, including Derivatives and Hedging , ASC 815, and determined that the note hedges should be accounted for as derivatives. These derivatives were capitalized on the balance sheet as long-term assets and were adjusted to reflect fair value each quarter. All note hedge options relating to the 2022 Notes expired on June 1, 2022. The company entered into separate, privately negotiated warrant transactions with the option counterparty at a higher strike price relating to the same number of the company's common shares, subject to customary anti-dilution adjustments, pursuant to which the company sold warrants to the option counterparties. The warrants could have a dilutive effect on the company's outstanding common shares and the company's earnings per share to the extent that the price of the company's common shares exceeds the strike price of those warrants. The initial strike price of the warrants was $21.4375 per share and were subject to certain adjustments under the terms of the warrant transactions. The company evaluated the warrants under the applicable accounting literature, including Derivatives and Hedging , ASC 815, and determined that the warrants met the definition of a derivative, were indexed to the company's own shares and should be classified in shareholder's equity. The amount paid for the warrants and capitalized in shareholder's equity was $14,100,000. Warrants relating to the 2022 Notes outstanding on December 31, 2022 were 4,215,212. If exercised, one common share is issued upon exercise of each warrant, but may be adjusted under certain circumstances if the relevant share price exceeds the warrant strike price for the relevant measurement period at the time of exercise. Common shares are reserved for issuance upon exercise of the remaining warrants relating to the 2022 Notes at two common shares per warrant. The warrants began to expire on September 1, 2022 and partially expire on each trading day over the 220 trading day period following September 1, 2022. The net proceeds from the offering of the 2022 Notes were approximately $115,289,000, after deducting fees and offering expenses of $4,711,000, which were paid in 2017. These debt issuance costs were capitalized and were being amortized as interest expense through June 2022. Debt issuance costs are presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. A portion of the net proceeds from the offering were used to pay the cost of the convertible note hedge transactions (after such cost is partially offset by the proceeds to the company from the warrant transactions), which net cost was $10,680,000. During the second quarter of 2020, the company entered into separate, privately negotiated agreements with certain holders of the company's previously outstanding convertible notes due 2021 (the “2021 Notes”) and certain holders of its 2022 Notes to exchange $35,375,000 in aggregate principal amount of 2021 Notes and $38,500,000 in aggregate principal amount of 2022 Notes, for aggregate consideration of $73,875,000 in aggregate principal amount of new Series II 2024 Notes and $5,593,000 in cash. During the first quarter of 2021, the company repurchased $78,850,000 in principal amount of 2022 Notes, resulting in a loss on debt extinguishment of $709,000. The liability components of the 2022 Notes consist of the following (in thousands): December 31, 2022 December 31, 2021 Principal amount of liability component $ — $ 2,650 Debt fees — (8) Net carrying amount of liability component $ — $ 2,642 The effective interest rate on the liability component was 10.9% upon original issuance including consideration of the discount. Total interest expense subsequent to adoption of ASU 2020-06 includes coupon interest and amortization of debt fees. Interest expense of $50,000 and $859,000 was accrued for the 2022 and 2021 periods, respectively, based on the stated coupon rate of 4.5%. Convertible senior notes Series I due 2024 During the fourth quarter of 2019, the company entered into separate privately negotiated agreements with certain holders of its 2021 Notes to exchange $72,909,000 in aggregate principal amount of 2021 Notes for aggregate consideration of $72,909,000 in aggregate principal amount of new 5.00% Convertible Senior Notes due 2024 (the “Series I 2024 Notes”) of the company and $6,928,000 in cash. The notes bear interest at a rate of 5.00% per year payable semi-annually in arrears on May 15 and November 15 of each year, beginning May 15, 2020. The notes will mature on November 15, 2024, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to May 15, 2024, the Series I 2024 Notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The Series I 2024 Notes may be settled in cash, the company’s common shares or a combination of cash and the company’s common shares, at the company’s election. Prior to the maturity of the Series I 2024 Notes, the company may, at its election, redeem for cash all or part of the Series I 2024 Notes if the last reported sale price of the company’s common shares equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the company provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Series I 2024 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date (subject to certain limited exceptions). No sinking fund is provided for the Series I 2024 Notes, which means the company is not required to redeem or retire the Series I 2024 Notes periodically. Holders of the Series I 2024 Notes may convert their Series I 2024 Notes at their option at any time prior to the close of business on the business day immediately preceding May 15, 2024 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending December 31, 2019 (and only during such calendar quarter), if the last reported sale price of the company’s common shares for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Series I 2024 Notes on each applicable trading day; (2) during the five A loss of $5,885,000 was recorded a part of the exchange transaction, which included the write-off of fees related to the portion of the 2021 Notes exchanged. Debt issuance costs of $1,338,000 were capitalized and are being amortized as interest expense through November 15, 2024. Debt issuance costs are presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The liability components of the Series I 2024 Notes consist of the following (in thousands): December 31, 2022 December 31, 2021 Principal amount of liability component $ 72,909 $ 72,909 Debt fees (501) (769) Net carrying amount of liability component $ 72,408 $ 72,140 The effective interest rate on the liability component was 8.8% upon original issuance including consideration of the discount. Total interest expense subsequent to adoption of ASU 2020-06 includes coupon interest and amortization of debt fees. Interest expense of $3,645,000 and $3,645,000 was accrued in 2022 and 2021, respectively, based on the stated coupon rate of 5.0%. The effective interest rate of the Series I 2024 Notes as of December 31, 2022 was 5.4%. The Series I 2024 Notes were not convertible as of December 31, 2022, nor was the applicable conversion threshold met. The company was in compliance with the Series I 2024 Notes covenants at December 31, 2022. Convertible senior notes Series II due 2024 During the second quarter of 2020, the company entered into separate, privately negotiated agreements with certain holders of its 2021 Notes and certain holders of its 2022 Notes to exchange $35,375,000 in aggregate principal amount of 2021 Notes and $38,500,000 in aggregate principal amount of 2022 Notes, for aggregate consideration of $73,875,000 in aggregate principal amount of new 5.00% Series II Convertible Senior Notes due 2024 (the “Series II 2024 Notes”) of the company and $5,593,000 in cash. The Series II 2024 Notes bear interest at a rate of 5.00% per year, payable semi-annually in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The Series II 2024 Notes will mature on November 15, 2024, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to May 15, 2024, the Series II 2024 Notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The Series II 2024 Notes may be settled in cash, the company’s common shares or a combination of cash and the company’s common shares, at the company’s election. Prior to the maturity of the Series II 2024 Notes, the company may, at its election, redeem for cash all or part of the Series II 2024 Notes, if the last reported sale price of the company’s common shares equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the company provides notice of redemption. The redemption price will be equal to 100% of the accreted principal amount of the Series II 2024 Notes to be redeemed, plus any accrued and unpaid interest, if any, on the original principal amount of the New Notes redeemed to, but excluding, the redemption date (subject to certain limited exceptions). No sinking fund is provided for the Series II 2024 Notes, which means the company is not required to redeem or retire the Series II 2024 Notes periodically. Holders of the Series II 2024 Notes may convert their Series II 2024 Notes at their option at any time prior to the close of business on the business day immediately preceding May 15, 2024 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending June 30, 2020 (and only during such calendar quarter), if the last reported sale price of the company’s common shares for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than 130% of the conversion price for the Series II 2024 Notes on each applicable trading day; (2) during the five price of approximately $14.78 per common share). On or after May 15, 2024 until the close of business on the second scheduled trading day immediately preceding the maturity of the Series II 2024 Notes, holders may convert their Series II 2024 Notes, at the option of the holder, regardless of the foregoing circumstances. The principal amount of the Series II 2024 Notes also will accrete at a rate of approximately 4.7% per year commencing June 4, 2020, compounding on a semi-annual basis. The accreted portion of the principal is payable in cash upon maturity but does not bear interest and is not convertible into the company’s common shares. The total amount accreted as of December 31, 2022 was $8,434,000 and $5,347,000 as of December 31, 2021. Remaining accretion until maturity (at current principal) was $8,188,000 as of December 31, 2022. A loss of $6,599,000 was recorded a part of the exchange transaction, which included the write-off of fees related to portions of the 2021 Notes and 2022 Notes exchanged. Debt issuance costs of $1,505,000 were capitalized and are being amortized as interest expense through November 2024. Debt issuance costs are presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. In the third quarter of 2022, $5,000,000 aggregate principal amount of Series II 2024 Notes were retired as part of the Secured 2026 Notes and Secured Term Loan transactions discussed below. The liability components of the Series II 2024 Notes consist of the following (in thousands): December 31, 2022 December 31, 2021 Principal amount of liability component - including accretion $ 77,309 $ 79,222 Debt fees (590) (971) Net carrying amount of liability component $ 76,719 $ 78,251 The effective interest rate on the liability component was 9.0% upon original issuance including consideration of the discount. Total interest expense subsequent to adoption includes coupon interest, accretion and amortization of debt fees. Non-cash interest expense, including accretion, of $3,590,000 and $3,534,000 was recognized in 2022 and 2021, respectively. Interest expense of $3,507,000 and $3,693,000 was accrued in 2022 and 2021, respectively based on the stated coupon rate of 5.0%. The effective interest rate of the Series II 2024 Notes as of December 31, 2022 including coupon interest, amortization of debt fees and accretion to maturity was 10.4%. The Series II 2024 Notes were not convertible as of December 31, 2022 nor was the applicable conversion threshold met. The company was in compliance with the Series II 2024 Notes covenants at December 31, 2022. Convertible senior notes due 2026 In the first quarter of 2021, the company issued $125,000,000 aggregate principal amount of 4.25% Convertible Senior Notes due 2026 (the “2026 Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The notes bear interest at a rate of 4.25% per year payable semi-annually in arrears on March 15 and September 15 of each year, beginning September 15, 2021. The notes will mature on March 15, 2026, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to September 15, 2025, the 2026 Notes will be convertible only upon satisfaction of c

Other Long-Term Obligations

Other Long-Term Obligations	12 Months Ended
	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities Disclosure	Other Long-Term Obligations Other long-term obligations as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Deferred income taxes $ 18,771 $ 21,664 Product liability 10,438 11,342 Deferred compensation 4,970 6,174 Deferred gain on sale leaseback 4,834 5,174 Supplemental Executive Retirement Plan liability 4,383 5,106 Uncertain tax obligation including interest 2,891 3,171 Death benefit obligation plan 2,533 4,568 Pension 1,019 7,814 Secured Convertible 2026 debt conversion liability 85 — Other 478 1,783 Other Long-Term Obligations $ 50,402 $ 66,796 The Secured Convertible 2026 debt conversion liability amounts included in the above table represent the fair values of the conversion liabilities. On April 23, 2015, the company entered into a real estate sales leaseback transaction which resulted in the recording of an initial deferred gain of $7,414,000, the majority of which is included in Other Long-Term Obligations and will be recognized over the 20-year life of the leases. The gain realized was $328,000 and $317,000 for December 31, 2022 and 2021, respectively.

Leases and Commitments

Leases and Commitments	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Lessee, Operating Leases	Leases and Commitments The company reviews new contracts to determine if the contracts include a lease. To the extent a lease agreement includes an extension option that is reasonably certain to be exercised, the company has recognized those amounts as part of the right-of-use assets and lease liabilities. The company does not combine lease and certain non-lease components, such as common area maintenance, in the calculation of the lease assets and related liabilities. As most lease agreements do not provide an implicit rate, the company uses an incremental borrowing rate (IBR) based on information available at commencement date in determining the present value of lease payments and to help classify the lease as operating or financing. The company calculates its IBR based on the secured rates of the company's recent debt issuances, the credit rating of the company, changes in currencies, lease repayment timing as well as other publicly available data. The company leases a portion of its facilities, transportation equipment, data processing equipment and certain other equipment. These leases have terms from 1 to 20 years and provide for renewal options. Generally, the company is required to pay taxes and normal expenses associated with operating the facilities and equipment. As of December 31, 2022, the company is committed under non-cancelable leases, which have initial or remaining terms in excess of one year and expire on various dates through 2040. On April 23, 2015, the company sold and leased back, under four separate lease agreements, four properties located in Ohio and one property in Florida for net proceeds of $23,000,000, which were used to reduce debt under the North America Credit Facility . The initial total annual rent for the properties was $2,275,000 and can increase annually over the 20-year term of the leases based on the applicable geographical consumer price index (CPI). Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then- current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases. In connection with the transaction, the requirements for sale lease-back accounting were met. Accordingly, the company recorded the sale of the properties, removed the related property and equipment from the company's balance sheet, recognized an initial deferred gain of $7,414,000 and an immediate loss of $257,000 related to one property and recorded new lease liabilities. Specifically, the company recorded four finance leases totaling $32,339,000 and one operating lease related to leased land, which was not a material component of the transaction. The gains on the sales of the properties were required to be deferred and recognized over the life of the leases as the property sold is being leased back. The deferred gain is classified under Other Long-Term Obligations on the consolidated balance sheet. The gains realized were $328,000, $317,000, and $305,000 in 2022, 2021, and 2020 respectively. In July of 2020, the company entered into a 19.75-year lease agreement in Germany. The lease increased the company's finance lease obligation by $38,704,000 and increased the finance lease expense compared to previous periods. Lease expenses for the year ended December 31, 2022, December 31, 2021, December 31, 2020, respectively, were as follows (in thousands): 2022 2021 2020 Operating leases $ 5,712 $ 7,394 $ 8,138 Variable and short-term leases 2,549 3,541 3,968 Total operating leases $ 8,261 $ 10,935 $ 12,106 Finance lease interest cost $ 4,256 $ 4,601 $ 2,544 Finance lease depreciation 4,246 4,996 3,479 Total finance leases $ 8,502 $ 9,597 $ 6,023 Future minimum operating and finance lease commitments, as of December 31, 2022, are as follows (in thousands): Finance Operating Leases 2023 $ 6,828 $ 4,181 2024 6,764 3,085 2025 6,667 2,482 2026 6,554 1,303 2027 6,441 395 Thereafter 62,531 1,341 Total future minimum lease payments 95,785 12,787 Amounts representing interest (34,685) (2,108) Present value of minimum lease payments 61,100 10,679 Less: current maturities of lease obligations (3,106) (3,420) Long-term lease obligations $ 57,994 $ 7,259 Supplemental cash flow amounts for the year ended December 31, 2022, December 31, 2021 and December 31, 2020, respectively, were as follows (in thousands): Cash Activity: Cash paid in measurement of amounts for lease liabilities December 31, 2022 December 31, 2021 December 31, 2020 Operating leases $ 7,618 $ 11,089 $ 12,527 Finance leases 7,260 8,166 5,316 Total $ 14,878 $ 19,255 $ 17,843 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations December 31, 2022 December 31, 2021 December 31, 2020 Operating leases $ 4,652 $ 7,491 $ 6,155 Finance leases 969 6,572 40,078 Total $ 5,621 $ 14,063 $ 46,233 Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of December 31, 2022 and December 31, 2021, respectively,: December 31, 2022 December 31, 2021 Weighted-average remaining lease term - finance leases 14.8 years 15.8 years Weighted-average remaining lease term - operating leases 4.6 years 5.0 years Weighted-average discount rate - finance leases 3.74% 6.43% Weighted-average discount rate - operating leases 9.36% 7.1%
Lessee, Finance Leases	Leases and Commitments The company reviews new contracts to determine if the contracts include a lease. To the extent a lease agreement includes an extension option that is reasonably certain to be exercised, the company has recognized those amounts as part of the right-of-use assets and lease liabilities. The company does not combine lease and certain non-lease components, such as common area maintenance, in the calculation of the lease assets and related liabilities. As most lease agreements do not provide an implicit rate, the company uses an incremental borrowing rate (IBR) based on information available at commencement date in determining the present value of lease payments and to help classify the lease as operating or financing. The company calculates its IBR based on the secured rates of the company's recent debt issuances, the credit rating of the company, changes in currencies, lease repayment timing as well as other publicly available data. The company leases a portion of its facilities, transportation equipment, data processing equipment and certain other equipment. These leases have terms from 1 to 20 years and provide for renewal options. Generally, the company is required to pay taxes and normal expenses associated with operating the facilities and equipment. As of December 31, 2022, the company is committed under non-cancelable leases, which have initial or remaining terms in excess of one year and expire on various dates through 2040. On April 23, 2015, the company sold and leased back, under four separate lease agreements, four properties located in Ohio and one property in Florida for net proceeds of $23,000,000, which were used to reduce debt under the North America Credit Facility . The initial total annual rent for the properties was $2,275,000 and can increase annually over the 20-year term of the leases based on the applicable geographical consumer price index (CPI). Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then- current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases. In connection with the transaction, the requirements for sale lease-back accounting were met. Accordingly, the company recorded the sale of the properties, removed the related property and equipment from the company's balance sheet, recognized an initial deferred gain of $7,414,000 and an immediate loss of $257,000 related to one property and recorded new lease liabilities. Specifically, the company recorded four finance leases totaling $32,339,000 and one operating lease related to leased land, which was not a material component of the transaction. The gains on the sales of the properties were required to be deferred and recognized over the life of the leases as the property sold is being leased back. The deferred gain is classified under Other Long-Term Obligations on the consolidated balance sheet. The gains realized were $328,000, $317,000, and $305,000 in 2022, 2021, and 2020 respectively. In July of 2020, the company entered into a 19.75-year lease agreement in Germany. The lease increased the company's finance lease obligation by $38,704,000 and increased the finance lease expense compared to previous periods. Lease expenses for the year ended December 31, 2022, December 31, 2021, December 31, 2020, respectively, were as follows (in thousands): 2022 2021 2020 Operating leases $ 5,712 $ 7,394 $ 8,138 Variable and short-term leases 2,549 3,541 3,968 Total operating leases $ 8,261 $ 10,935 $ 12,106 Finance lease interest cost $ 4,256 $ 4,601 $ 2,544 Finance lease depreciation 4,246 4,996 3,479 Total finance leases $ 8,502 $ 9,597 $ 6,023 Future minimum operating and finance lease commitments, as of December 31, 2022, are as follows (in thousands): Finance Operating Leases 2023 $ 6,828 $ 4,181 2024 6,764 3,085 2025 6,667 2,482 2026 6,554 1,303 2027 6,441 395 Thereafter 62,531 1,341 Total future minimum lease payments 95,785 12,787 Amounts representing interest (34,685) (2,108) Present value of minimum lease payments 61,100 10,679 Less: current maturities of lease obligations (3,106) (3,420) Long-term lease obligations $ 57,994 $ 7,259 Supplemental cash flow amounts for the year ended December 31, 2022, December 31, 2021 and December 31, 2020, respectively, were as follows (in thousands): Cash Activity: Cash paid in measurement of amounts for lease liabilities December 31, 2022 December 31, 2021 December 31, 2020 Operating leases $ 7,618 $ 11,089 $ 12,527 Finance leases 7,260 8,166 5,316 Total $ 14,878 $ 19,255 $ 17,843 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations December 31, 2022 December 31, 2021 December 31, 2020 Operating leases $ 4,652 $ 7,491 $ 6,155 Finance leases 969 6,572 40,078 Total $ 5,621 $ 14,063 $ 46,233 Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of December 31, 2022 and December 31, 2021, respectively,: December 31, 2022 December 31, 2021 Weighted-average remaining lease term - finance leases 14.8 years 15.8 years Weighted-average remaining lease term - operating leases 4.6 years 5.0 years Weighted-average discount rate - finance leases 3.74% 6.43% Weighted-average discount rate - operating leases 9.36% 7.1%

Retirement and Benefit Plans

Retirement and Benefit Plans	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Retirement and Benefit Plans	Retirement and Benefit Plans Substantially all full-time salaried and hourly domestic employees are included in the Invacare Retirement Savings Plan sponsored by the company. The company makes matching cash contributions up to 66.7% of employees' contributions up to 3% of compensation. The company also may make quarterly contributions to this Plan equal to a percentage of qualified wages. The company may make discretionary contributions to the domestic plans based on an annual resolution of the Board of Directors. Contribution expense for the Invacare Retirement Savings Plan in 2022, 2021 and 2020 was $845,000, $1,022,000 and $1,214,000, respectively. The company sponsors a Deferred Compensation Plus Plan covering certain employees, which provides for elective deferrals and the company retirement deferrals so that the total retirement deferrals equal amounts that would have contributed to the company's principal retirement plans if it were not for limitations imposed by income tax regulations. The company sponsors a non-qualified defined benefit Supplemental Executive Retirement Plan (SERP) for certain key executives. Effective December 31, 2008, the SERP was amended, in part to comply with IRS Section 409A. As a result of the amendment, the plan became a defined benefit cash balance plan for the non-retired participants and thus, payments by the company since December 31, 2008 have been based upon a cash balance formula with interest credited at a rate determined annually by the Compensation and Management Development Committee of the Board of Directors. In 2022, 2021 and 2020, respectively, interest was credited at 0% for active participants in the SERP. The plan continues to be unfunded with individual hypothetical accounts maintained for each participant. The SERP projected benefit obligation related to this unfunded plan was $4,774,000 and $5,497,000 at December 31, 2022 and December 31, 2021, respectively, and the accumulated benefit obligation was $4,774,000 and $5,497,000 at December 31, 2022 and December 31, 2021, respectively. The assumed discount rate, relevant for three participants unaffected by the plan conversion, as well as the Death Benefit Only plan discussed below was 5.02% and 2.83% for 2022 and 2021, respectively, based upon the discount rate on high-quality fixed-income investments without adjustment. The retirement age was 67 for 2022 and 2021, respectively. The mortality assumptions used for 2022 and 2021 were based upon the Pri-2012 White Collar Mortality for Males and Females projected using Scale MP-2021 and the Pri.A-2012 White Collar Fully Generational Mortality Table projected using Scale MP-2021, respectively. SERP income for 2022 was $332,000, compared to SERP expense in 2021 and 2020 of $129,000 and $326,000, respectively. The expense was composed of interest income in 2022 of $541,000, and interest expense in 2021 and 2020 of $4,000 and $213,000, respectively, with the remaining non-interest expense related to service costs, prior service costs and other gains/losses. Benefit payments in 2022, 2021 and 2020 were $391,000 in each year. The company also sponsors a Death Benefit Only Plan (DBO) for certain key executives that provides a benefit equal to three times the participant's final target earnings should the participant's death occur while an employee and a benefit equal to one time the participant's final earnings upon the participant's death if a participant dies after his or her employment with the company is terminated following a change in control of the company. Income for the plan in 2022 was $1,099,000, driven by an increase in the discount rate and participant turnover, compared to expense in 2021 and 2020 of $30,000, and $640,000, respectively. The 2022 and 2021 amounts included service and accrual adjustment income of $1,274,000 and $68,000, respectively, compared to 2020 amounts which included service and accrual adjustment expense of $569,000, with the remaining activity in each year related to interest costs. There were no benefit payments in 2022, 2021 and 2020. The projected benefit obligations for the plan were calculated using an assumed future salary increase of 3.25% at December 31, 2022 and 2021, respectively. In conjunction with the company's DBO, the company has invested in life insurance policies related to certain employees to help satisfy the DBO obligations. In Europe, the company maintains a defined benefit plan in Switzerland. The statutory pension plan is maintained with a private insurance company and, in accordance with Swiss law, the plan functions as a defined contribution plan whereby employee and employer contributions are defined as a percentage of individual salary depending on the age of the employee and a guaranteed interest rate, which is annually defined by the Swiss Pension Fund. Under U.S. GAAP, the plan is treated as defined benefit plan. Income for 2022 and 2021 for the European plan was $633,000 and $823,000, respectively, compared to expense of $1,678,000 in 2020.

Revenues (Notes)

Revenues (Notes)	12 Months Ended
	Dec. 31, 2022
Revenue Recognition [Abstract]
Revenue Disclosure	Revenue The company has two revenue streams: products and services. Services include repair, refurbishment, preventive maintenance and rental of products. Services for the North America (N.A.) segment include maintenance and repair of products. Services for the Europe segment include repair, refurbishment and preventive maintenance services. Services in All Other, are in the Asia Pacific region, and include rental and repair of products. The following tables disaggregate the company's revenues by major source and by reportable segment for the year ended December 31, 2022 and December 31, 2021 (in thousands): 2022 Products Service Total Europe $ 422,440 $ 11,932 $ 434,372 N.A. 275,508 1,383 276,891 All Other 25,592 4,878 30,470 Total $ 723,540 $ 18,193 $ 741,733 % Split 98% 2% 100% 2021 Products Service Total Europe $ 486,190 $ 12,928 $ 499,118 N.A. 340,269 711 340,980 All Other 27,221 5,138 32,359 Total $ 853,680 $ 18,777 $ 872,457 % Split 98% 2% 100% The company's revenues are principally related to the sale of products, approximately 98%, with the remaining 2% related to services including repair, refurbishment, preventive maintenance and rental of products. While the company has a significant amount of contract types, the sales split by contract type is estimated as follows: general terms and conditions (25%), large national customers (20%), governments, principally pursuant to tender contracts (23%) and other customers including buying groups and independent customers (32%). All product revenues and substantially all service revenues are recognized at a point in time. The remaining service revenue, recognized over time, are reflected in the Europe segment and include multiple performance obligations. For such contracts, the company allocates revenue to each performance obligation based on its relative standalone selling price. The company generally determines the standalone selling price based on the expected cost-plus margin methodology. Revenue is recognized when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the company's products and services. The amount of consideration received and revenue recognized by the company can vary as a result of variable consideration terms included in the contracts related to customer rebates, cash discounts and return policies. Revenue is measured as the amount of consideration probable of not having a significant reversal of cumulative revenue recognized when related uncertainties are resolved. Customer rebates and cash discounts are estimated based on the most likely amount principle and these estimates are based on historical experience and anticipated performance. In addition, customers have the right to return products within the company's normal terms policy, and as such the company estimates the expected returns based on an analysis of historical experience. The company adjusts its estimate of revenue at the earlier of when the most likely amount of consideration it expects to receive changes or when the consideration becomes fixed. The company generally does not expect that there will be significant changes to its estimates of variable consideration (refer to “Receivables” and “Accrued Expenses” in the Notes to the Consolidated Financial Statements include elsewhere in this report for more detail). Depending on the terms of the contract, the company may defer the recognition of a portion of the revenue at the end of a reporting period to align with transfer of control of the company's products to the customer. In addition, to the extent performance obligations are satisfied over time, the company defers revenue recognition until the performance obligations are satisfied. As of December 31, 2022 and December 31, 2021, the company had deferred revenue of $2,279,000 and $4,156,000, respectively, related to outstanding performance obligations.

Equity Compensation

Equity Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Equity Compensation	Equity Compensation The company's common shares have a $0.25 stated value. The common shares and the Class B common shares generally have identical rights, terms and conditions and vote together as a single class on most issues, except that the Class B common shares have ten votes per share and, in general, can only be transferred to family members or for estate planning purposes. Holders of Class B common shares are entitled to convert their shares into common shares at any time on a share-for-share basis. When Class B common shares are transferred out of a familial relationship, they automatically convert to common shares. As of December 31, 2022, 3,667 Class B common shares remained outstanding. Prior conversions of Class B common shares have virtually eliminated the company's dual class voting structure. As of December 31, 2022, the holders of the common shares represented approximately 99.9% of the company's total outstanding voting power. Equity Compensation Plan On May 17, 2018, the shareholders of the company approved the Invacare Corporation 2018 Equity Compensation Plan (the “2018 Plan”), which was adopted on March 27, 2018 by the company's Board of Directors (the “Board”). The company's Board adopted the 2018 Plan in order to authorize additional Common Shares for grant as equity compensation, and to reflect changes to Section 162(m) of the Internal Revenue Code (the “Code”) resulting from the U.S. Tax Cuts and Jobs Act of 2017. Following shareholder approval of the 2018 Plan, all of the common shares then-remaining available for issuance under the Invacare Corporation 2013 Equity Compensation Plan (the “2013 Plan”) and all of the common shares that were forfeited or remained unpurchased or undistributed upon termination or expiration of awards under the 2013 Plan and under the Invacare Corporation 2003 Performance Plan (the “2003 Plan”), become available for issuance under the 2018 Plan. Awards granted previously under the 2013 Plan and 2003 Plan will remain in effect under their original terms. The 2018 Plan uses a fungible share-counting method, under which each common share underlying an award of stock options or stock appreciation rights (“SAR”) will count against the number of total shares available under the 2018 Plan as one share; and each common share underlying any award other than a stock option or a SAR will count against the number of total shares available under the 2018 Plan as two shares. Shares underlying awards made under the 2003 Plan or 2013 Plan that are forfeited or remain unpurchased or undistributed upon termination or expiration of the awards will become available under the 2018 Plan for use in future awards. Any common shares that are added back to the 2018 Plan as the result of forfeiture, termination or expiration of an award granted under the 2018 Plan or the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2018 Plan or 2013 Plan, as applicable. Each common share that is added back to the 2018 Plan due to a forfeiture, termination or expiration of an award granted under the 2003 Plan will be added back as one common share. The Compensation and Management Development Committee of the Board (the “Compensation Committee”), in its discretion, may grant an award under the 2018 Plan to any director or employee of the company or an affiliate. As of December 31, 2022, common shares of 5,285,644 were available for future issuance under the 2018 Plan in connection with the following types of awards with respect to the company's common shares: incentive stock options, nonqualified stock options, SARs, restricted stock, restricted stock units, unrestricted stock and performance shares. The Compensation Committee also may grant performance units that are payable in cash. The Compensation Committee has the authority to determine which participants will receive awards, the amount of the awards and the other terms and conditions of the awards. The 2018 Plan provides that shares granted come from the company's authorized but unissued common shares or treasury shares. In addition, the company's stock-based compensation plans allow employee participants to exchange shares for minimum withholding taxes, which results in the company acquiring treasury shares. Under these provisions, the company acquired approximately 139,000 treasury shares for $151,000 in 2022, 213,000 shares for $1,754,000 in 2021 and 231,000 shares for $1,707,000 in 2020. The amounts of equity-based compensation expense (income) recognized as part of SG&A expenses in All Other in business segment reporting were as follows (in thousands): 2022 2021 2020 Restricted stock / units 2,924 5,450 5,332 Performance shares / units (844) (1,127) 3,313 Total stock-based compensation expense $ 2,080 $ 4,323 $ 8,645 As of December 31, 2022, unrecognized compensation expense related to equity-based compensation arrangements granted under the company's 2018 Plan and previous plans, which is related to non-vested shares, was as follows (in thousands): 2022 2021 2020 Restricted stock and restricted stock units 2,146 6,866 7,489 Performance shares and performance share units 75 1,746 7,260 Total unrecognized stock-based compensation expense $ 2,221 $ 8,612 $ 14,749 Total unrecognized compensation cost will be adjusted for future changes in actual and estimated forfeitures and for updated vesting assumptions for the performance share awards (refer to “Stock Options” and “Performance Shares and Performance Share Units” below). No tax benefits for stock compensation were realized during 2022, 2021 and 2020 due to a valuation allowance against deferred tax assets. In accordance with ASC 718, any tax benefits resulting from tax deductions in excess of the compensation expense recognized is classified as a component of financing cash flows. Stock Options Generally, non-qualified stock option awards have a term of ten years and were granted with an exercise price per share equal to the fair market value of the company's common shares on the date of grant. The following table summarizes information about stock option activity for the three years ended 2022, 2021 and 2020: 2022 Weighted 2021 Weighted 2020 Weighted Options outstanding at January 1 750,159 $ 12.69 1,081,804 $ 16.07 1,441,202 $ 18.26 Forfeited (560,470) 12.44 (331,645) 23.71 (359,398) 24.84 Options outstanding at December 31 189,689 $ 13.43 750,159 $ 12.69 1,081,804 $ 16.07 Options exercise price range at December 31 $ 12.15 $ 12.15 $ 12.15 to to to $ 14.49 $ 17.47 $ 33.36 Options exercisable at December 31 189,689 750,159 1,081,804 Shares available for grant at December 31* 5,285,644 3,475,496 3,540,534 ________________________ * Shares available for grant under the 2018 Plan as of December 31, 2022 reduced by awards and increased by forfeitures or expirations. At December 31, 2022, an aggregate of 1,363,107 common shares underlie awards which were forfeited or expired unexercised under the 2003 and 2013 Plans and thus are available for future issuance under the 2018 Plan upon transfer. The following table summarizes information about stock options outstanding at December 31, 2022: Options Outstanding Options Exercisable Exercise Prices Number Weighted Average Weighted Average Number Weighted Average $12.15 – $20.00 189,689 2.0 $ 13.43 189,689 $ 13.43 The 2018 Plan provides for a one-year minimum vesting period for stock options and, generally, options must be exercised within ten years from the date granted. No stock options were issued in 2022, 2021 or 2020. Restricted Stock and Restricted Stock Units The following table summarizes information about restricted stock and restricted stock units (primarily for non-U.S. recipients): 2022 Weighted Average Fair Value 2021 Weighted Average Fair Value 2020 Weighted Average Fair Value Stock / Units unvested at January 1 1,160,847 $ 8.17 1,145,058 $ 8.62 965,085 $ 11.32 Granted 1,341,019 1.22 652,743 8.42 764,012 7.11 Vested (803,550) 5.94 (558,424) 9.33 (475,113) 11.39 Forfeited (636,449) 4.40 (78,530) 8.44 (108,926) 9.90 Stock / Units unvested at December 31 1,061,867 $ 2.75 1,160,847 $ 8.17 1,145,058 $ 8.62 The restricted stock awards generally vest ratably over the three years after the award date. Unearned restricted stock compensation, determined as the market value of the shares at the date of grant, is being amortized on a straight-line basis over the vesting period as adjusted for forfeiture estimates. Performance Shares and Performance Share Units The following table summarizes information about performance shares and performance share units (primarily for non-U.S. recipients): 2022 Weighted Average Fair Value 2021 Weighted Average Fair Value 2020 Weighted Average Fair Value Shares / Units unvested at January 1 972,288 $ 7.76 1,026,785 $ 8.55 753,272 $ 11.82 Granted 460,187 1.48 471,819 8.49 523,329 7.82 Vested — — — — (183,840) 17.48 Forfeited (1,114,404) 5.92 (526,316) 9.25 (65,976) 9.48 Shares / Units unvested at December 31 318,071 $ 5.15 972,288 $ 7.76 1,026,785 $ 8.55 During 2022, 2021 and 2020, the performance shares and performance share units (for non-U.S. recipients) were granted. Performance awards have a three upon vesting. The number of shares earned will be determined at the end of the three-year performance period based on achievement of performance criteria for January 1, 2020 through December 31 2022, January 1, 2021 through December 31 2023 and January 1, 2022 through December 31, 2024, respectively, established by the

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss) by Component	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss) by Component	Accumulated Other Comprehensive Income (Loss) by Component Changes in accumulated other comprehensive income (loss) (“OCI”) during the year ended December 31, 2022 were as follows (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2021 $ 18,961 $ 2,127 $ (4,101) $ 1 $ 16,988 OCI before reclassifications (42,840) (5,357) 6,953 3,483 (37,761) Amount reclassified from accumulated OCI — — (466) (3,484) (3,950) Net current-period OCI (42,840) (5,357) 6,487 (1) (41,711) December 31, 2022 $ (23,879) $ (3,230) $ 2,386 $ — $ (24,723) Changes in OCI during the year ended December 31, 2021 were as follows (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2020 $ 50,329 $ (517) $ (3,674) $ (702) $ 45,436 OCI before reclassifications (31,368) 2,644 (457) (557) (29,738) Amount reclassified from accumulated OCI — — 30 1,260 1,290 Net current-period OCI (31,368) 2,644 (427) 703 (28,448) December 31, 2021 $ 18,961 $ 2,127 $ (4,101) $ 1 $ 16,988 Reclassifications out of accumulated OCI for the year ended December 31, 2022 and December 31, 2021 were as follows (in thousands): Amount reclassified from OCI Affected line item in the Statement of Comprehensive (Income) Loss 2022 2021 Defined Benefit Plans: Service and interest costs $ (466) $ 30 Selling, general and administrative Tax — — Income taxes Total after tax $ (466) $ 30 Derivatives: Foreign currency forward contracts hedging sales $ (137) $ 1,058 Net sales Foreign currency forward contracts hedging purchases (3,610) 428 Cost of products sold Total loss (income) before tax (3,747) 1,486 Tax 263 (226) Income taxes Total after tax $ (3,484) $ 1,260

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Capital Stock	Capital Stock Capital stock activity for 2022, 2021 and 2020 consisted of the following (in thousands of shares): Common Stock Class B Treasury December 31, 2020 Balance 38,613 4 (4,184) Restricted and performance stock awards 803 — (213) December 31, 2021 Balance 39,416 4 (4,397) Restricted and performance stock awards 424 — (139) Issuance of common shares 2,700 — — December 31, 2022 Balance 42,540 4 (4,536) Restricted stock and restricted stock unit awards of 636,449, 78,530 and 108,926 shares were forfeited in 2022, 2021 and 2020, respectively. On July 26, 2022, as part of the transactions for the closing of the Secured Term Loan and exchange of the 2026 Notes for Secured 2026 Notes, 2,700,000 common shares were issued.

Charges Related To Restructurin

Charges Related To Restructuring Activities	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Charges Related To Restructuring Activities	Charges Related to Restructuring Activities The company's restructuring charges were originally necessitated primarily by continued declines in Medicare and Medicaid reimbursement by the U.S. government, as well as similar healthcare reimbursement pressures abroad, which negatively affected the company's customers (e.g. home health care providers) and continued pricing pressures faced by the company due to the outsourcing by competitors to lower cost locations. Restructuring decisions were also the result of reduced profitability in each of the segments. Restructuring actions have continued into 2022. Charges for the year ended December 31, 2022 totaled $25,820,000 which were related to North America ($10,646,000), Europe ($13,918,000) and All Other ($1,256,000). Charges were related to severance costs and other restructuring costs (primarily advisory professional fees). The accrual balance at December 31, 2022 is expected to be paid out within 12 months. Charges for the year ended December 31, 2021 totaled $2,534,000 which were related to North America ($964,000), Europe ($1,560,000) and All Other ($10,000). The North America and All Other costs were for severance costs. The European charges were incurred related to severance ($886,000) and lease termination costs of ($674,000) related to the closure of a German manufacturing facility. Charges for the year ended December 31, 2020 totaled $7,358,000 which were related to North America ($1,306,000), Europe ($5,934,000) and All Other ($118,000). The North America and All Other costs were for severance costs. The European charges were incurred related to severance ($5,588,000) and lease termination costs ($346,000) primarily related to the closure of a German Manufacturing facility. There have been no material changes in accrued balances related to the charges, either as a result of revisions to the plans or changes in estimates. In addition, the savings anticipated as a result of the company's restructuring plans have been or are expected to be achieved, primarily resulting in reduced salary and benefit costs principally impacting selling, general and administrative expenses, and to a lesser extent, costs of products sold. To date, the company's liquidity has been sufficient to absorb these charges and payments. A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands): Severance Other Total January 1, 2020 Balance North America 211 — 211 Europe 6,406 4 6,410 All Other 406 — 406 Total 7,023 4 7,027 Charges North America 1,306 — 1,306 Europe 5,588 346 5,934 All Other 118 — 118 Total 7,012 346 7,358 Payments North America (1,338) — (1,338) Europe (6,090) (346) (6,436) All Other (358) — (358) Total (7,786) (346) (8,132) December 31, 2020 Balance North America 179 — 179 Europe 5,904 4 5,908 All Other 166 — 166 Total 6,249 4 6,253 Severance Other Total Charges North America 964 — 964 Europe 886 674 1,560 All Other 10 — 10 Total 1,860 674 2,534 Payments North America (661) — (661) Europe (6,790) (678) (7,468) All Other (176) — (176) Total (7,627) (678) (8,305) December 31, 2021 Balance North America 482 — 482 Total $ 482 $ — $ 482 Charges North America 2,472 8,174 10,646 Europe 5,359 8,559 13,918 All Other 1,256 — 1,256 Total $ 9,087 $ 16,733 $ 25,820 Payments North America (1,987) (5,148) (7,135) Europe (4,045) (7,066) (11,111) All Other (65) — (65) Total $ (6,097) $ (12,214) $ (18,311) December 31, 2022 Balance North America 967 3,026 3,993 Europe 1,314 1,493 2,807 All Other 1,191 — 1,191 Total $ 3,472 $ 4,519 $ 7,991

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Earnings (loss) before income taxes consist of the following (in thousands): 2022 2021 2020 Domestic $ (95,070) $ (53,916) $ (42,213) Foreign (2,931) 14,798 17,774 $ (98,001) $ (39,118) $ (24,439) The company has provided for income taxes (benefits) as follows (in thousands): 2022 2021 2020 Current: Federal $ 362 $ 85 $ 45 State (105) (12) (180) Foreign 3,054 6,596 6,168 3,311 6,669 6,033 Deferred: Federal — (662) (26) State — — — Foreign (241) 438 (2,166) (241) (224) (2,192) Income Taxes $ 3,070 $ 6,445 $ 3,841 The 2021 deferred federal benefit results from the goodwill impairment the company recorded, a reversal of deferred taxes related to the tax-deductible goodwill previously deducted by the company, resulting in the company recognizing a tax benefit of $662,000. The company has historically considered the undistributed earnings of the company's foreign subsidiaries to be indefinitely reinvested, and, accordingly, no taxes have been provided on such earnings (other than earnings from the company's Chinese subsidiary which was sold in March 2020 as part of the sale of the Dynamic business). The company reversed withholding taxes in the amount of $988,000 which were previously provided as a result of the company position that the earnings from the Chinese subsidiary were not permanently reinvested. The sale of the business occurred without dividends paid from this subsidiary. The company continues to evaluate its plans for reinvestment or repatriation of unremitted foreign. As a result of U.S. tax reform legislation, distributions of profits from non-U.S. subsidiaries are not expected to cause a significant incremental U.S. tax impact in the future. However, these distributions may be subject to non-U.S. withholding taxes if profits are distributed from certain jurisdictions. Undistributed profits of non-U.S. subsidiaries of approximately $38,702,000 are considered indefinitely reinvested. Determination of the amount of unrecognized deferred tax liability related to indefinitely reinvested profits is not practicable. The company regularly reviews its cash positions and its determination of permanent reinvestment of foreign earnings. If the company determines all or a portion of such foreign earnings are no longer indefinitely reinvested, the company may be subject to additional foreign withholding taxes and U.S. state income taxes. A reconciliation to the effective income tax rate from the federal statutory rate is as follows: 2022 2021 2020 Statutory federal income tax rate (benefit) (21.0) % (21.0) % (21.0) % State and local income taxes, net of federal income tax benefit (0.1) — (0.6) Non-taxable disposition of subsidiaries — — (11.2) Expiring foreign tax credits 0.2 1.7 16.5 Foreign taxes at other than the federal statutory rate 1.0 3.9 8.8 Federal and foreign valuation allowances 21.3 20.4 (4.3) Withholding taxes — 0.1 0.1 Unremitted earnings — — (4.0) Debt repurchase — — 3.2 Foreign branch activity 1.0 4.0 19.3 Uncertain tax positions — 0.6 2.9 Nontaxable loan forgiveness — (5.4) — Foreign goodwill write-off — 9.0 — Other, net 0.7 3.2 6.0 Effective federal income tax rate 3.1 % 16.5 % 15.7 % At December 31, 2022, total deferred tax assets were $221,178,000, total deferred tax liabilities were $40,050,000 and the tax valuation allowances total was $198,797,000 for a net deferred income tax liability of $17,669,000 compared to total deferred tax assets of $200,042,000, total deferred tax liabilities of $43,936,000 and a tax valuation allowances total of $176,230,000 for a net deferred income tax liability of $20,124,000 at December 31, 2021. The company recorded a valuation allowance for its U.S. and certain foreign country net deferred tax assets where it is or is projected to be in a three-year cumulative loss. Significant components of long-term deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows (in thousands): 2022 2021 Bad debt $ 483 $ 387 Warranty 1,011 1,426 Other accrued expenses and reserves 398 484 Inventory 4,625 3,624 Goodwill and intangibles (17,556) (19,910) Convertible debt 3,327 5,193 Fixed assets (22,494) (24,026) Compensation and benefits 3,432 4,271 Loss and credit carryforwards 149,853 127,397 Product liability 870 1,596 State and local taxes 37,584 34,794 Valuation allowances (198,797) (176,230) Lease liability 17,496 19,649 Other, net 2,099 1,221 Net Deferred Income Taxes $ (17,669) $ (20,124) The company made net payments for income taxes of $3,999,000, $6,877,000, and $4,377,000 during the years ended December 31, 2022, 2021 and 2020, respectively. The company has a federal domestic net operating loss carryforward of $465,473,000 of which $276,315,000 expires between 2034 and 2037 and the remaining are non-expiring; domestic interest carryforward of $133,697,000 which is non-expiring and federal tax credit carryforwards of $11,028,000 of which $9,071,000 expires between 2024 and 2027, and $1,957,000 expires beginning 2031. At December 31, 2022, the company also had $690,125,000 of domestic state and local tax loss carryforwards, of which $124,958,000 expire between 2023 and 2026, $361,184,000 expire between 2027 and 2036 and $156,384,000 expire after 2036 and $47,599,000 have an unlimited carryforward. At December 31, 2022, the company had foreign federal tax loss carryforwards of approximately $60,463,000 of which $12,899,000 expire between 2023 and 2026, $20,080,000 expire after 2027 and the remaining are non-expiring all of which are offset by valuation allowances, except for $2,511,000. Additionally, the company had foreign local tax loss carryforwards of $18,376,000 expiring after 2027 subject to valuation allowance. As of December 31, 2022 and 2021, the company had a liability for uncertain tax positions, excluding interest and penalties of $2,368,000 and $2,646,000, respectively. The total liabilities associated with unrecognized tax benefits that, if recognized, would impact the effective tax rates were $2,368,000 and $2,646,000 at December 31, 2022 and 2021, respectively. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): 2022 2021 Balance at beginning of year $ 3,149 $ 3,262 Additions to: Positions taken during the current year 13 238 Positions taken during a prior year — 3 Exchange rate impact — — Deductions due to: Exchange rate impact (139) (66) Positions taken during a prior year (11) (76) Lapse of statute of limitations (216) (212) Balance at end of year $ 2,796 $ 3,149 The company recognizes interest and penalties associated with uncertain tax positions in income tax expense. During 2022, 2021 and 2020 the expense (benefit) for interest and penalties was $(2,000), $15,000 and $(20,000), respectively. The company had approximately $523,000 and $525,000 of accrued interest and penalties as of December 31, 2022 and 2021, respectively. The company and its subsidiaries file income tax returns in the U.S. and certain foreign jurisdictions. The company is subject to U.S. federal income tax examinations for calendar years 2019 to 2022 with limited

Net Earnings (Loss) Per Common

Net Earnings (Loss) Per Common Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Earnings (Loss) Per Common Share	Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated. 2022 2021 2020 (In thousands, except per share data) Basic Weighted average common shares outstanding 36,517 34,875 34,266 Net loss $ (101,071) $ (45,563) $ (28,280) Net loss per common share $ (2.77) $ (1.31) $ (0.83) Diluted Weighted average common shares outstanding 36,517 34,875 34,266 Stock options and awards 112 399 109 Weighted average common shares assuming dilution 36,629 35,274 34,375 Net loss $ (101,071) $ (45,563) $ (28,280) Net loss per common share * $ (2.77) $ (1.31) $ (0.83) * Net loss per share assuming dilution calculated utilizing weighted average shares outstanding - basic for the periods in which there was a net loss. At December 31, 2022, 2021 and 2020, incremental shares associated with equity compensation plans of 817,295, 1,414,155 and 2,275,832, respectively, were excluded from the average common shares assuming dilution, as they were anti-dilutive. At December 31, 2022, the majority of the anti-dilutive shares were granted at an exercise price above $12.14, which was higher than the average fair market value price of $1.26 for 2022. In 2021, the majority of the anti-dilutive shares were granted at an exercise price above $12.14, which was higher than the average fair market value price of $7.13 for 2021. In 2020, the majority of the anti-dilutive shares were granted at an exercise price above $12.14, which was higher than the average fair market value price of $7.42 for 2020. For 2022, 2021 and 2020 the diluted net loss per share calculation, all the shares associated with stock options were anti-dilutive because of the company's loss.

Concentration Of Credit Risk

Concentration Of Credit Risk	12 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Concentration Of Credit Risk	Concentration of Credit Risk The company manufactures and distributes durable medical equipment to the home health care, retail and extended care markets. The company performs credit evaluations of its customers' financial condition. The company utilizes De Lage Landen, Inc. (“DLL”), a third-party financing company, to provide lease financing to Invacare's U.S. customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The company retains a recourse obligation of $2,573,000 at December 31, 2022 to DLL for events of default under the contracts, which total $8,074,000 at December 31, 2022. Guarantees, ASC 460, requires the company to record a guarantee liability as it relates to the limited recourse obligation. As such, the company has recorded an immaterial liability for this guarantee obligation within other long-term obligations. The company's recourse is reevaluated by DLL biannually, considers activity between the biannual dates and excludes any receivables purchased by the company from DLL. The company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4 . Credit losses are provided for in the financial statements. Substantially all the company's receivables are due from health care, medical equipment providers and long-term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe or also direct from governmental entities in certain countries. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. Changes in these programs can have a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the company's customers. The company's top 10 customers accounted for approximately 21.6% of 2022 net sales. The loss of business of one or more of these customers may have a significant impact on the company, although no single customer accounted for more than 6.6% of the company's 2022 net sales. Providers who are part of a buying group generally make individual purchasing decisions and are invoiced directly by the company.

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives ASC 815 requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. Cash Flow Hedging Strategy The company uses derivative instruments in an attempt to manage its exposure to transactional foreign currency exchange risk. Foreign forward exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. The company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. All of the company's derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change. To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the consolidated statement of comprehensive income (loss). If it is later determined that a hedged forecasted transaction is unlikely to occur, any prospective gains or losses on the forward contracts would be recognized in earnings. The company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months. The company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the company generally limits its hedges to between 50% and 90% of total forecasted transactions for a given entity's exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, most of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $95,160,000 and $122,624,000 matured during the twelve months ended December 31, 2022 and 2021, respectively. Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD): December 31, 2022 December 31, 2021 Notional Unrealized Notional Unrealized USD / MXN — — 23 1 $ — $ — $ 23 $ 1 Derivatives Not Qualifying or Designated for Hedge Accounting Treatment The company utilizes foreign currency forward contracts that are not designated as hedges in accordance with ASC 815. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The currency forward contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward contract. No material net gain or loss was realized by the company in 2022 or 2021 related to these contracts and the associated short-term intercompany trading receivables and payables. Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment, as well as ineffective hedges, entered into in 2022 and 2021, respectively, and outstanding were as follows (in thousands USD): December 31, 2022 December 31, 2021 Notional Gain Notional Gain USD / AUD $ — $ — $ 3,792 $ (57) USD / CAD — — 14,556 $ (24) USD / EUR 60,964 980 70,454 (1,104) USD / DKK — — 10,850 (257) USD / GBP — — 4,028 32 AUD / NZD — — 7,366 (17) USD / NOK — — 2,352 (81) USD / SEK — — 2,344 (131) USD / THB — — 4,500 86 $ 60,964 $ 980 $ 120,242 $ (1,553) The fair values of the company's derivative instruments were as follows (in thousands): December 31, 2022 December 31, 2021 Assets Liabilities Assets Liabilities Derivatives designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts $ — $ — $ 1 $ — Derivatives not designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts 1,117 137 385 1,938 Total derivatives $ 1,117 $ 137 $ 386 $ 1,938 The fair values of the company's foreign currency forward exchange contract assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the Consolidated Balance Sheets. The effect of derivative instruments on Accumulated Other Comprehensive Income (OCI) and the Consolidated Statements of Comprehensive Income (Loss) was as follows (in thousands): Derivatives (foreign currency forward exchange contracts) in ASC 815 cash flow hedge relationships Amount of Gain Amount of Gain (Loss) Amount of Gain (Loss) Year ended December 31, 2022 $ 3,483 $ 3,484 $ — Year ended December 31, 2021 $ (557) $ (1,260) $ — Derivatives (foreign currency forward exchange contracts) not designated as hedging instruments under ASC 815 Amount of Gain (Loss) Year ended December 31, 2022 $ 980 Year ended December 31, 2021 $ (1,553) The gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward contracts are recognized in net sales for hedges of inventory sales and in cost of products sold for hedges of inventory purchases. In 2022, net sales were increased by $ 137,000 3,610,000 1,058,000 428,000 1,359,000 2,826,000 A gain of $ 980,000 1,553,000 703,000 The company's derivative agreements provide the counterparties with a right of set off in the event of a default. The right of set off would enable the counterparty to offset any net payment due by the counterparty to the company under the applicable agreement by any amount due by the company to the counterparty under any other agreement. For example, the terms of the agreement would permit a counterparty to a derivative contract that is also a lender under the company's Prior Credit Agreement and ABL Credit Agreement to reduce any derivative settlement amounts owed to the company under the derivative contract by any amounts owed to the counterparty by the company under the Prior Credit Agreement and ABL Credit Agreement. In addition, the agreements contain cross-default provisions that could trigger a default by the company under the agreement in the event of a default by the company under another agreement with the same counterparty. Subsequent to year-end, as a result of the Debtors filing for bankruptcy, any outstanding cash flow hedges were required to be settled and the company is not able to enter into such transactions while in Bankruptcy. During 2022, the company entered into privately negotiated Secured Convertible 2026 Notes of $41,475,000 in aggregate principal amount. Convertible debt conversion liabilities of $1,595,000 were recorded based on initial fair values and these fair values are updated quarterly with the offset to the income statement. Refer to “Long-Term Debt” in the notes to the consolidated financial statements for more detail. The fair values of the outstanding convertible note derivatives as of December 31, 2022 and their effect on the Statement of Comprehensive Income (Loss) were as follows (in thousands): Fair Value Gain Secured Convertible 2026 Notes conversion long-term liability $ 85 $ 1,510

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Values Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level I, II or III priority, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable. The following table provides a summary of the company's assets and liabilities that are measured on a recurring basis (in thousands): Basis for Fair Value Measurements at Reporting Date Quoted Prices in Active Markets Significant Significant Level I Level II Level III December 31, 2022 Forward exchange contracts—net — $ 980 — Secured convertible 2026 debt conversion liability — (85) — December 31, 2021 Forward exchange contracts—net — $ (1,552) — The carrying and fair values of the company's financial instruments at December 31, 2022 and 2021 are as follows (in thousands): 2022 2021 Carrying Fair Value Carrying Fair Value Cash and cash equivalents $ 58,792 $ 58,792 $ 83,745 $ 83,745 Forward contracts in Other Current Assets 1,117 1,117 386 386 Forward contracts in Accrued Expenses (137) (137) (1,938) (1,938) Total debt (including current maturities of long-term debt) * (354,241) (278,027) (308,129) (259,472) 2022 Notes — — (2,642) (2,632) Series I 2024 Notes (72,408) (62,460) (72,140) (64,897) Series II 2024 Notes (76,719) (64,678) (78,251) (74,165) 2026 Notes (67,665) (32,276) (119,036) (81,718) 2026 Secured Notes (37,240) (34,341) — — 2026 Term Loan (82,808) (66,871) — — Other (17,401) (17,401) (36,060) (36,060) Secured Convertible 2026 debt conversion liability in Other Long-Term Obligations (85) (85) — — ________ * The company's total debt is shown net of discount and fees associated with the convertible senior notes and term loan due in 2022, 2024 and 2026 on the company's consolidated balance sheets. Accordingly, the fair values due in 2022, 2024 and 2026 are included in the long-term debt presented in this table are also shown net of the discount and fees. Total debt amounts exclude operating and finance lease obligations. The company, in estimating its fair value disclosures for financial instruments, used the following methods and assumptions: Cash, cash equivalents: The carrying values reported in the balance sheet for cash, cash equivalents equal their fair values. The fair values are deemed to be categorized as Level 1. Forward Contracts: The company operates internationally, and as a result, is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany loans and third-party sales or payments. In an attempt to reduce this exposure, foreign currency forward contracts are utilized and accounted for as hedging instruments. The forward contracts are used to hedge the following currencies: AUD, CAD, DKK, EUR, GBP, MXN, NOK, NZD, SEK, THB, and USD. The company does not use derivative financial instruments for speculative purposes. Fair values for the company’s foreign exchange forward contracts are based on quoted market prices for contracts with similar maturities. The fair values are deemed to be categorized as Level 2. The company's forward contracts are included in Other Current Assets or Accrued Expenses in the condensed consolidated balance sheets. Total debt: Fair value for the company’s convertible debt other than the 2026 Secured Notes and Secured Term Loan is based on quoted market-based estimates as of the end of the period, while the revolving credit facility fair value is based on an estimate of the market for similar borrowing arrangements. The fair values are deemed to be categorized as Level 2 in the fair value hierarchy. The 2026 Secured Notes and Secured Term Loan fair values are based on valuation models in which significant inputs are observable in active markets. The fair values are deemed to be categorized as Level 2. Other total debt is primarily attributable to credit facilities borrowings where the carrying value reported in the balance approximates its fair value. Convertible debt derivative: The fair value for the convertible debt conversion liability is based on valuation models in which significant inputs are observable in active markets. The fair values are deemed to be categorized as Level 2.

Business Segments

Business Segments	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Business Segments	Business Segments The company operates in two primary business segments: North America and Europe with each selling the company's primary product categories, which include: lifestyle and mobility and seating products. Sales in Asia Pacific are reported in All Other and include products similar to those sold in North America and Europe. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the company's consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Segment performance is measured and resources are allocated based on a number of factors, with the primary income or loss measure being segment operating income (loss). Segment operating income (loss) represents net sales less cost of products sold less selling general and administrative expenses. Segment operating income (loss) excludes unallocated corporate general and administrative expenses not allocated to the segments and intersegment sales and profit eliminations, which are included in All Other. In addition, segment operating income (loss) further excludes charges related to restructuring activities, asset impairments and gain (loss) on sale of business (as applicable). This performance measure, segment operating income (loss), is used by the Chief Operating Decision Maker (CODM) for purposes of making decisions about allocating resources to a segment and assessing its performance. In addition, this metric is reviewed by the company's Board of Directors regarding segment performance and is a key metric in the performance management assessment of the company's employees. The information by segment is as follows (in thousands): 2022 2021 2020 Revenues from external customers Europe (1) $ 434,372 $ 499,118 $ 468,041 North America (2) 276,891 340,980 348,307 All Other (Asia Pacific) 30,470 32,359 34,341 Consolidated $ 741,733 $ 872,457 $ 850,689 Intersegment revenues Europe $ 14,708 $ 21,864 $ 17,384 North America 32,229 56,681 80,748 All Other (Asia Pacific) — — 2,528 Consolidated $ 46,937 $ 78,545 $ 100,660 Restructuring charges before income taxes Europe $ 13,918 $ 1,560 $ 5,934 North America 10,646 964 1,306 All Other 1,256 10 118 Consolidated $ 25,820 $ 2,534 $ 7,358 Depreciation and amortization Europe $ 6,513 $ 8,557 $ 7,615 North America 8,427 7,623 6,013 All Other (3) 551 641 689 Consolidated $ 15,491 $ 16,821 $ 14,317 Net interest expense Europe $ 483 $ 2,790 $ 1,884 North America 27,773 21,764 26,510 All Other 208 (248) 12 Consolidated $ 28,464 $ 24,306 $ 28,406 Operating income (loss) Europe $ 13,413 $ 33,769 $ 22,682 2022 2021 2020 North America (34,197) (1,928) 9,449 All Other (3) (30,603) (24,977) (23,236) Charges related to restructuring activities (25,820) (2,534) (7,358) Gain on sale of business — — 9,790 Impairment of goodwill — (28,564) — Impairment of intangible assets (3,259) — — Consolidated operating income (loss) (80,466) (24,234) 11,327 Net gain on convertible derivatives 1,510 — — Gain (loss) on debt extinguishment including debt finance charges and fees 9,419 9,422 (7,360) Net interest expense (28,464) (24,306) (28,406) Loss before income taxes $ (98,001) $ (39,118) $ (24,439) Assets Europe $ 575,632 $ 675,051 $ 705,314 North America 170,997 205,998 207,347 All Other 24,340 28,482 33,320 Consolidated $ 770,969 $ 909,531 $ 945,981 Long-lived assets Europe (4) $ 404,433 $ 450,026 $ 472,599 North America (5) 61,738 68,240 92,195 All Other 5,480 5,877 6,721 Consolidated $ 471,651 $ 524,143 $ 571,515 Expenditures for assets Europe $ 727 $ 2,419 $ 5,221 North America (6) 2,530 14,055 16,473 All Other 521 1,224 610 Consolidated $ 3,778 $ 17,698 $ 22,304 ________________________ (1) Europe's commissionaire structure reflects the majority of revenues to external customers through Switzerland. (2) Revenues from external customers for the United States were $256,888,000, $312,805,000 and $316,687,000 for 2022, 2021 and 2020, respectively. (3) Consists of unallocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments, and operating profit (loss related to the company's Asia Pacific business). (4) Property and Equipment net book value within France were $6,136,000, $7,342,000 and $8,452,000 and Germany were $3,376,000, $4,119,000 and $5,904,000 at the end of 2022, 2021 and 2020, respectively. (5) Property and Equipment net book value within the United States were $33,901,000, $38,411,000 and $27,882,000 at the end of 2022, 2021 and 2020, respectively. (6) 2021 and 2020 expenditures for assets primarily driven by the company's ERP project. Net sales by product category, are as follows (in thousands): 2022 2021 2020 Europe Lifestyle $ 216,325 $ 248,325 $ 222,668 Mobility and Seating 186,153 214,398 200,687 Respiratory Therapy 14,003 19,348 24,786 Other (1) 17,891 17,047 19,900 $ 434,372 $ 499,118 $ 468,041 North America Lifestyle $ 135,615 $ 148,369 $ 165,267 Mobility and Seating 99,116 110,998 109,923 Respiratory Therapy 41,083 80,903 72,285 Other (1) 1,077 710 832 $ 276,891 $ 340,980 $ 348,307 All Other (Asia Pacific) Mobility and Seating $ 11,917 $ 12,112 $ 14,150 Lifestyle 11,221 11,438 13,503 Respiratory Therapy 2,049 3,101 1,383 Other (1) 5,283 5,708 5,305 $ 30,470 $ 32,359 $ 34,341 Total Consolidated $ 741,733 $ 872,457 $ 850,689 ________________________ (1) Includes various services, including repair services, equipment rentals and external contracting.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies General In the ordinary course of its business, the company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All the product liability lawsuits that were asserted against the company in the United States prior to January 31, 2023 had been referred to the company's captive insurance company, Invatection Insurance Company (“Invatection”), and/or excess insurance carriers. All non-U.S. lawsuits have been referred to the company's commercial insurance carriers. All such lawsuits are generally contested vigorously. The coverage territory of the company's insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures. On January 31, 2023, the company entered into a Commutation and Release Agreement with Invatection pursuant to which, among other things, the company assumed all outstanding insured claims and cancelled the captive insurance policy. The company will self-insure product liability claims for the first $10 million per claim beyond which the company has commercial excess liability insurance coverage. As a medical device manufacturer, the company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documenting, developing, testing, manufacturing, labeling, promoting, distributing and other practices of health care suppliers and medical device manufacturers are all subject to government scrutiny. Most of the company's facilities are subject to inspection at any time by the FDA or similar medical device regulatory agencies in other jurisdictions. Violations of law or regulations can result in administrative, civil and criminal penalties and sanctions, which could have a material adverse effect on the company's business. Medical Device Regulatory Matters The FDA in the United States and comparable medical device regulatory authorities in other jurisdictions regulate virtually all aspects of the marketing, invoicing, documenting, development, testing, manufacturing, labeling, promotion, distribution and other practices regarding medical devices. The company and its products are subject to the laws and regulations of the FDA and other regulatory bodies in the various jurisdictions where the company's products are manufactured or sold. The company's failure to comply with the regulatory requirements of the FDA and other applicable medical device regulatory requirements can subject the company to administrative or judicially imposed sanctions or enforcement actions. These sanctions include injunctions, consent decrees, warning letters, civil penalties, criminal penalties, product seizure or detention, product recalls and total or partial suspension of production. In December 2012, the company became subject to a consent decree of injunction filed by the FDA with respect to the company's Corporate facility and its Taylor Street manufacturing facility in Elyria, Ohio. The consent decree initially limited the company's (i) manufacture and distribution of power and manual wheelchairs, wheelchair components and wheelchair sub-assemblies at or from its Taylor Street manufacturing facility (“Taylor Street products”) , except in verified cases of medical necessity, (ii) design activities related to wheelchairs and power beds that take place at the impacted Elyria facilities and (iii) replacement, service and repair of products already in use from the Taylor Street manufacturing facility. Under the terms of the consent decree, in order to resume full operations, the company had to successfully complete independent, third-party expert certification audits at the impacted Elyria facilities, comprising three distinct certification reports separately submitted to, and subject to acceptance by, the FDA; submit its own report to the FDA; and successfully complete a reinspection by the FDA of the company's Corporate and Taylor Street facilities. On July 24, 2017, following its June 2017 reinspection of the Corporate and Taylor Street facilities, the FDA notified the company that it was in substantial compliance with the FDA Act, FDA regulations and the terms of the consent decree and, that the company was permitted to resume full operations at those facilities including the resumption of unrestricted sales of products made in those facilities. Since July 24, 2017, an independent company-retained audit firm conducted two semi-annual audits in the first year and then four annual audits in the next four years of the company's headquarters and Taylor Street facilities, as required under the consent decree. The expert audit firm determined that the facilities remained in continuous compliance with the Federal Food, Drug and Cosmetic Act (“FDA Act”), FDA regulations and the terms of the consent decree and issued post-audit reports contemporaneously to the FDA. The FDA has the authority to inspect these facilities and any other FDA registered facility, at any time. The FDA has continued to actively inspect the company's facilities, other than through the processes established under the consent decree. The company expects that the FDA will, from time to time, inspect substantially all the company's domestic and foreign FDA-registered facilities. In 2021, FDA conducted an inspection of the company’s Corporate and Taylor Street facilities from May 25 through June 24, 2021. At the close of the inspection, six FDA Form 483 observations were issued, and the company timely responded to FDA, has diligently taken actions to address FDA’s inspectional observations, and has provided FDA monthly updates on the corrective actions taken to address these observations. On November 18, 2021, the company received a warning letter from the FDA concerning certain of the inspectional observations in the June 2021 FDA Form 483 related to the complaint handling process, the corrective and preventive action (“CAPA”) process, and medical device reporting (“MDR”) associated with oxygen concentrators (the “Warning Letter”). On November 16, 2021, the company received a consent decree non-compliance letter from the FDA concerning the same complaint and CAPA handling matters as in the Warning Letter observations but associated with the Taylor Street products (this letter, together with the Warning Letter, the “FDA Letters”). The company timely responded to the FDA Letters, has diligently taken actions to address FDA’s concerns, and has provided FDA with periodic updates on the corrective actions taken to address the matters in the FDA Letters. The company remains committed to resolving the FDA’s concerns; however, it is not possible to predict the outcome or timing of a resolution at this time. There can be no assurance that the FDA will be satisfied with the company’s responses to the FDA Letters, nor any assurance as to the timeframe that may be required for the company to adequately address the FDA’s concerns or whether the matters in the FDA Letters will result in an extension in the duration of the consent decree. As of the date of filing of the company’s Annual Report on Form 10-K, there has been no impact on the company’s ability to produce and market its products as a result of the FDA Letters. The FDA conducted an inspection at the company’s Alber GmbH facility in Albstadt, Germany from December 12 through December 15, 2022. At the completion of the inspection, the FDA issued no findings or observations. The FDA conducted an inspection at the company’s Corporate and Taylor Street facilities from March 1 through March 30, 2023. At the conclusion of the inspection, two FDA Form 483 observations were issued. The company intends to timely respond to the FDA and address the observations. Under the consent decree, the FDA has the authority to order the company to take a wide variety of actions if the FDA finds that the company is not in compliance with the consent decree, FDA Act or FDA regulations, including requiring the company to cease all operations relating to Taylor Street products. The FDA also can order the company to undertake a partial cessation of operations or a recall, issue a safety alert, public health advisory, or press release, or to take any other corrective action the FDA deems necessary with respect to Taylor Street products. The FDA also has authority under the consent decree to assess liquidated damages of $15,000 per violation per day for any violations of the consent decree, FDA regulations or the FDA Act. The FDA also may assess liquidated damages for shipments of adulterated or misbranded devices in the amount of twice the sale price of any such adulterated or misbranded device. The liquidated damages, if assessed, are limited to a total of $7,000,000 for each calendar year. The authority to assess liquidated damages is in addition to any other remedies otherwise available to the FDA, including civil money penalties. The results of regulatory claims, proceedings, investigations, or litigation are difficult to predict. An unfavorable resolution or outcome of the FDA Letters, any other FDA warning letters or inspectional observations, or other FDA enforcement related to company facilities, could materially and adversely affect the company's business, financial condition, and results of operations. The limitations previously imposed by the FDA consent decree negatively affected net sales in the North America segment and, to a certain extent, the Asia Pacific region beginning in 2012. The limitations led to delays in new product introductions. Further, uncertainty regarding how long the limitations would be in effect limited the company's ability to renegotiate and bid on certain customer contracts and otherwise led to a decline in customer orders. Although the company has been permitted to resume full operations at the Corporate and Taylor Street facilities, the negative effect of the consent decree on customer orders and net sales in the North America segment and Asia Pacific region has been considerable, and it is uncertain as to whether, or how quickly, the company will be able to rebuild net sales to more typical historical levels, irrespective of market conditions. Accordingly, when compared to the company's historic results, the previous limitations in the consent decree had, and likely may continue to have, a material adverse effect on the company's business, financial condition and results of operations. Warranty Matters The company's warranty reserves are subject to adjustment in future periods based on historical analysis of warranty claims and as new developments occur that may change the company's estimates related to specific product recalls. Refer to Current Liabilities in the Notes to the Consolidated Financial Statements for the total provision amounts and a reconciliation of the changes in the warranty accrual.

Interim Financial Information

Interim Financial Information	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Information	Interim Financial Information (Unaudited) (In thousands, except per share data) QUARTER ENDED 2022 March 31, June 30, September 30, December 31, Net sales $ 200,988 $ 189,017 $ 170,408 $ 181,320 Gross profit 47,729 47,982 31,379 48,303 Income (Loss) before income taxes (22,877) (21,023) (33,434) (20,667) Net income (loss) (24,197) (21,943) (34,354) (20,577) Net income (loss) per share—basic (0.69) (0.62) (0.92) (0.54) Net income (loss) per share—assuming dilution * (0.69) (0.62) (0.92) (0.54) 2021 March 31, June 30, September 30, December 31, Net sales $ 196,202 $ 225,864 $ 224,200 $ 226,191 Gross profit 54,638 60,818 60,310 63,340 Income (Loss) from before income taxes (12,174) (9,578) (20,919) 3,553 Net income (loss) (14,044) (10,698) (22,759) 1,938 Net income (loss) per share—basic (0.41) (0.31) (0.65) 0.06 Net income (loss) per share—assuming dilution * (0.41) (0.31) (0.65) 0.05 ________________________ * Net earnings (loss) per share assuming dilution calculated utilizing weighted average shares outstanding - basic in periods in which there is a net loss. The description of significant items affecting each quarter presented are detailed below. Loss and loss per share for the quarter ended March 31, 2022, reflects restructuring charges of $3,790,000 ($3,525,000 after tax or $0.10 per share assuming dilution). Loss and loss per share for the quarter ended June 30, 2022, reflects restructuring charges of $4,153,000 ($3,889,000 after tax or $0.11 per share assuming dilution). Loss and loss per share for the quarter ended September 30, 2022, reflects restructuring charges of $8,440,000 ($8,383,000 after tax or $0.22 per share assuming dilution), net gain on debt extinguishment including debt finance charges and fees of $6,398,000 ($6,398,000 after tax or $0.17 per share assuming dilution), impairment on a North America trademark of $1,012,000 ($729,000 after tax or $0.02 per share assuming dilution) and gain on convertible debt derivatives of $950,000 ($950,000 after tax or $0.03 per share assuming dilution). Loss and loss per share for the quarter ended December 31, 2022, reflects restructuring charges of $9,437,000 ($9,129,000 after tax or $0.24 per share assuming dilution), gain on debt extinguishment including debt finance charges and fees of $3,021,000 ($3,021,000 after tax or $0.08 per share assuming dilution), impairment on Europe trademarks of $2,247,000 ($1,605,000 after tax or $0.04 per share assuming dilution) and gain on convertible debt derivatives of $560,000 ( $560,000 after tax or $0.01 per share assuming dilution). Loss and loss per share for the quarter ended March 31, 2021, reflects restructuring charges of $1,552,000 ($1,376,000 after tax or $0.04 per share assuming dilution) and loss on debt extinguishment including debt finance charges and fees of $709,000 ( $709,000 after tax or $0.02 per share assuming dilution). Loss and loss per share for the quarter ended June 30, 2021, reflects restructuring charges of $547,000 ($413,000 after tax or $0.01 per share assuming dilution) . Loss and loss per share for the quarter ended September 30, 2021, reflects restructuring charges of $377,000 ($277,000 after tax or $0.01 per share assuming dilution), gain on debt extinguishment for forgiveness of the CARES Act debt along with its accrued interest of $10,131,000 ($10,131,000 after tax or $0.29 per share assuming dilution), and impairment of goodwill of $28,564,000 ($27,903,000 after tax or $0.80 per share assuming dilution). Income and income per share for the quarter ended December 31, 2021, reflects benefits of lower selling, general and administrative expenses, specifically performance bonus and stock compensation expense for performance awards.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS COL A. COL B. COL C. COL D. Balance Charged Additions Balance (In thousands) Year Ended December 31, 2022 Deducted from asset accounts— Allowance for doubtful accounts 3,642 862 (1,225) (A) 3,279 Inventory obsolescence reserve 19,201 7,574 (2,202) (B)(E) 24,573 Tax valuation allowances 176,230 21,025 1,542 (C) 198,797 Accrued warranty cost 11,198 2,360 (5,577) (B) 7,981 Accrued product liability 13,704 1,478 (2,619) (D) 12,563 Year Ended December 31, 2021 Deducted from asset accounts— Allowance for doubtful accounts $ 4,518 $ (16) $ (860) (A) $ 3,642 Inventory obsolescence reserve 20,665 2,389 (3,853) (B) 19,201 Tax valuation allowances 163,298 10,311 2,621 (C) 176,230 Accrued warranty cost 10,991 6,925 (6,718) (B) 11,198 Accrued product liability 14,757 1,084 (2,137) (D) 13,704 Year Ended December 31, 2020 Deducted from asset accounts— Allowance for doubtful accounts $ 6,318 $ 427 $ (2,227) (A) $ 4,518 Inventory obsolescence reserve 18,178 3,304 (817) (B) 20,665 Tax valuation allowances 162,790 (701) 1,209 (C) 163,298 Accrued warranty cost 11,626 7,408 (8,043) (B) 10,991 Accrued product liability 16,150 1,139 (2,532) (D) 14,757 ________________________ Note (A)—Uncollectible accounts written off, net of recoveries and net of foreign currency translation adjustment. Note (B)—Amounts written off or payments incurred, net of foreign currency translation adjustment. Note (C)—Other activity not affecting federal or foreign tax expense, net of foreign currency translation adjustment. Note (D)—Losses paid and loss adjustments, net of foreign currency translation adjustment.

Subsequent Events

Subsequent Events	3 Months Ended
	Apr. 14, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events (Unaudited) Divestitures On January 30, 2023, the company completed the sale of its respiratory business assets (the “Transaction”) to Ventec Life Systems, Inc, a Delaware corporation and subsidiary of React Health, LLC (the “Purchaser”), pursuant to an Asset Purchase Agreement dated as of January 30, 2023 (the “Purchase Agreement”). The purchase price paid by the Purchaser in the Transaction was $11,925,644 in cash payable at closing. The Purchase Agreement contains customary indemnification obligations of each party with respect to breaches of their respective representations, warranties and covenants, and certain other specified matters, which are subject to certain exceptions, terms and limitations described further in the Purchase Agreement. The company agreed to non-competition obligations with respect to respiratory products for a five-year period following the Transaction, which are more fully described in the Purchase Agreement. In addition, the company entered into a supply agreement and a transition services agreement with the Purchaser to provide for, among other matters, the ongoing parts and service and support for the warranty and non-warranty service of respiratory products in the field. On January 27, 2023, the company completed the sale of its Top End™ ® sports and recreational wheelchair and handcycle business to Top End Sports, LLC. Termination of Information Technology Services Agreement Effective October 1, 2019, the company entered into a Master Information Technology Services Agreement (the “Master Services Agreement”) with Birlasoft Solutions Inc. and certain of its affiliates (collectively, “Birlasoft”), which are part of The CK Birla Group, to outsource substantially all of the company's information technology business service activities, including, among other things, support, rationalization and upgrading of the company's legacy information technology systems and implementation of a global enterprise resource planning system and eCommerce platform. On January 27, 2023, the company terminated the Master Services Agreement following Birlasoft's breach of the Master Services Agreement, including but not limited to Birlasoft's failure to meet transformation milestones, failure to provide services, and breach of representations, warranties and covenants in the Master Services Agreement. Bankruptcy On January 31, 2023 (the “Petition Date”), the company and two of its U.S. subsidiaries (collectively, the “Debtors” or “Company Parties”) filed voluntary petitions under chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). The Debtors obtained joint administration of their chapter 11 cases under the caption In re Invacare Corporation, et al. , Case No. 23-90068 (CML) (the “Chapter 11 Cases”). The Debtors continue to operate their business and manage their properties as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. To ensure ordinary course operations, the Company Parties obtained approval from the Bankruptcy Court for certain “first day” motions, including motions to obtain customary relief intended to continue ordinary course operations after the Petition Date. Restructuring Support Agreement On January 31, 2023, the Debtors entered into a Restructuring Support Agreement (the “Restructuring Support Agreement” or “RSA”) with certain prepetition stakeholders (the “Consenting Stakeholders”). The Consenting Stakeholders represent holders of at least a majority of the aggregate principal amount of the Company Parties’ debt obligations under various debt agreements. Under the RSA, the Consenting Stakeholders have agreed, subject to certain terms and conditions, to support a financial restructuring (the “Restructuring”) of the existing debt of, existing equity interests in, and certain other obligations of the Debtors. The Restructuring Support Agreement contemplated: (a) the Debtors’ entry into the $70 million debtor-in-possession term loan facility, (b) the Debtors’ entry into the $17.4 million debtor-in-possession ABL facility; (c) the consummation of a rights offering, backstopped by members of the Ad Hoc Committee of Noteholders (the “Backstop Parties”) pursuant to a certain Backstop Commitment Agreement (the “Backstop Commitment Agreement”); (d) issuance of the new common equity; (e) exit takeback financing in the form of an Exit Term Loan Facility and Exit Secured Convertible Notes, and (f) as necessary, exit financing in the form of the Exit NA ABL Facility and Exit EMEA ABL Facility. Chapter 11 Plan Since the Petition Date, the Debtors have developed the Restructuring Support Agreement into a chapter 11 plan of reorganization (as may be modified, amended, or supplemented from time to time, the “Plan”). The Plan, among other plan treatment, contemplates the following: • Each holder of an allowed term loan claim shall receive (i) with respect to allowed term loan claims representing principal amounts owed, its pro rata share of the exit term loan facility and (ii) with respect to allowed term loan claims representing principal amounts owed, its pro rata share of the exit term loan facility and (ii) with respect to all other allowed term loan claims, payment in full in cash. • Each holder of an allowed secured notes claim shall receive (i) with respect to allowed secured notes claims representing principal amounts owed, its pro rata share of the exit secured convertible notes and (ii) with respect to all other allowed secured notes claims, payment in full in cash; provided that, if applicable pursuant to and in accordance with the Plan, such holder will also receive its pro rata share of the applicable portion of the excess new money in cash. • Each holder of an allowed unsecured notes claim shall receive (i) the unsecured noteholder rights, in accordance with the rights offering procedures; (ii) with respect to any residual unsecured notes claims, its share (on a pro rata basis with other holders of allowed unsecured notes claims and holders of allowed general unsecured claims that select the class 6 equity option) of 100% of the new common equity after the distribution of the new common equity on account of the backstop commitment premium (subject to dilution on account of the exit secured convertible notes, the new convertible preferred equity, the backstop commitment premium, and the management incentive plan); (iii) and the distributions in respect of its litigation trust interests, to the extent provided in the Plan. • Each holder of an allowed general unsecured claim shall receive its pro rata either (x) (i) if such holder of an allowed general unsecured claim does not elect to receive the class 6 equity option, the general unsecured claims cash settlement and (ii) its pro rata share of the distributions in respect of its litigation trust interests, to the extent provided in the Plan; or (y) if such holder of an allowed general unsecured claim elects to receive the class 6 equity option in lieu of the general unsecured creditors cash settlement, its share (on a pro rata basis with holders of allowed unsecured notes claims in respect of their residual unsecured notes claims and other holders of allowed general unsecured claims that select the class 6 equity option) of 100% of the new common equity after the distribution of the new common equity on account of the backstop commitment premium (subject to dilution on account of the exit secured convertible notes, the new convertible preferred equity, and the management incentive plan); and (z) its pro rata share of the distributions in respect of its litigation trust interests, to the extent provided in the Plan. • All existing equity interests shall be discharged, cancelled, released, and extinguished without any distribution, and will be of no further force or effect, and each holder of an existing equity interest shall not receive or retain any distribution, property, or other value on account of such existing equity interest. Although the company intends to pursue the Restructuring in accordance with the terms set forth in the Plan, there can be no assurance that the company will be successful in completing a restructuring or any other similar transaction on the terms set forth in the Plan, on different terms or at all. DIP Credit Agreements The company and certain lenders (the “DIP Parties”) have agreed to a superpriority, senior secured and priming debtor-in-possession term loan credit facility in an aggregate principal amount of $70 million subject to the terms and conditions set forth in the superpriority secured credit agreement dated as of February 2, 2023 (the “Term DIP Credit Agreement”) and a superpriority senior secured and priming debtor-in-possession asset-based revolving facility in an aggregate amount of $17.4 million subject to the terms and conditions set forth in the debtor-in-possession revolving credit and security agreement dated as of February 2, 2023 (the “ABL DIP Credit Agreement” and together with the Term DIP Credit Agreement, the “DIP Credit Agreements”). The DIP Credit Agreements include conditions precedent, representations and warranties, affirmative and negative covenants, and events of default customary for financings of this type and size. Cash flow hedges are precluded under the DIP Credit Agreements. The proceeds of all or a portion of the proposed DIP Credit Agreements may be used for, among other things, post-petition working capital for the company and its subsidiaries, payment of costs to administer the Chapter 11 Cases, payment of expenses and fees of the transactions contemplated by the Chapter 11 Cases, payment of court-approved adequate protection obligations under the DIP Credit Agreements, and payment of other costs in an approved budget and other such purposes permitted under the DIP Credit Agreements. The foregoing description of the RSA and the DIP Credit Agreements is not complete and is qualified in its entirety by reference to each of the Restructuring Support Agreement and each DIP Credit Agreement, which were filed on February 1, 2023 on the Current Report on Form 8-K, February 3, 2023 on the Current Report on Form 8-K, as applicable. Additionally, the foregoing description of the Backstop Commitment Agreement is not complete and is qualified in its entirety by reference to the Backstop Commitment Agreement filed in this Annual Report on Form 10-K. The company cannot predict the ultimate outcome of its Chapter 11 Cases at this time or the satisfaction of any of the RSA milestones yet to come. For the duration of the company’s Chapter 11 Cases, the company’s operations and ability to develop and execute its business plan are subject to the risks and uncertainties associated with the Chapter 11 process. As a result of these risks and uncertainties, the amount and composition of the company’s assets, liabilities, officers and/or directors could be significantly different following the outcome of the Chapter 11 Cases, and the description of the company’s operations, properties and liquidity and capital resources included in this annual report may not accurately reflect its operations, properties and liquidity and capital resources following the Chapter 11 process. In addition, related to the bankruptcy filing, on January 31, 2023, the company entered into a Commutation and Release Agreement with Invatection Insurance Company pursuant to which, among other things, the company assumed all outstanding insured claims and cancelled the captive insurance policy. The company will self-insure product liability claims for the first $10 million per claim beyond which the company has commercial excess liability insurance coverage. Exiting Sanford, Florida Production and Distribution Facility On April 5, 2023, the company announced the decision to close its Sanford, Florida production and distribution facility, effective at the end of September 2023. The manufacturing and distribution activities currently conducted at the Sanford facility will be performed at other company locations or by third parties. The consolidation is expected to impact approximately 90 associates in Florida. This decision is supportive of the company’s transformation efforts and is part of the company’s long-term plan to increase enterprise value by targeting significant contributions from cost reduction activities in North America.

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations: Invacare Corporation is a leading manufacturer and distributor of medical equipment used in the home based upon the company's distribution channels, breadth of product line and net sales. The company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and continuing care markets.
Principles of Consolidation	Principles of Consolidation: The consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of December 31, 2022 and the results of its operations and its cash flow for the years ended December 31, 2022, 2021 and 2020, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a November 30 fiscal year end to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated. Going Concern: The company's financial statements have been prepared under the assumption that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the normal course of business. In connection with the preparation of the consolidated financial statements, the company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, that raised substantial doubt as to the company's ability to continue as a going concern. On January 31, 2023, the company and two of its U.S. subsidiaries filed voluntary petitions under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). The Debtors obtained joint administration of their chapter 11 cases under the caption In re Invacare Corporation, et al. , Case No. 23-90068 (CML) (the “Chapter 11 Cases”). In light of the company's Chapter 11 Cases, the company's ability to continue as a going concern is contingent upon, among other things, the company's ability to, subject to approval by the Bankruptcy Court, implement a business plan of reorganization, emerge from the Chapter 11 proceedings and generate sufficient liquidity following the reorganization to meet contractual obligations and operating needs. The Chapter 11 Cases create certain risks and uncertainties related to, among other things, (i) the
Use of Estimates	Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.
Cash and Cash Equivalents, Policy	Cash and Cash Equivalents : The company's policy is to treat investments that are readily convertible to cash and with maturities so near that there is little risk of changes in value due to changes in interest rates as cash and cash equivalents. Cash and cash equivalents are carried at cost, which approximates fair value.
Accounts Receivables	Accounts Receivable: The company records accounts receivable when control of the product or service transfers to its unaffiliated customers, risk of loss is passed and title is transferred. The estimated allowance for uncollectible amounts is based primarily on management's evaluation of the financial condition of specific customers. The company records accounts receivable reserves for amounts that may become uncollectible in the future. The company writes off accounts receivable when it becomes apparent, based upon customer circumstances, that such amounts will not be collected and legal remedies are exhausted. Reserves for customer bonus and cash discounts are recorded as a reduction in revenue and netted against gross accounts receivable. Customer rebates in excess of a given customer's accounts receivable balance are classified in Accrued Expenses. Customer rebates and cash discounts are estimated based on the most likely amount principal as well as historical experience and anticipated performance. In addition, customers have the right to return product within the company's normal terms policy, and as such, the company estimates the expected returns based on an analysis of historical experience and adjusts revenue accordingly.
Inventories	Inventories: Inventories are stated at the lower of cost or net realizable value with cost determined by the first-in, first-out method. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Finished goods and work in process inventories include material, labor and manufacturing overhead costs. Inventories have been reduced by an allowance for excess and obsolete inventories. The estimated allowance is based on management's review of inventories on hand compared to estimated future usage and sales.
Property and Equipment	Property and Equipment: Property and equipment are stated based on cost. The company principally uses the straight-line method of depreciation for financial reporting purposes based on annual rates sufficient to amortize the cost of the assets over their estimated useful lives. Machinery and equipment, internal use software as well as furniture and fixtures are generally depreciated using lives of 3 to 10 years, while buildings and improvements are depreciated using lives of 5 to 40 years. Accelerated methods of depreciation are used for federal income tax purposes. Expenditures for maintenance and repairs are charged to expense as incurred. Amortization of assets under finance leases is included in depreciation expense. Long-lived assets are assessed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An asset would be considered impaired when the future net undiscounted cash flows generated by the asset or asset group are less than its carrying value. An impairment loss would be recognized based on the amount by which the carrying value of the asset exceeds its fair value.
Goodwill and Other Intangibles	Goodwill and Other Intangibles: In accordance with Intangibles—Goodwill and Other , ASC 350, goodwill and indefinite lived intangibles are subject impairment. The company completes its annual impairment assessment in the fourth quarter of each year or whenever events or changes in circumstances indicate the carrying value could be below a reporting unit's fair value. For purposes of the goodwill impairment assessment, the fair value of each reporting unit is estimated using an income approach by forecasting cash flows and discounting those cash flows using an appropriate weighted average cost of capital (WACC) as well as considering market and cost approaches, as appropriate. The fair values are then compared to the carrying value of the net assets of each reporting unit. Intangible assets are also assessed for impairment by estimating forecasted cash flows and discounting those cash flows as needed to calculate impairment amounts. The fair value of trademarks were calculated using a relief from royalty payment methodology which requires applying an estimated market royalty rate to forecasted net sales and discounting the resulting cash flows to determine fair value.
Accrued Warranty Cost	Accrued Warranty Cost: Generally, the company's products are covered by assurance-type warranties against defects in material and workmanship for various periods depending on the product from the date of sale to the customer. Certain components carry a lifetime warranty. In addition, the company has sold extended warranties that, while immaterial, require the company to defer the revenue associated with those warranties until earned. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments, as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted, as needed. However, the company does consider other events, such as a product recall, which could necessitate additional warranty reserve provisions. Refer to Accrued Expenses in the Notes to the Consolidated Financial Statements for a reconciliation of the changes in the warranty accrual.
Product Liability Cost	Product Liability Cost: The company was self-insured in North America for product liability exposures for losses up to $10,000,000 per occurrence and $13,000,000 in the aggregate. The company also has additional layers of external insurance coverage, related to all lines of insurance coverage, insuring up to $75,000,000 in aggregate losses per policy year arising from individual claims anywhere in the world that exceed the captive insurance company policy limits or the limits of the company's per country foreign liability limits, as applicable. There can be no assurance that Invacare's current insurance levels will continue to be adequate or available at affordable rates. Product liability reserves are recorded for individual claims based upon historical experience, industry expertise
Revenue Recognition	Revenue Recognition: The company recognizes revenues when control of the product or service is transferred to unaffiliated customers. Revenues from Contracts with Customers , ASC 606, provides guidance on the application of generally accepted accounting principles to revenue recognition issues. The company has concluded that its revenue recognition policy is appropriate and in accordance with GAAP under ASC 606. All of the company's product-related contracts, and a portion related to services, have a single performance obligation, which is the promise to transfer an individual good or service, with revenue recognized at a point in time. Certain service-related contracts contain multiple performance obligations that require the company to allocate the transaction price to each performance obligation. For such contracts, the company allocates revenue to each performance obligation based on its relative standalone selling price at inception of the contract. The company determined the standalone selling price based on the expected cost-plus margin methodology. Revenue related to the service contracts with multiple performance obligations is recognized over time. To the extent performance obligations are satisfied over time, the company defers revenue recognition until the performance obligations are satisfied. The determination of when and how much revenue to recognize can require the use of significant judgment. Revenue is recognized when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the company's products and services to the customer. Revenue is measured as the amount of consideration expected to be received in exchange for transferring the product or providing services. The amount of consideration received and recognized as revenue by the company can vary as a result of variable consideration terms included in the contracts such as customer rebates, cash discounts and return policies. Customer rebates and cash discounts are estimated based on the most likely amount principle and these estimates are based on historical experience and anticipated performance. Customers have the right to return product within the company's normal terms policy, and as such, the company estimates the expected returns based on an analysis of historical experience. The company adjusts its estimate of revenue at the earlier of when the most likely amount of consideration the company expects to receive changes or when the consideration becomes fixed. The company generally does not expect that there will be significant changes to its estimates of variable consideration (refer to Receivables in the Notes to the Consolidated Financial Statements include elsewhere in this report). Depending on the terms of the contract, the company may defer recognizing a portion of the revenue at the end of a given period as the result of title transfer terms that are based upon delivery and or acceptance which align with transfer of control of the company's products to its customers. Sales are made only to customers with whom the company believes collection is probable based upon a credit analysis, which may include obtaining a credit application, a signed security agreement, personal guarantee and/or a cross corporate guarantee depending on the credit history of the customer. Credit lines are established for new customers after an evaluation of their credit report and/or other relevant financial information. Existing credit lines are regularly reviewed and adjusted with consideration given to any outstanding past due amounts. The company records distributed product sales gross as a principal since the company takes title to the products and has the risks of loss for collections, delivery and returns. The company's payment terms are for relatively short periods and thus do not contain any element of financing. Additionally, no contract costs are incurred that would require capitalization and amortization. Sales, value added, and other taxes the company collects concurrent with revenue producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense. Shipping and handling costs are included in cost of products sold. The majority of the company's warranties are considered assurance-type warranties and continue to be recognized as expense when the products are sold (refer to
Research and Development	Research and Development: Research and development costs are expensed as incurred and included in cost of products sold. The company's annual expenditures for product development and engineering were approximately $3,492,000, $8,656,000 and $12,275,000 for 2022, 2021 and 2020, respectively.
Advertising	Advertising: Advertising costs are expensed as incurred and included in selling, general an d administrative expenses. Advertising expenses amounted to $4,511,000, $5,062,000 and $5,107,000 for 2022, 2021 and 2020, respectively, the majority of which is in curred for advertising in the United States and Europe.
Income Taxes	Income Taxes: The company uses the liability method in measuring the provision for income taxes and recognizing deferred tax assets and liabilities on the balance sheet. The liability method requires that deferred income taxes reflect the tax consequences of currently enacted rates for differences between the tax and financial reporting bases of assets and liabilities. Taxes related to Global Intangible Low-Taxes Income (GILTI) are treated as current period expense when incurred.
Value Added Taxes, Policy	Value Added Taxes: The company operates internationally and is required to comply with value added tax (VAT) or goods and service tax (GST) regulations, particularly in Europe and Asia Pacific. VAT and GST are taxes on consumption in which the company pays tax on its purchases of goods and services and charges customers on the sale of product. The difference between billings to customers and payments on purchases is then remitted or received from the government as filings are due. The company records tax assets and liabilities related to these
Derivative Instruments	Derivative Instruments: Derivatives and Hedging, ASC 815, requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. A majority of the company's derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change.
Foreign Currency Translation	Foreign Currency Translation: The functional currency of the company's subsidiaries outside the United States is the applicable local currency. The assets and liabilities of the company's foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Revenues and expenses are translated at monthly average exchange rates. Gains and losses resulting from translation of balance sheet items are included in accumulated other comprehensive earnings.
Net Earnings Per Share	Net Earnings Per Share: Basic earnings per share are computed based on the weighted-average number of common shares and Class B common shares outstanding during the year. Diluted earnings per share are computed based on the weighted-average number of common shares and Class B common shares outstanding plus the effects of dilutive stock options and awards outstanding during the year. For periods in which there was a net loss, loss per share assuming dilution utilized weighted average shares-basic.
Defined Benefit Plans	Defined Benefit Plans: The company's benefit plans are accounted for in accordance with Compensation-Retirement Benefits , ASC 715 which requires plan sponsors to recognize the funded status of their defined benefit postretirement benefit plans in the consolidated balance sheet, measure the fair value of plan assets and benefit obligations as of the balance sheet date and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
Reclassifications
Recent Accounting Pronouncements	Recent Accounting Pronouncements (Already Adopted): In August 2020, the FASB issued ASU 2020-06 “Debt with Conversion and Other Options” (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity's Own Equity (Subtopic 815-40)”, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU 2020-06 removes from U.S. GAAP the separation models for (1) convertible debt with a cash conversion feature (CCF) and (2) convertible instrument with a beneficial conversion feature (BCF). As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (2) a convertible debt instrument was issued at a substantial premium. The guidance may be early adopted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The company adopted ASU 2020-06 effective January 1, 2021, using the modified retrospective method, which resulted in the removal of convertible debt discounts of $25,218,000, adjustment of $34,798,000 to additional paid-in-capital and $9,670,000 adjustment to retained earnings. Convertible debt discounts prior to adoption of ASU 2020-06 were amortized over the convertible debt term through interest expense. Subsequent to adoption, convertible debt discounts are not applicable when accounting for debt as a single unit of account. Interest expense for 2020 related to debt discount amortization (which was not recognized in 2021 or 2022 due to adoption) was $9,673,000 or $0.28 per basic and diluted share. There was no impact of adoption on performance metrics used for short-term or long-term incentive compensation. Accretion specific to the Series II 2024 Notes was unaffected by adoption. Due to the valuation allowance, there was no net impact to income taxes for the adoption. Subsequent to adoption weighted average shares when calculating diluted earnings per share requires the application of the if-converted method for all convertible instruments. In March 2020, the FASB issued ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting,” which is intended to provide temporary optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burden related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates if certain criteria are met. The guidance may be adopted in any period prior to the guidance expiration on December 31, 2022.

Operations Held for Sale (Table

Operations Held for Sale (Tables)	2 Months Ended
	Mar. 07, 2020
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities of Divested Business	The assets and liabilities of Dynamic Controls as of March 7, 2020 consisted of the following (in thousands): March 7, 2020 Trade receivables, net $ 4,129 Inventories, net 3,082 Other assets 855 Property and equipment, net 600 Operating lease assets, net 2,127 Total assets $ 10,793 Accounts payable $ 4,692 Accrued expenses 2,473 Current taxes payable 41 Current portion of operating lease obligations 366 Long-term obligations 1,019 Total liabilities $ 8,591

Receivables (Tables)

Receivables (Tables)	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Schedule of Accounts Receivable	Receivables as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Accounts receivable, gross $ 112,659 $ 142,806 Customer rebate reserve (11,569) (12,267) Allowance for doubtful accounts (3,279) (3,642) Cash discount reserves (8,756) (9,179) Other, principally returns and allowances reserves (1,103) (603) Accounts receivable, net $ 87,952 $ 117,115
Allowance for Credit Losses	The movement in the trade receivables allowance for doubtful accounts was as follows (in thousands): 2022 Balance as of beginning of period $ 3,642 Current period provision 862 Recoveries (direct write-offs), net (1,225) Balance as of end of period $ 3,279
Schedule of Installment Receivables	Installment receivables as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Current Long- Total Current Long- Total Installment receivables $ 311 $ 266 $ 577 $ 218 $ 734 $ 952 Less: Unearned interest — — — — — — 311 266 577 218 734 952 Allowance for doubtful accounts — — — — — — Installment receivables, net $ 311 $ 266 $ 577 $ 218 $ 734 $ 952
Schedule of Installment Receivables Allowance for Doubtful Accounts	The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands): 2022 2021 Balance as of beginning of period $ — $ 487 Current period provision (benefit) — (75) Direct write-offs charged against the allowance — (412) Balance as of end of period $ — $ —
Schedule of Installment Receivables by Class	Installment receivables by class as of December 31, 2022 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 577 577 — — Total Non-impaired installment receivables with no related allowance recorded 577 577 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 577 $ 577 $ — $ — Installment receivables by class as of December 31, 2021 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 952 952 — — Total Non-impaired installment receivables with no related allowance recorded 952 952 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 952 $ 952 $ — $ —
Schedule of Financing Receivables	Installment receivables by class as of December 31, 2022 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 577 577 — — Total Non-impaired installment receivables with no related allowance recorded 577 577 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 577 $ 577 $ — $ — Installment receivables by class as of December 31, 2021 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 952 952 — — Total Non-impaired installment receivables with no related allowance recorded 952 952 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 952 $ 952 $ — $ —
Schedule of Aging of Installment Receivables	The aging of the company's installment receivables was as follows as of December 31, 2022 and 2021 (in thousands): December 31, 2022 December 31, 2021 Total U.S. Asia Pacific Total U.S. Canada Current $ 533 $ — $ 533 $ 952 $ — $ 952 0-30 days past due 44 — 44 — — — 31-60 days past due — — — — — — 61-90 days past due — — — — — — 90+ days past due — — — — — — $ 577 $ — $ 577 $ 952 $ — $ 952

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories, net as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Raw materials $ 57,174 $ 69,371 Finished goods 45,476 62,124 Work in process 9,911 12,779 Inventories, net $ 112,561 $ 144,274 In the third quarter of 2022, with the decision to exit the respiratory products business, the company recorded a charge to gross margin totaling $8,651,000, with $5,387,000 increasing the inventory reserve and $3,264,000 for purchase obligations. No significant adjustments were recorded to adjust this estimate in the fourth quarter of 2022.

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Current Assets	Other current assets as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Tax receivables principally value added taxes $ 22,946 $ 21,943 Prepaid insurance 1,223 4,462 Prepaid inventory and freight 3,077 2,394 Recoverable income taxes 1,990 2,301 Service contracts 1,366 304 Derivatives (foreign currency forward contracts) 1,117 386 Receivable due from information technology provider 934 612 Prepaid debt fees 339 379 Prepaid and other current assets 6,710 7,255 Other Current Assets $ 39,702 $ 40,036

Other Long-Term Assets (Tables)

Other Long-Term Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets, Noncurrent	Other long-term assets as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Cash surrender value of life insurance policies 2,686 2,481 Deferred income taxes 1,102 1,540 Deferred financing fees 733 409 Installment receivables 266 734 Investments 85 86 Other 287 112 Other Long-Term Assets $ 5,159 $ 5,362

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Machinery and equipment $ 269,835 $ 278,347 Capitalized software 30,923 30,448 Land, buildings and improvements 25,095 27,299 Furniture and fixtures 8,053 8,943 Leasehold improvements 4,802 6,782 Property and Equipment, gross 338,708 351,819 Accumulated depreciation (287,175) (290,898) Property and Equipment, net $ 51,533 $ 60,921

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The carrying amount of goodwill by reporting unit is as follows (in thousands): North America Europe Consolidated Balance at December 31, 2020 $ 28,485 $ 373,976 $ 402,461 Foreign currency translation adjustments 79 (18,101) (18,022) Impairment of goodwill (28,564) — (28,564) Balance at December 31, 2021 — 355,875 355,875 Foreign currency translation adjustments — (29,594) (29,594) Balance at December 31, 2022 $ — $ 326,281 $ 326,281

Intangibles (Tables)

Intangibles (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets	The company's intangibles consist of the following (in thousands): December 31, 2022 December 31, 2021 Historical Accumulated Historical Accumulated Customer lists $ 48,515 $ 48,515 $ 52,447 $ 52,447 Trademarks 18,867 — 24,137 — Developed technology 7,154 6,859 7,652 7,149 Patents 4,092 4,092 5,543 5,543 License agreements 3,981 1,480 2,905 1,196 Other 1,148 1,142 1,147 1,140 Intangibles $ 83,757 $ 62,088 $ 93,831 $ 67,475
Schedule of Finite Lived Intangible Assets	The company's intangibles consist of the following (in thousands): December 31, 2022 December 31, 2021 Historical Accumulated Historical Accumulated Customer lists $ 48,515 $ 48,515 $ 52,447 $ 52,447 Trademarks 18,867 — 24,137 — Developed technology 7,154 6,859 7,652 7,149 Patents 4,092 4,092 5,543 5,543 License agreements 3,981 1,480 2,905 1,196 Other 1,148 1,142 1,147 1,140 Intangibles $ 83,757 $ 62,088 $ 93,831 $ 67,475

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses as of December 31, 2022 and 2021 consisted of accruals for the following (in thousands): 2022 2021 Taxes other than income taxes, primarily value added taxes $ 27,106 $ 24,012 Salaries and wages 19,307 23,217 Professional 11,267 8,697 Warranty 7,981 11,198 Interest 6,900 3,297 IT service contracts 5,581 4,013 Rebates 4,923 6,569 Freight 4,542 5,460 Product line exit obligations 3,743 — Severance 3,472 400 Deferred revenue 2,279 4,156 Product liability, current portion 2,125 2,362 Insurance 951 625 Supplemental Executive Retirement Program liability Plan (SERP) 391 391 Derivatives (foreign currency forward exchange contracts) 137 1,938 Other items, principally trade accruals 5,386 6,636 Accrued Expenses $ 106,091 $ 102,971
Accrued Warranty Costs	The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands): 2022 2021 Balance as of January 1 $ 11,198 $ 10,991 Warranties provided during the period 2,202 6,361 Settlements made during the period (5,577) (6,718) Changes in liability for pre-existing warranties during the period, including expirations 158 564 Balance as of December 31 $ 7,981 $ 11,198

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Debt as of December 31, 2022 and 2021 consisted of the following (in thousands): 2022 2021 Convertible senior notes at 4.50%, due in June 2022 $ — $ 2,642 Convertible senior notes Series I at 5.00%, due in November 2024 72,408 72,140 Convertible senior notes Series II at 5.00%, due in November 2024 76,719 78,251 Convertible senior notes at 4.25%, due in March 2026 67,665 119,036 Secured convertible senior notes at 5.68%, due in July 2026 37,240 — Term loan, due in July 2026 82,808 — Other obligations 17,401 36,060 354,241 308,129 Less current maturities of long-term debt (154) (3,107) Long-Term Debt $ 354,087 $ 305,022
Liability Components of Convertible 2022 Note	The liability components of the 2022 Notes consist of the following (in thousands): December 31, 2022 December 31, 2021 Principal amount of liability component $ — $ 2,650 Debt fees — (8) Net carrying amount of liability component $ — $ 2,642
Liability Components of Convertible 2024 Note	The liability components of the Series I 2024 Notes consist of the following (in thousands): December 31, 2022 December 31, 2021 Principal amount of liability component $ 72,909 $ 72,909 Debt fees (501) (769) Net carrying amount of liability component $ 72,408 $ 72,140
Liability Components of Convertible Series II 2024 Note	The liability components of the Series II 2024 Notes consist of the following (in thousands): December 31, 2022 December 31, 2021 Principal amount of liability component - including accretion $ 77,309 $ 79,222 Debt fees (590) (971) Net carrying amount of liability component $ 76,719 $ 78,251
Liability Components of Convertible 2026 Notes	The liability components of the 2026 Notes consist of the following (in thousands): December 31, 2022 December 31, 2021 Principal amount of liability component $ 69,700 $ 125,000 Debt fees (2,035) (5,964) Net carrying amount of liability component $ 67,665 $ 119,036

Other Long-Term Obligations (Ta

Other Long-Term Obligations (Tables)	12 Months Ended
	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Schedule of Other Liabilities, Noncurrent	Other long-term obligations as of December 31, 2022 and 2021 consist of the following (in thousands): 2022 2021 Deferred income taxes $ 18,771 $ 21,664 Product liability 10,438 11,342 Deferred compensation 4,970 6,174 Deferred gain on sale leaseback 4,834 5,174 Supplemental Executive Retirement Plan liability 4,383 5,106 Uncertain tax obligation including interest 2,891 3,171 Death benefit obligation plan 2,533 4,568 Pension 1,019 7,814 Secured Convertible 2026 debt conversion liability 85 — Other 478 1,783 Other Long-Term Obligations $ 50,402 $ 66,796

Leases and Commitments (Tables)

Leases and Commitments (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Lease Expense	Lease expenses for the year ended December 31, 2022, December 31, 2021, December 31, 2020, respectively, were as follows (in thousands): 2022 2021 2020 Operating leases $ 5,712 $ 7,394 $ 8,138 Variable and short-term leases 2,549 3,541 3,968 Total operating leases $ 8,261 $ 10,935 $ 12,106 Finance lease interest cost $ 4,256 $ 4,601 $ 2,544 Finance lease depreciation 4,246 4,996 3,479 Total finance leases $ 8,502 $ 9,597 $ 6,023
Schedule of Cash Flow, Supplemental Disclosures	Supplemental cash flow amounts for the year ended December 31, 2022, December 31, 2021 and December 31, 2020, respectively, were as follows (in thousands): Cash Activity: Cash paid in measurement of amounts for lease liabilities December 31, 2022 December 31, 2021 December 31, 2020 Operating leases $ 7,618 $ 11,089 $ 12,527 Finance leases 7,260 8,166 5,316 Total $ 14,878 $ 19,255 $ 17,843 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations December 31, 2022 December 31, 2021 December 31, 2020 Operating leases $ 4,652 $ 7,491 $ 6,155 Finance leases 969 6,572 40,078 Total $ 5,621 $ 14,063 $ 46,233
Weighted-Average Remaining Lease Terms and Discount Rates	Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of December 31, 2022 and December 31, 2021, respectively,: December 31, 2022 December 31, 2021 Weighted-average remaining lease term - finance leases 14.8 years 15.8 years Weighted-average remaining lease term - operating leases 4.6 years 5.0 years Weighted-average discount rate - finance leases 3.74% 6.43% Weighted-average discount rate - operating leases 9.36% 7.1%
Lessee, Operating Lease, Liability, Maturity	Future minimum operating and finance lease commitments, as of December 31, 2022, are as follows (in thousands): Finance Operating Leases 2023 $ 6,828 $ 4,181 2024 6,764 3,085 2025 6,667 2,482 2026 6,554 1,303 2027 6,441 395 Thereafter 62,531 1,341 Total future minimum lease payments 95,785 12,787 Amounts representing interest (34,685) (2,108) Present value of minimum lease payments 61,100 10,679 Less: current maturities of lease obligations (3,106) (3,420) Long-term lease obligations $ 57,994 $ 7,259
Finance Lease, Liability, Fiscal Year Maturity	Future minimum operating and finance lease commitments, as of December 31, 2022, are as follows (in thousands): Finance Operating Leases 2023 $ 6,828 $ 4,181 2024 6,764 3,085 2025 6,667 2,482 2026 6,554 1,303 2027 6,441 395 Thereafter 62,531 1,341 Total future minimum lease payments 95,785 12,787 Amounts representing interest (34,685) (2,108) Present value of minimum lease payments 61,100 10,679 Less: current maturities of lease obligations (3,106) (3,420) Long-term lease obligations $ 57,994 $ 7,259

Revenues (Tables)

Revenues (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]	The following tables disaggregate the company's revenues by major source and by reportable segment for the year ended December 31, 2022 and December 31, 2021 (in thousands): 2022 Products Service Total Europe $ 422,440 $ 11,932 $ 434,372 N.A. 275,508 1,383 276,891 All Other 25,592 4,878 30,470 Total $ 723,540 $ 18,193 $ 741,733 % Split 98% 2% 100% 2021 Products Service Total Europe $ 486,190 $ 12,928 $ 499,118 N.A. 340,269 711 340,980 All Other 27,221 5,138 32,359 Total $ 853,680 $ 18,777 $ 872,457 % Split 98% 2% 100%

Equity Compensation (Tables)

Equity Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	The amounts of equity-based compensation expense (income) recognized as part of SG&A expenses in All Other in business segment reporting were as follows (in thousands): 2022 2021 2020 Restricted stock / units 2,924 5,450 5,332 Performance shares / units (844) (1,127) 3,313 Total stock-based compensation expense $ 2,080 $ 4,323 $ 8,645
Schedule of Unrecognized Compensation Cost, Nonvested Awards	As of December 31, 2022, unrecognized compensation expense related to equity-based compensation arrangements granted under the company's 2018 Plan and previous plans, which is related to non-vested shares, was as follows (in thousands): 2022 2021 2020 Restricted stock and restricted stock units 2,146 6,866 7,489 Performance shares and performance share units 75 1,746 7,260 Total unrecognized stock-based compensation expense $ 2,221 $ 8,612 $ 14,749
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes information about stock option activity for the three years ended 2022, 2021 and 2020: 2022 Weighted 2021 Weighted 2020 Weighted Options outstanding at January 1 750,159 $ 12.69 1,081,804 $ 16.07 1,441,202 $ 18.26 Forfeited (560,470) 12.44 (331,645) 23.71 (359,398) 24.84 Options outstanding at December 31 189,689 $ 13.43 750,159 $ 12.69 1,081,804 $ 16.07 Options exercise price range at December 31 $ 12.15 $ 12.15 $ 12.15 to to to $ 14.49 $ 17.47 $ 33.36 Options exercisable at December 31 189,689 750,159 1,081,804 Shares available for grant at December 31* 5,285,644 3,475,496 3,540,534 ________________________ * Shares available for grant under the 2018 Plan as of December 31, 2022 reduced by awards and increased by forfeitures or expirations. At December 31, 2022, an aggregate of 1,363,107 common shares underlie awards which were forfeited or expired unexercised under the 2003 and 2013 Plans and thus are available for future issuance under the 2018 Plan upon transfer.
Schedule of Share-based Compensation, Stock Options Outstanding	The following table summarizes information about stock options outstanding at December 31, 2022: Options Outstanding Options Exercisable Exercise Prices Number Weighted Average Weighted Average Number Weighted Average $12.15 – $20.00 189,689 2.0 $ 13.43 189,689 $ 13.43
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes information about restricted stock and restricted stock units (primarily for non-U.S. recipients): 2022 Weighted Average Fair Value 2021 Weighted Average Fair Value 2020 Weighted Average Fair Value Stock / Units unvested at January 1 1,160,847 $ 8.17 1,145,058 $ 8.62 965,085 $ 11.32 Granted 1,341,019 1.22 652,743 8.42 764,012 7.11 Vested (803,550) 5.94 (558,424) 9.33 (475,113) 11.39 Forfeited (636,449) 4.40 (78,530) 8.44 (108,926) 9.90 Stock / Units unvested at December 31 1,061,867 $ 2.75 1,160,847 $ 8.17 1,145,058 $ 8.62
Share-based Compensation, Performance Shares Award Unvested Activity	The following table summarizes information about performance shares and performance share units (primarily for non-U.S. recipients): 2022 Weighted Average Fair Value 2021 Weighted Average Fair Value 2020 Weighted Average Fair Value Shares / Units unvested at January 1 972,288 $ 7.76 1,026,785 $ 8.55 753,272 $ 11.82 Granted 460,187 1.48 471,819 8.49 523,329 7.82 Vested — — — — (183,840) 17.48 Forfeited (1,114,404) 5.92 (526,316) 9.25 (65,976) 9.48 Shares / Units unvested at December 31 318,071 $ 5.15 972,288 $ 7.76 1,026,785 $ 8.55

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) by Component (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive income (loss) (“OCI”) during the year ended December 31, 2022 were as follows (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2021 $ 18,961 $ 2,127 $ (4,101) $ 1 $ 16,988 OCI before reclassifications (42,840) (5,357) 6,953 3,483 (37,761) Amount reclassified from accumulated OCI — — (466) (3,484) (3,950) Net current-period OCI (42,840) (5,357) 6,487 (1) (41,711) December 31, 2022 $ (23,879) $ (3,230) $ 2,386 $ — $ (24,723) Changes in OCI during the year ended December 31, 2021 were as follows (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2020 $ 50,329 $ (517) $ (3,674) $ (702) $ 45,436 OCI before reclassifications (31,368) 2,644 (457) (557) (29,738) Amount reclassified from accumulated OCI — — 30 1,260 1,290 Net current-period OCI (31,368) 2,644 (427) 703 (28,448) December 31, 2021 $ 18,961 $ 2,127 $ (4,101) $ 1 $ 16,988
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	Reclassifications out of accumulated OCI for the year ended December 31, 2022 and December 31, 2021 were as follows (in thousands): Amount reclassified from OCI Affected line item in the Statement of Comprehensive (Income) Loss 2022 2021 Defined Benefit Plans: Service and interest costs $ (466) $ 30 Selling, general and administrative Tax — — Income taxes Total after tax $ (466) $ 30 Derivatives: Foreign currency forward contracts hedging sales $ (137) $ 1,058 Net sales Foreign currency forward contracts hedging purchases (3,610) 428 Cost of products sold Total loss (income) before tax (3,747) 1,486 Tax 263 (226) Income taxes Total after tax $ (3,484) $ 1,260

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Capital Stock	Capital stock activity for 2022, 2021 and 2020 consisted of the following (in thousands of shares): Common Stock Class B Treasury December 31, 2020 Balance 38,613 4 (4,184) Restricted and performance stock awards 803 — (213) December 31, 2021 Balance 39,416 4 (4,397) Restricted and performance stock awards 424 — (139) Issuance of common shares 2,700 — — December 31, 2022 Balance 42,540 4 (4,536)

Charges Related To Restructur_2

Charges Related To Restructuring Activities (Tables)	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands): Severance Other Total January 1, 2020 Balance North America 211 — 211 Europe 6,406 4 6,410 All Other 406 — 406 Total 7,023 4 7,027 Charges North America 1,306 — 1,306 Europe 5,588 346 5,934 All Other 118 — 118 Total 7,012 346 7,358 Payments North America (1,338) — (1,338) Europe (6,090) (346) (6,436) All Other (358) — (358) Total (7,786) (346) (8,132) December 31, 2020 Balance North America 179 — 179 Europe 5,904 4 5,908 All Other 166 — 166 Total 6,249 4 6,253 Severance Other Total Charges North America 964 — 964 Europe 886 674 1,560 All Other 10 — 10 Total 1,860 674 2,534 Payments North America (661) — (661) Europe (6,790) (678) (7,468) All Other (176) — (176) Total (7,627) (678) (8,305) December 31, 2021 Balance North America 482 — 482 Total $ 482 $ — $ 482 Charges North America 2,472 8,174 10,646 Europe 5,359 8,559 13,918 All Other 1,256 — 1,256 Total $ 9,087 $ 16,733 $ 25,820 Payments North America (1,987) (5,148) (7,135) Europe (4,045) (7,066) (11,111) All Other (65) — (65) Total $ (6,097) $ (12,214) $ (18,311) December 31, 2022 Balance North America 967 3,026 3,993 Europe 1,314 1,493 2,807 All Other 1,191 — 1,191 Total $ 3,472 $ 4,519 $ 7,991

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Earnings (loss) before income taxes consist of the following (in thousands): 2022 2021 2020 Domestic $ (95,070) $ (53,916) $ (42,213) Foreign (2,931) 14,798 17,774 $ (98,001) $ (39,118) $ (24,439)
Schedule of Components of Income Tax Expense (Benefit)	The company has provided for income taxes (benefits) as follows (in thousands): 2022 2021 2020 Current: Federal $ 362 $ 85 $ 45 State (105) (12) (180) Foreign 3,054 6,596 6,168 3,311 6,669 6,033 Deferred: Federal — (662) (26) State — — — Foreign (241) 438 (2,166) (241) (224) (2,192) Income Taxes $ 3,070 $ 6,445 $ 3,841
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation to the effective income tax rate from the federal statutory rate is as follows: 2022 2021 2020 Statutory federal income tax rate (benefit) (21.0) % (21.0) % (21.0) % State and local income taxes, net of federal income tax benefit (0.1) — (0.6) Non-taxable disposition of subsidiaries — — (11.2) Expiring foreign tax credits 0.2 1.7 16.5 Foreign taxes at other than the federal statutory rate 1.0 3.9 8.8 Federal and foreign valuation allowances 21.3 20.4 (4.3) Withholding taxes — 0.1 0.1 Unremitted earnings — — (4.0) Debt repurchase — — 3.2 Foreign branch activity 1.0 4.0 19.3 Uncertain tax positions — 0.6 2.9 Nontaxable loan forgiveness — (5.4) — Foreign goodwill write-off — 9.0 — Other, net 0.7 3.2 6.0 Effective federal income tax rate 3.1 % 16.5 % 15.7 %
Schedule of Deferred Tax Assets and Liabilities	Significant components of long-term deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows (in thousands): 2022 2021 Bad debt $ 483 $ 387 Warranty 1,011 1,426 Other accrued expenses and reserves 398 484 Inventory 4,625 3,624 Goodwill and intangibles (17,556) (19,910) Convertible debt 3,327 5,193 Fixed assets (22,494) (24,026) Compensation and benefits 3,432 4,271 Loss and credit carryforwards 149,853 127,397 Product liability 870 1,596 State and local taxes 37,584 34,794 Valuation allowances (198,797) (176,230) Lease liability 17,496 19,649 Other, net 2,099 1,221 Net Deferred Income Taxes $ (17,669) $ (20,124)
Summary of Deferred Tax Liability Not Recognized	A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): 2022 2021 Balance at beginning of year $ 3,149 $ 3,262 Additions to: Positions taken during the current year 13 238 Positions taken during a prior year — 3 Exchange rate impact — — Deductions due to: Exchange rate impact (139) (66) Positions taken during a prior year (11) (76) Lapse of statute of limitations (216) (212) Balance at end of year $ 2,796 $ 3,149

Net Earnings Per Common Share (

Net Earnings Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated. 2022 2021 2020 (In thousands, except per share data) Basic Weighted average common shares outstanding 36,517 34,875 34,266 Net loss $ (101,071) $ (45,563) $ (28,280) Net loss per common share $ (2.77) $ (1.31) $ (0.83) Diluted Weighted average common shares outstanding 36,517 34,875 34,266 Stock options and awards 112 399 109 Weighted average common shares assuming dilution 36,629 35,274 34,375 Net loss $ (101,071) $ (45,563) $ (28,280) Net loss per common share * $ (2.77) $ (1.31) $ (0.83) * Net loss per share assuming dilution calculated utilizing weighted average shares outstanding - basic for the periods in which there was a net loss.

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD): December 31, 2022 December 31, 2021 Notional Unrealized Notional Unrealized USD / MXN — — 23 1 $ — $ — $ 23 $ 1
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location	Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment, as well as ineffective hedges, entered into in 2022 and 2021, respectively, and outstanding were as follows (in thousands USD): December 31, 2022 December 31, 2021 Notional Gain Notional Gain USD / AUD $ — $ — $ 3,792 $ (57) USD / CAD — — 14,556 $ (24) USD / EUR 60,964 980 70,454 (1,104) USD / DKK — — 10,850 (257) USD / GBP — — 4,028 32 AUD / NZD — — 7,366 (17) USD / NOK — — 2,352 (81) USD / SEK — — 2,344 (131) USD / THB — — 4,500 86 $ 60,964 $ 980 $ 120,242 $ (1,553)
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location	The fair values of the company's derivative instruments were as follows (in thousands): December 31, 2022 December 31, 2021 Assets Liabilities Assets Liabilities Derivatives designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts $ — $ — $ 1 $ — Derivatives not designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts 1,117 137 385 1,938 Total derivatives $ 1,117 $ 137 $ 386 $ 1,938
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)	The effect of derivative instruments on Accumulated Other Comprehensive Income (OCI) and the Consolidated Statements of Comprehensive Income (Loss) was as follows (in thousands): Derivatives (foreign currency forward exchange contracts) in ASC 815 cash flow hedge relationships Amount of Gain Amount of Gain (Loss) Amount of Gain (Loss) Year ended December 31, 2022 $ 3,483 $ 3,484 $ — Year ended December 31, 2021 $ (557) $ (1,260) $ — Derivatives (foreign currency forward exchange contracts) not designated as hedging instruments under ASC 815 Amount of Gain (Loss) Year ended December 31, 2022 $ 980 Year ended December 31, 2021 $ (1,553)

Fair Values of Financial Instru

Fair Values of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides a summary of the company's assets and liabilities that are measured on a recurring basis (in thousands): Basis for Fair Value Measurements at Reporting Date Quoted Prices in Active Markets Significant Significant Level I Level II Level III December 31, 2022 Forward exchange contracts—net — $ 980 — Secured convertible 2026 debt conversion liability — (85) — December 31, 2021 Forward exchange contracts—net — $ (1,552) —
Fair Value, by Balance Sheet Grouping	The carrying and fair values of the company's financial instruments at December 31, 2022 and 2021 are as follows (in thousands): 2022 2021 Carrying Fair Value Carrying Fair Value Cash and cash equivalents $ 58,792 $ 58,792 $ 83,745 $ 83,745 Forward contracts in Other Current Assets 1,117 1,117 386 386 Forward contracts in Accrued Expenses (137) (137) (1,938) (1,938) Total debt (including current maturities of long-term debt) * (354,241) (278,027) (308,129) (259,472) 2022 Notes — — (2,642) (2,632) Series I 2024 Notes (72,408) (62,460) (72,140) (64,897) Series II 2024 Notes (76,719) (64,678) (78,251) (74,165) 2026 Notes (67,665) (32,276) (119,036) (81,718) 2026 Secured Notes (37,240) (34,341) — — 2026 Term Loan (82,808) (66,871) — — Other (17,401) (17,401) (36,060) (36,060) Secured Convertible 2026 debt conversion liability in Other Long-Term Obligations (85) (85) — — ________ * The company's total debt is shown net of discount and fees associated with the convertible senior notes and term loan due in 2022, 2024 and 2026 on the company's consolidated balance sheets. Accordingly, the fair values due in 2022, 2024 and 2026 are included in the long-term debt presented in this table are also shown net of the discount and fees. Total debt amounts exclude operating and finance lease obligations.

Business Segments (Tables)

Business Segments (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The information by segment is as follows (in thousands): 2022 2021 2020 Revenues from external customers Europe (1) $ 434,372 $ 499,118 $ 468,041 North America (2) 276,891 340,980 348,307 All Other (Asia Pacific) 30,470 32,359 34,341 Consolidated $ 741,733 $ 872,457 $ 850,689 Intersegment revenues Europe $ 14,708 $ 21,864 $ 17,384 North America 32,229 56,681 80,748 All Other (Asia Pacific) — — 2,528 Consolidated $ 46,937 $ 78,545 $ 100,660 Restructuring charges before income taxes Europe $ 13,918 $ 1,560 $ 5,934 North America 10,646 964 1,306 All Other 1,256 10 118 Consolidated $ 25,820 $ 2,534 $ 7,358 Depreciation and amortization Europe $ 6,513 $ 8,557 $ 7,615 North America 8,427 7,623 6,013 All Other (3) 551 641 689 Consolidated $ 15,491 $ 16,821 $ 14,317 Net interest expense Europe $ 483 $ 2,790 $ 1,884 North America 27,773 21,764 26,510 All Other 208 (248) 12 Consolidated $ 28,464 $ 24,306 $ 28,406 Operating income (loss) Europe $ 13,413 $ 33,769 $ 22,682 2022 2021 2020 North America (34,197) (1,928) 9,449 All Other (3) (30,603) (24,977) (23,236) Charges related to restructuring activities (25,820) (2,534) (7,358) Gain on sale of business — — 9,790 Impairment of goodwill — (28,564) — Impairment of intangible assets (3,259) — — Consolidated operating income (loss) (80,466) (24,234) 11,327 Net gain on convertible derivatives 1,510 — — Gain (loss) on debt extinguishment including debt finance charges and fees 9,419 9,422 (7,360) Net interest expense (28,464) (24,306) (28,406) Loss before income taxes $ (98,001) $ (39,118) $ (24,439) Assets Europe $ 575,632 $ 675,051 $ 705,314 North America 170,997 205,998 207,347 All Other 24,340 28,482 33,320 Consolidated $ 770,969 $ 909,531 $ 945,981 Long-lived assets Europe (4) $ 404,433 $ 450,026 $ 472,599 North America (5) 61,738 68,240 92,195 All Other 5,480 5,877 6,721 Consolidated $ 471,651 $ 524,143 $ 571,515 Expenditures for assets Europe $ 727 $ 2,419 $ 5,221 North America (6) 2,530 14,055 16,473 All Other 521 1,224 610 Consolidated $ 3,778 $ 17,698 $ 22,304 ________________________ (1) Europe's commissionaire structure reflects the majority of revenues to external customers through Switzerland. (2) Revenues from external customers for the United States were $256,888,000, $312,805,000 and $316,687,000 for 2022, 2021 and 2020, respectively. (3) Consists of unallocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments, and operating profit (loss related to the company's Asia Pacific business). (4) Property and Equipment net book value within France were $6,136,000, $7,342,000 and $8,452,000 and Germany were $3,376,000, $4,119,000 and $5,904,000 at the end of 2022, 2021 and 2020, respectively. (5) Property and Equipment net book value within the United States were $33,901,000, $38,411,000 and $27,882,000 at the end of 2022, 2021 and 2020, respectively. (6) 2021 and 2020 expenditures for assets primarily driven by the company's ERP project.
Revenue from External Customers by Products and Services	Net sales by product category, are as follows (in thousands): 2022 2021 2020 Europe Lifestyle $ 216,325 $ 248,325 $ 222,668 Mobility and Seating 186,153 214,398 200,687 Respiratory Therapy 14,003 19,348 24,786 Other (1) 17,891 17,047 19,900 $ 434,372 $ 499,118 $ 468,041 North America Lifestyle $ 135,615 $ 148,369 $ 165,267 Mobility and Seating 99,116 110,998 109,923 Respiratory Therapy 41,083 80,903 72,285 Other (1) 1,077 710 832 $ 276,891 $ 340,980 $ 348,307 All Other (Asia Pacific) Mobility and Seating $ 11,917 $ 12,112 $ 14,150 Lifestyle 11,221 11,438 13,503 Respiratory Therapy 2,049 3,101 1,383 Other (1) 5,283 5,708 5,305 $ 30,470 $ 32,359 $ 34,341 Total Consolidated $ 741,733 $ 872,457 $ 850,689 ________________________ (1) Includes various services, including repair services, equipment rentals and external contracting.

Interim Financial Information (

Interim Financial Information (Tables)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	(In thousands, except per share data) QUARTER ENDED 2022 March 31, June 30, September 30, December 31, Net sales $ 200,988 $ 189,017 $ 170,408 $ 181,320 Gross profit 47,729 47,982 31,379 48,303 Income (Loss) before income taxes (22,877) (21,023) (33,434) (20,667) Net income (loss) (24,197) (21,943) (34,354) (20,577) Net income (loss) per share—basic (0.69) (0.62) (0.92) (0.54) Net income (loss) per share—assuming dilution * (0.69) (0.62) (0.92) (0.54) 2021 March 31, June 30, September 30, December 31, Net sales $ 196,202 $ 225,864 $ 224,200 $ 226,191 Gross profit 54,638 60,818 60,310 63,340 Income (Loss) from before income taxes (12,174) (9,578) (20,919) 3,553 Net income (loss) (14,044) (10,698) (22,759) 1,938 Net income (loss) per share—basic (0.41) (0.31) (0.65) 0.06 Net income (loss) per share—assuming dilution * (0.41) (0.31) (0.65) 0.05 ________________________ * Net earnings (loss) per share assuming dilution calculated utilizing weighted average shares outstanding - basic in periods in which there is a net loss.

Accounting Policies - Property

Accounting Policies - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2022
Furniture and fixtures | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Furniture and fixtures | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years
Building and Building Improvements [Member] | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Building and Building Improvements [Member] | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	40 years

Accounting Policies - Product L

Accounting Policies - Product Liability Cost (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Accounting Policies [Abstract]
Annual policy losses insured per occurence	$ 10,000,000
Annual policy losses, in aggregate	13,000,000
Annual policy losses, external insurance coverage, in aggregate	$ 75,000,000

Accounting Policies - Additiona

Accounting Policies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Research and development expense	$ 3,492,000	$ 8,656,000	$ 12,275,000
Advertising expense	$ 4,511,000	5,062,000	5,107,000
Recent Accounting Pronouncements Already Adopted [Line Items]
Adoption of ASU 2020-06, Convertible Debt Discounts Removed		25,218,000
Amortization of convertible debt discount, term loan original issuance discount and accretion of convertible debt			$ 9,673,000
Debt Discount Amortization, per Basic and Diluted Share			$ 0.28
Retained Earnings
Recent Accounting Pronouncements Already Adopted [Line Items]
Adoption of ASU 2020-06		(9,670,000)
Additional Paid-in- Capital
Recent Accounting Pronouncements Already Adopted [Line Items]
Adoption of ASU 2020-06		$ 34,798,000

Accounting Policies - Derivativ

Accounting Policies - Derivative Instruments (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2022	Sep. 30, 2022	Jul. 26, 2022
Debt Instrument [Line Items]
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 1,595,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2021
Debt Instrument [Line Items]
Debt Instrument Exchange Amount	$ 35,375,000
Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 41,475,000	$ 31,106,000
Interest rate (as a percent)				5.68%

Accounting Policies (Details)

Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021
Accounting Policies [Abstract]
Adoption of ASU 2020-06, Convertible Debt Discounts Removed		$ 25,218,000
Amortization of convertible debt discount, term loan original issuance discount and accretion of convertible debt	$ 9,673,000
Debt Discount Amortization, per Basic and Diluted Share	$ 0.28

Operations Held for Sale (Detai

Operations Held for Sale (Details) - USD ($)	1 Months Ended	2 Months Ended	12 Months Ended
	Jan. 31, 2023	Mar. 07, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue		$ 5,331,000
Disposal Group, Including Discontinued Operation, Inter-company Revenue		2,532,000
Disposal Group, Including Discontinued Operation, Earnings Before Taxes		445,000
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net		4,129,000
Disposal Group, Including Discontinued Operation, Inventory		3,082,000
Disposal Group, Including Discontinued Operation, Other Assets		855,000
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment		600,000
Disposal Group, Including Discontinued Operation, Operating Lease Right-of-Use Asset		2,127,000
Disposal Group, Including Discontinued Operation, Assets		10,793,000
Disposal Group, Including Discontinued Operation, Accounts Payable		4,692,000
Disposal Group, Including Discontinued Operation, Accrued Liabilities		2,473,000
Disposal Group, Including Discontinued Operation, Accrued Income Tax Payable		41,000
Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current		366,000
Disposal Group, Including Discontinued Operation, Operating Lease, Liability, NonCurrent		1,019,000
Disposal Group, Including Discontinued Operation, Liabilities		$ 8,591,000
Proceeds from sale of business			$ 0	$ 0	$ 14,563,000
Gain on sale of business			$ 0	$ 0	$ 9,790,000
Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business	$ 11,925,644

Receivables - Narrative (Detail

Receivables - Narrative (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) payment	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Receivables [Abstract]
Number of missed payments before delinquent | payment	3
Credit amount requiring additional analysis	$ 250,000
Average period of adjudication	18 months
Contingent Liability, Guarantee	$ 333,000
Accounts, Notes, Loans and Financing Receivable [Line Items]
Adoption of Credit Loss Standard		$ (25,128,000)	$ (243,000)
Risk Level, Low
Receivables [Abstract]
Receivables, Expected Loss Percentage, North America excluding Canada	1%
Receivables, Expected Loss Percentage, Canada	0.10%
Receivables, Expected Loss Percentage, Europe	0.30%
Receivables, Expected Loss Percentage, AsiaPac	1%
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, Europe	0.30%
Receivables, Expected Loss Percentage, Canada	0.10%
Receivables, Expected Loss Percentage, AsiaPac	1%
Receivables, Expected Loss Percentage, North America excluding Canada	1%
Risk Level, Medium
Receivables [Abstract]
Receivables, Expected Loss Percentage, Canada	0.80%
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, Canada	0.80%
Risk Level, High
Receivables [Abstract]
Receivables, Expected Loss Percentage, Canada	2.70%
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, Canada	2.70%

Receivables - Accounts Receivab

Receivables - Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable [Abstract]
Accounts Receivable, Gross	$ 112,659	$ 142,806
Customer Rebate Reserve	(11,569)	(12,267)
Cash Discount Reserves	(8,756)	(9,179)
Allowance for Doubtful Accounts Receivable	(3,279)	(3,642)
Returns and Allowances Reserve	(1,103)	(603)
Accounts Receivable, Net	$ 87,952	$ 117,115

Receivables - Installment Recei

Receivables - Installment Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Receivables [Abstract]
Installment receivables, current	$ 311	$ 218
Installment receivables, long-term	266	734
Total Installment Receivables	577	952
Unearned Interest - Current	0	0
Unearned interest, long-term	0	0
Unearned Interest	0	0
Installment receivables net of unearned interest, current	311	218
Installment receivables net of unearned interest, long-term	266	734
Total installment receivables net of unearned interest	577	952
Allowance for doubtful accounts, current	0	0
Allowance for doubtful accounts, long-term	0	0
Allowance for doubtful accounts	0	0	$ (487)
Installment receivables, net	311	218
Installment receivables, long-term	266	734
Total installment receivables, net	$ 577	$ 952

Receivables - Rollforward of Al

Receivables - Rollforward of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Allowance for Doubtful Accounts [Roll Forward]
Balance as of beginning of period	$ 0	$ 487
Current period provision (benefit)	0	(75)
Direct write-offs charged against the allowance	0	(412)
Balance as of end of period	$ 0	$ 0

Receivables - Installment Rec_2

Receivables - Installment Receivables by Class (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total Installment Receivables
Non-impaired installment receivables with no related allowance recorded	$ 577,000	$ 952,000
Impaired installment receivables with a related allowance recorded	0	0
Total installment receivables	577,000	952,000
Unpaid Principal Balance
Non-impaired installment receivables with no related allowance recorded	577,000	952,000
Impaired installment receivables with a related allowance recorded	0	0
Total installment receivables	577,000	952,000
Related Allowance for Doubtful Accounts
Impaired installment receivables with a related allowance recorded	0	0
Interest Income Recognized
Non-impaired installment receivables with no related allowance recorded	0	0
Impaired installment receivables with a related allowance recorded	0	0
Total installment receivables	0	0
All Other
Total Installment Receivables
Non-impaired installment receivables with no related allowance recorded		952,000
Impaired installment receivables with a related allowance recorded	577,000
Unpaid Principal Balance
Non-impaired installment receivables with no related allowance recorded		$ 952,000
Impaired installment receivables with a related allowance recorded	577,000
Interest Income Recognized
Impaired installment receivables with a related allowance recorded	$ 0

Receivables - Allowance for Cre

Receivables - Allowance for Credit losses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Financing Receivable, Allowance for Credit Loss [Line Items]
Allowance for Credit Losses	$ 3,279	$ 3,642
Allowance for Losses, Adjustments, Other	862
Allowance for Credit Losses, Write-downs	$ (1,225)

Receivables - Aging of Installm

Receivables - Aging of Installment Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financing Receivable, Recorded Investment, Past Due [Line Items]
Current	$ 533	$ 952
Installment Receivable, 1 to 29 Days Past Due	44	0
Installment Receivable, 30 to 59 Days Past Due	0	0
Installment Sales, 60 to 89 Days Past Due	0	0
Installment Receivable, Greater than 90 Days Past Due	0	0
Total	577	952
USA
Financing Receivable, Recorded Investment, Past Due [Line Items]
Current	0	0
Installment Receivable, 1 to 29 Days Past Due	0	0
Installment Receivable, 30 to 59 Days Past Due	0	0
Installment Sales, 60 to 89 Days Past Due	0	0
Installment Receivable, Greater than 90 Days Past Due	0	0
Total	0	0
IVC Canada
Financing Receivable, Recorded Investment, Past Due [Line Items]
Current		952
Installment Receivable, 1 to 29 Days Past Due		0
Installment Receivable, 30 to 59 Days Past Due		0
Installment Sales, 60 to 89 Days Past Due		0
Installment Receivable, Greater than 90 Days Past Due		0
Total		$ 952
All Other
Financing Receivable, Recorded Investment, Past Due [Line Items]
Current	533
Installment Receivable, 1 to 29 Days Past Due	44
Installment Receivable, 30 to 59 Days Past Due	0
Installment Sales, 60 to 89 Days Past Due	0
Installment Receivable, Greater than 90 Days Past Due	0
Total	$ 577

Inventories - (Details)

Inventories - (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods		$ 62,124		$ 45,476
Raw materials		69,371		57,174
Work in process		12,779		9,911
Inventory, Net		144,274		$ 112,561
Inventory Adjustments	$ 5,387
Purchase Obligation	3,264
Inventory Write-down	$ 8,651	$ 0	$ 0

Other Current Assets - Componen

Other Current Assets - Components of Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Tax receivables principally value added taxes	$ 22,946	$ 21,943
Prepaid insurance	1,223	4,462
Prepaid inventory and freight	3,077	2,394
Recoverable income taxes	1,990	2,301
Receivable due from information technology provider	934	612
Derivatives (foreign currency forward contracts)	1,117	386
Prepaid debt fees	339	379
Service contracts	1,366	304
Prepaid and other current assets	6,710	7,255
Other current assets	$ 39,702	$ 40,036

Other Long-Term Assets - (Detai

Other Long-Term Assets - (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Cash surrender value of life insurance policies	$ 2,686	$ 2,481
Installment receivables	266	734
Deferred financing fees	733	409
Investments	85	86
Other	287	112
Other Assets	5,159	5,362
Deferred Tax Assets, Tax Deferred Expense	$ 1,102	$ 1,540

Property And Equipment - (Detai

Property And Equipment - (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 338,708	$ 351,819
Less allowance for depreciation	(287,175)	(290,898)
Property and equipment, net	51,533	60,921
Capitalized Computer Software, Net	26,015	28,715
Unpaid Purchases of Property and Equipment	0	1,090
Capitalized Computer Software, Amortization	3,176	1,733
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	269,835	278,347
Land, buildings and improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	25,095	27,299
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,053	8,943
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,802	6,782
Capitalized software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 30,923	$ 30,448

Goodwill - (Details)

Goodwill - (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Beginning Balance	$ 355,875	$ 402,461
Foreign currency translation adjustments	(29,594)	(18,022)
Goodwill and Intangible Asset Impairment		(28,564)
Ending Balance	$ 326,281	$ 355,875	$ 402,461
Discounted cash flow, discount rate	14.51%	11.19%	11.27%
Institutional Products Group
Goodwill [Roll Forward]
Beginning Balance	$ 0	$ 28,485
Foreign currency translation adjustments	0	79
Goodwill and Intangible Asset Impairment		(28,564)
Ending Balance	0	0	$ 28,485
Europe
Goodwill [Roll Forward]
Beginning Balance	355,875	373,976
Foreign currency translation adjustments	(29,594)	(18,101)
Ending Balance	$ 326,281	$ 355,875	$ 373,976

Intangibles - Narrative (Detail

Intangibles - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets			$ 507,000	$ 404,000	$ 377,000
Impairment of intangible assets			3,259,000	0	0
Impairment of intangible assets			3,259,000	0	$ 0
Europe
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 2,247,000		2,247,000
Impairment of intangible assets	2,247,000		2,247,000
North America
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets		$ 1,012,000	1,012,000
Impairment of intangible assets		$ 1,012,000	1,012,000
Trademarks
Finite-Lived Intangible Assets [Line Items]
Historical Cost	$ 18,867,000		$ 18,867,000	$ 24,137,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets			2 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets			7 years
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets			5 years 7 months 6 days

Intangibles - Finite and Indefi

Intangibles - Finite and Indefinite Lived Intangibles (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	$ 83,757	$ 93,831
Accumulated Amortization	62,088	67,475
Customer lists
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	48,515	52,447
Accumulated Amortization	48,515	52,447
License agreements
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	3,981	2,905
Accumulated Amortization	1,480	1,196
Developed technology
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	7,154	7,652
Accumulated Amortization	6,859	7,149
Patents
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	4,092	5,543
Accumulated Amortization	4,092	5,543
Other
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	1,148	1,147
Accumulated Amortization	1,142	1,140
Trademarks
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	$ 18,867	$ 24,137

Intangibles - Finite-Lived Inta

Intangibles - Finite-Lived Intangible Asset Future Amortization Expense (Details)	Dec. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Future amortization expense, 2022	$ 611,000
Future amortization expense, 2023	562,000
Future amortization expense, 2024	439,000
Future amortization expense, 2025	437,000
Future amortization expense, 2026	$ 311,000

Accrued Expenses - Components o

Accrued Expenses - Components of Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Salaries and wages	$ 19,307	$ 23,217
Taxes other than income taxes, primarily value added taxes	27,106	24,012
Warranty	7,981	11,198	$ 10,991
Professional	11,267	8,697
Rebates	4,923	6,569
Freight	4,542	5,460
Restructuring Reserve, Current	3,743	0
Deferred revenue	2,279	4,156
IT service contracts	5,581	4,013
Interest	6,900	3,297
Product liability, current portion	2,125	2,362
Derivatives (foreign currency forward exchange contracts)	137	1,938
Insurance	951	625
Severance	3,472	400
Supplemental Executive Retirement Program liability Plan (SERP)	391	391
Other items, principally trade accruals	5,386	6,636
Accrued expenses	$ 106,091	$ 102,971

Accrued Expenses - Warranty Sch

Accrued Expenses - Warranty Schedule (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Product Warranty Liability [Line Items]
Balance as of January 1	$ 11,198	$ 10,991
Warranties provided during the period	2,202	6,361
Settlements made during the period	(5,577)	(6,718)
Changes in liability for pre-existing warranties during the period, including expirations	158	564
Balance as of December 31	$ 7,981	$ 11,198

Long-Term Debt - Debt (Details)

Long-Term Debt - Debt (Details) $ / shares in Units, € in Thousands	3 Months Ended							12 Months Ended
	Dec. 31, 2022 USD ($) shares $ / shares	Sep. 30, 2022 USD ($) payment	Sep. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) $ / shares	Dec. 31, 2022 USD ($) payment shares $ / shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Jul. 26, 2022 USD ($)	Dec. 31, 2021 EUR (€) shares	Mar. 11, 2021 USD ($)	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Long-term Debt and Capital Lease Obligations, Including Current Maturities	$ 354,241,000							$ 354,241,000	$ 308,129,000
Less current maturities of long-term debt	(154,000)							(154,000)	(3,107,000)
Long-term debt of current maturities	354,087,000							354,087,000	305,022,000
Lifetime to date - Accretion Expense								8,434,000	5,347,000
Remaining Accretion	8,188,000							8,188,000
Loss (gain) on debt extinguishment including debt finance charges and associated fees	$ 3,021,000	$ 6,398,000	$ 10,131,000	$ 709,000				$ 9,419,000	9,422,000	$ (7,360,000)
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022
Debt Instrument [Line Items]
Effective Interest Rate	10.90%							10.90%
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2024
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 72,909,000							$ 72,909,000	72,909,000
Long-term Debt and Capital Lease Obligations, Including Current Maturities	72,408,000							72,408,000	72,140,000
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	(501,000)							(501,000)	(769,000)
Debt Instrument, Net Carrying Amount	$ 72,408,000							$ 72,408,000	72,140,000
Debt Instrument, Loss on Exchange						$ 5,885,000
Effective Interest Rate	5.40%							5.40%
Interest rate (as a percent)	5%							5%
Percent of the Applicable Conversion Price	130%							130%
Last Reported Sales Price Period, Common Stock								20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days								30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%							100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal						$ 1,000
Debt Instrument, Convertible, Threshold Trading Days								10
Business Day Period								5 days
Percent of the Product of the Last Reported Sale Price, Common Shares	98%							98%
Convertible Preferred Stock, Shares Issued upon Conversion | shares						67.6819
Initial conversion price | $ / shares						$ 14.78
Debt Instrument, Fee Amount						$ 1,338,000
Debt Instrument, Increase, Accrued Interest								$ 3,645,000	3,645,000
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 77,309,000							77,309,000	79,222,000
Long-term Debt and Capital Lease Obligations, Including Current Maturities	76,719,000							76,719,000	78,251,000
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	(590,000)							(590,000)	(971,000)
Debt Instrument, Net Carrying Amount	$ 76,719,000							$ 76,719,000	78,251,000
Debt Instrument, Loss on Exchange					$ 6,599,000
Effective Interest Rate	10.40%							10.40%
Interest rate (as a percent)	5%							5%
Percent of the Applicable Conversion Price	130%							130%
Last Reported Sales Price Period, Common Stock								20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days								30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%							100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal										$ 1,000
Debt Instrument, Convertible, Threshold Trading Days								10
Business Day Period								5 days
Percent of the Product of the Last Reported Sale Price, Common Shares	98%							98%
Convertible Preferred Stock, Shares Issued upon Conversion | shares										67.6819
Initial conversion price | $ / shares										$ 14.78
Debt Instrument, Fee Amount										$ 1,505,000
Debt Instrument, Increase, Accrued Interest								$ 3,507,000	3,693,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 69,700,000							69,700,000	125,000,000				$ 125,000,000
Long-term Debt and Capital Lease Obligations, Including Current Maturities	67,665,000							67,665,000	119,036,000
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	(2,035,000)							(2,035,000)	(5,964,000)
Debt Instrument, Net Carrying Amount	$ 67,665,000							$ 67,665,000
Effective Interest Rate	4.10%							4.10%
Interest rate (as a percent)	4.25%							4.25%
Percent of the Applicable Conversion Price	130%							130%
Last Reported Sales Price Period, Common Stock								20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days | payment								30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%							100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000							$ 1,000	$ 1,000
Debt Instrument, Convertible, Threshold Trading Days | payment								10
Business Day Period								5 days
Percent of the Product of the Last Reported Sale Price, Common Shares	98%							98%
Convertible Preferred Stock, Shares Issued upon Conversion | shares									94.6096			94.6096
Initial conversion price | $ / shares	$ 10.57							$ 10.57	$ 10.57
Debt Instrument, Fee Amount													$ 5,697,000
Debt Instrument, Increase, Accrued Interest								$ 4,467,000	$ 4,220,000
Cap Price of Capped Call Transaction | $ / shares	$ 16.58							$ 16.58
Capped Call Options, Outstanding | shares	125,000							125,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 0						$ 120,000,000	$ 0	2,650,000
Long-term Debt and Capital Lease Obligations, Including Current Maturities	0							0	2,642,000
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	0							0	(8,000)
Debt Instrument, Net Carrying Amount	$ 0							$ 0	2,642,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 21.4375
Proceeds from Issuance of Warrants							$ 14,100,000
Class of Warrant or Right, Outstanding | shares	4,215,212							4,215,212
Debt Instrument, Repurchase Amount				78,850,000
Debt Instrument, Loss on Exchange				$ 709,000
Interest rate (as a percent)	4.50%							4.50%
Debt Instrument, Fee Amount														$ 4,711,000
Debt Instrument, Increase, Accrued Interest								$ 50,000	859,000
Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 41,475,000	$ 31,106,000						41,475,000
Long-term Debt and Capital Lease Obligations, Including Current Maturities	37,240,000							37,240,000	0
Debt Instrument, Unamortized Discount	(1,447,000)							(1,447,000)
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	(2,788,000)							(2,788,000)
Interest rate (as a percent)											5.68%
Debt Instrument, Increase, Accrued Interest								905,000
Other obligations
Debt Instrument [Line Items]
Long-term Debt and Capital Lease Obligations, Including Current Maturities	17,401,000							17,401,000	36,060,000
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026
Debt Instrument [Line Items]
Percent of the Applicable Conversion Price											150%
Last Reported Sales Price Period, Common Stock		20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days | payment		30
Convertible Senior Notes, Percentage of Principal Required for Repurchase											100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal											$ 1,000
Secured Debt | Secured Term Loans due July 2026
Debt Instrument [Line Items]
Debt Instrument, Face Amount	90,500,000							90,500,000			104,500,000
Long-term Debt and Capital Lease Obligations, Including Current Maturities	82,808,000							82,808,000	0
Debt Instrument, Unamortized Discount	(1,846,000)							(1,846,000)
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	$ (5,846,000)							$ (5,846,000)
Interest rate (as a percent)	5.68%							5.68%
Debt Instrument, Fee Amount											$ 6,480,000
Debt Instrument, Increase, Accrued Interest								$ 3,352,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Letters of credit outstanding	$ 15,220,000							$ 15,220,000	22,150,000
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent	11.25%							11.25%
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (North America Credit Agreement)
Debt Instrument [Line Items]
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent	12.50%							12.50%
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France)									$ 7,366,000
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent	12.50%							12.50%
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) | Euro Member Countries, Euro
Debt Instrument [Line Items]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France) | €												€ 6,500
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Prior Credit Agreement)
Debt Instrument [Line Items]
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent	11.25%							11.25%

Long-Term Debt - Convertible De

Long-Term Debt - Convertible Debt (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Interest Paid, Including Capitalized Interest, Operating and Investing Activities	$ 18,309,000	$ 17,243,000	$ 16,909,000
Long-term Debt and Capital Lease Obligations, Including Current Maturities	$ 354,241,000	308,129,000
Convertible Senior Notes at 5.00% February 2024 | Convertible Subordinated Debt
Debt Disclosure [Abstract]
Initial conversion price				$ 14.78
Debt Instrument [Line Items]
Interest rate (as a percent)	5%
Debt Instrument, Face Amount	$ 72,909,000	72,909,000
Effective Interest Rate	5.40%
Long-term Debt and Capital Lease Obligations, Including Current Maturities	$ 72,408,000	72,140,000
Debt Instrument, Increase, Accrued Interest	3,645,000	3,645,000
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	(501,000)	(769,000)
Debt Instrument, Net Carrying Amount	$ 72,408,000	$ 72,140,000

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) $ / shares in Units, € in Thousands, £ in Thousands	3 Months Ended							12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares	Sep. 30, 2022 USD ($) payment Rate shares	Sep. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) $ / shares	Dec. 31, 2022 USD ($) payment $ / shares Rate	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 23, 2022 USD ($)	Oct. 03, 2022 USD ($)	Jul. 26, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2021 GBP (£) shares	Mar. 11, 2021 USD ($)	May 15, 2020 USD ($)	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Interest Paid, Including Capitalized Interest, Operating and Investing Activities								$ 18,309,000	$ 17,243,000	$ 16,909,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Year One	$ 154,000							154,000
Year Two	150,245,000							150,245,000
Year Three	0							0
Year Four	216,895,000							216,895,000
Year Five	0							0
Payments for Repurchase of Common Stock								151,000	1,754,000	1,707,000
Loss (gain) on debt extinguishment including debt finance charges and associated fees	$ 3,021,000	$ 6,398,000	$ 10,131,000	$ 709,000				$ 9,419,000	9,422,000	(7,360,000)
Accretion Rate	4.70%							4.70%
Purchases of capped calls								$ 0	(18,787,000)	$ 0
Long-term Debt and Capital Lease Obligations, Including Current Maturities	$ 354,241,000							$ 354,241,000	308,129,000
Borrowing Against Cash Surrender Value of Life Insurance														$ 2,000,000
CARES Act Loan
Debt Instrument [Line Items]
Interest rate (as a percent)	1%							1%
Long-term Debt, Fiscal Year Maturity [Abstract]
Unsecured Debt																		$ 10,000,000
Secured Term Loans due July 2026
Long-term Debt, Fiscal Year Maturity [Abstract]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net													$ 2,000,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2024
Debt Instrument [Line Items]
Interest rate (as a percent)	5%							5%
Debt Instrument, Net Carrying Amount	$ 72,408,000							$ 72,408,000	72,140,000
Debt Instrument, Face Amount	$ 72,909,000							$ 72,909,000	72,909,000
Initial conversion price | $ / shares						$ 14.78
Debt Instrument, Loss on Exchange						$ 5,885,000
Effective Interest Rate	5.40%							5.40%
Long-term Debt, Fiscal Year Maturity [Abstract]
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%							100%
Convertible Preferred Stock, Shares Issued upon Conversion | shares						67.6819
Convertible Debt, Conversion Rate of Commmon Shares, Principal						$ 1,000
Debt Instrument, Fee Amount						1,338,000
Debt Instrument, Increase, Accrued Interest								$ 3,645,000	3,645,000
Last Reported Sales Price Period, Common Stock								20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days								30
Percent of the Applicable Conversion Price	130%							130%
Debt Instrument, Convertible, Threshold Trading Days								10
Percent of the Product of the Last Reported Sale Price, Common Shares	98%							98%
Debt Instrument Repurchase Amount, Cash Paid						6,928,000
Debt Instrument Exchange Amount						$ 72,909,000
Business Day Period								5 days
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	$ (501,000)							$ (501,000)	(769,000)
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	8.80%							8.80%
Long-term Debt and Capital Lease Obligations, Including Current Maturities	$ 72,408,000							$ 72,408,000	72,140,000
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Interest rate (as a percent)	5%							5%
Debt Instrument, Net Carrying Amount	$ 76,719,000							$ 76,719,000	78,251,000
Debt Instrument, Face Amount	$ 77,309,000							$ 77,309,000	79,222,000
Initial conversion price | $ / shares										$ 14.78
Debt Instrument, Loss on Exchange					$ 6,599,000
Effective Interest Rate	10.40%							10.40%
Long-term Debt, Fiscal Year Maturity [Abstract]
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%							100%
Convertible Preferred Stock, Shares Issued upon Conversion | shares										67.6819
Convertible Debt, Conversion Rate of Commmon Shares, Principal										$ 1,000
Debt Instrument, Fee Amount										1,505,000
Debt Instrument, Non-Cash Interest Expense Recognized in the Period								$ 3,590,000	3,534,000
Debt Instrument, Increase, Accrued Interest								$ 3,507,000	3,693,000
Last Reported Sales Price Period, Common Stock								20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days								30
Percent of the Applicable Conversion Price	130%							130%
Debt Instrument, Convertible, Threshold Trading Days								10
Percent of the Product of the Last Reported Sale Price, Common Shares	98%							98%
Debt Instrument Repurchase Amount, Cash Paid										$ 5,593,000
Debt Instrument Exchange Amount		5,000,000			73,875,000
Business Day Period								5 days
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	$ (590,000)							$ (590,000)	(971,000)
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	9%							9%
Long-term Debt and Capital Lease Obligations, Including Current Maturities	$ 76,719,000							$ 76,719,000	78,251,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026
Debt Instrument [Line Items]
Interest rate (as a percent)	4.25%							4.25%
Debt Instrument, Net Carrying Amount	$ 67,665,000							$ 67,665,000
Debt Instrument, Face Amount	$ 69,700,000							$ 69,700,000	$ 125,000,000								$ 125,000,000
Initial conversion price | $ / shares	$ 10.57							$ 10.57	$ 10.57
Effective Interest Rate	4.10%							4.10%
Long-term Debt, Fiscal Year Maturity [Abstract]
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%							100%
Convertible Preferred Stock, Shares Issued upon Conversion | shares									94.6096						94.6096	94.6096
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000							$ 1,000	$ 1,000
Debt Instrument, Fee Amount																	$ 5,697,000
Debt Instrument, Increase, Accrued Interest								$ 4,467,000	4,220,000
Last Reported Sales Price Period, Common Stock								20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days | payment								30
Percent of the Applicable Conversion Price	130%							130%
Debt Instrument, Convertible, Threshold Trading Days | payment								10
Percent of the Product of the Last Reported Sale Price, Common Shares	98%							98%
Business Day Period								5 days
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	$ (2,035,000)							$ (2,035,000)	(5,964,000)
Long-term Debt and Capital Lease Obligations, Including Current Maturities	67,665,000							67,665,000	119,036,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026 | Round 1 funding
Long-term Debt, Fiscal Year Maturity [Abstract]
Debt Instrument Exchange Amount		41,475,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026 | Round 2 funding
Debt Instrument [Line Items]
Debt Instrument, Face Amount	69,700,000							69,700,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Debt Instrument Exchange Amount	$ 13,825,000
Convertible Subordinated Debt | Convertible Senior Subordinated Debentures at 5.00% February 2021
Debt Instrument [Line Items]
Amortization of Debt Issuance Costs								$ 1,011,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022
Debt Instrument [Line Items]
Interest rate (as a percent)	4.50%							4.50%
Debt Instrument, Net Carrying Amount	$ 0							$ 0	2,642,000
Debt Instrument, Face Amount	0						$ 120,000,000	0	2,650,000
Debt Instrument, Loss on Exchange				709,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Proceeds from Issuance of Warrants							$ 14,100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 21.4375
Debt Instrument, Net Proceeds							$ 115,289,000
Debt Instrument, Fee Amount																			$ 4,711,000
Derivative, Amount of Hedged Item							$ (10,680,000)
Debt Instrument, Increase, Accrued Interest								50,000	859,000
Debt Instrument Repurchase Amount, Cash Paid	2,650,000							2,650,000
Debt Instrument, Repurchase Amount				$ 78,850,000
Debt Instrument Exchange Amount					38,500,000
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	0							0	(8,000)
Long-term Debt and Capital Lease Obligations, Including Current Maturities	0							0	2,642,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2021
Long-term Debt, Fiscal Year Maturity [Abstract]
Debt Instrument Exchange Amount					$ 35,375,000
Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes
Long-term Debt, Fiscal Year Maturity [Abstract]
Debt Instrument Exchange Amount		5,000,000
Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount	(1,447,000)							(1,447,000)
Interest rate (as a percent)													5.68%
Debt Instrument, Face Amount	41,475,000	$ 31,106,000						41,475,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Debt Instrument, Non-Cash Interest Expense Recognized in the Period								148,000
Debt Instrument, Increase, Accrued Interest								905,000
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	$ (2,788,000)							$ (2,788,000)
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	10.10%							10.10%
Long-term Debt and Capital Lease Obligations, Including Current Maturities	$ 37,240,000							$ 37,240,000	0
Convertible Subordinated Debt | Secured Term Loans due July 2026 (round 2)
Debt Instrument [Line Items]
Debt Instrument, Face Amount												$ 18,500,000
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes
Debt Instrument [Line Items]
Interest rate (as a percent)												5.68%	5.68%
Debt Instrument, Face Amount												$ 20,739,000
Initial conversion price | $ / shares													$ 3
Long-term Debt, Fiscal Year Maturity [Abstract]
Convertible Preferred Stock, Shares Issued upon Conversion | shares													333.3333
Convertible Debt, Conversion Rate of Commmon Shares, Principal													$ 1,000
Debt Instrument, Fee Amount													$ 3,099,000
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche II Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount												20,736,000
Initial conversion price | $ / shares													$ 4.50
Long-term Debt, Fiscal Year Maturity [Abstract]
Convertible Preferred Stock, Shares Issued upon Conversion | shares													222.222
Convertible Debt, Conversion Rate of Commmon Shares, Principal													$ 1,000
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026
Long-term Debt, Fiscal Year Maturity [Abstract]
Convertible Senior Notes, Percentage of Principal Required for Repurchase													100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal													$ 1,000
Last Reported Sales Price Period, Common Stock		20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days | payment		30
Percent of the Applicable Conversion Price													150%
Convertible Senior Notes, Holders Aggregate Principal Minimum Requirement Percentage, in the event of default													25%
Convertible Senior Notes, Additional Accrued Interest in the Event of Failure to File Requirements													0.50%
Convertible Senior Notes, Additional Accrued Interest in Event of Restrictive Legends Not Being Removed													0.50%
Debt Instrument, Common Shares Exchanged | shares		2,700,000
Debt Instrument, Percent Limit on Issuing Common Shares upon Conversion of the New 2026 Notes													19.99%
Convertible Senior Notes, Holders Aggregate Principal Minimum Requirement Percentage, in the event of default													25%
Convertible Senior Notes, Additional Accrued Interest in the Event of Failure to File Requirements													0.50%
Convertible Senior Notes, Additional Accrued Interest in Event of Restrictive Legends Not Being Removed													0.50%
Debt Instrument, Common Shares Exchanged | shares		2,700,000
Debt Instrument, Percent Limit on Issuing Common Shares upon Conversion of the New 2026 Notes													19.99%
Secured Debt | Secured Term Loans due July 2026
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount	$ (1,846,000)							$ (1,846,000)
Interest rate (as a percent)	5.68%							5.68%
Debt Instrument, Face Amount	$ 90,500,000							$ 90,500,000					$ 104,500,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Debt Instrument, Fee Amount													6,480,000
Debt Instrument, Non-Cash Interest Expense Recognized in the Period								153,000
Debt Instrument, Increase, Accrued Interest								3,352,000
Debt Instrument, Fee Amount, Net Balance Shown as a Liability	$ (5,846,000)							$ (5,846,000)
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	14.40%							14.40%
Debt Instrument, Springing Maturity Date, days prior to maturity of Convertible Notes due 2024		91 days
Long-term Debt and Capital Lease Obligations, Including Current Maturities	$ 82,808,000							$ 82,808,000	0
Debt Instrument, Debt Default, Amount													20,000,000
Debt Instrument, Springing Maturity Date, days prior to maturity of Convertible Notes due 2024		91 days
Secured Debt | Secured Term Loans due July 2026 | Year 2 and on
Long-term Debt, Fiscal Year Maturity [Abstract]
Debt Instrument, Prepayment Premium, Percentage of aggregate principal amount | Rate		1%
Debt Instrument, Additional Prepayment Premium, Percentage of aggregate principal amount | Rate		3%
Secured Debt | Secured Term Loans due July 2026 | Round 2 funding
Debt Instrument [Line Items]
Debt Instrument, Face Amount													8,500,000
Secured Debt | Secured Term Loans due July 2026 | Initial amount at closing
Debt Instrument [Line Items]
Debt Instrument, Face Amount													66,500,000
Secured Debt | Secured Term Loans due July 2026 | Additional amount after closing (Round 3)
Debt Instrument [Line Items]
Debt Instrument, Face Amount													10,000,000
Secured Debt | Secured Term Loans due July 2026 | Additional amount after closing (Round 4)
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 14,000,000		19,500,000
Secured Debt | Secured Term Loans due July 2026 (round 2)
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 5,500,000
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes (round 2)
Debt Instrument [Line Items]
Debt Instrument, Face Amount												5,186,000
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche II Notes (round 2)
Debt Instrument [Line Items]
Debt Instrument, Face Amount												$ 5,183,000
Letters of Credit
Debt Instrument [Line Items]
Letters of credit outstanding	3,654,000							3,654,000	2,585,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Letters of Credit Outstanding, Amount	4,229,000							4,229,000	$ 3,450,000
Letters of Credit | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity	5,000,000							5,000,000
Letters of Credit | Line of Credit | Revolving Credit and Security Agreement (Prior Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity	$ 20,000,000							$ 20,000,000
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Weighted average interest rate	5.30%							5.30%	4.50%						4.50%	4.50%
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Letters of credit outstanding	$ 15,220,000							$ 15,220,000	$ 22,150,000
Line of Credit Facility, Covenant Feature, Dominion Trigger	$ 4,375,000							$ 4,375,000
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent	11.25%							11.25%
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity	$ 30,000,000							$ 30,000,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Trade Receivables, Europe, Percent								85%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Availability Reserve, Minimum	3,000,000							$ 3,000,000
Line of Credit Facility, Covenant Feature, Dominion Trigger	$ 3,750,000							$ 3,750,000
Line of Credit, Covenant Compliance, Consecutive Business Days for Undrawn Balance								5 days
Line of Credit, Covenant Compliance, Interruption of Manufacturing Facilities Period								10 days
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent	12.50%							12.50%
Remaining borrowing capacity	$ 30,000,000							$ 30,000,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France)									7,366,000
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (UK)									$ 5,986,000
Line of Credit Facility, Covenant Feature, Prior Increase Limit	10,000,000							10,000,000
Line of Credit Facility, Covenant Feature, Increase Limit Based on receivables	9,000,000							9,000,000
Line of Credit Facility, Covenant Feature, Dominion Trigger for Five Consecutive Days	3,750,000							3,750,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) | Euro Member Countries, Euro
Long-term Debt, Fiscal Year Maturity [Abstract]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France) | €															€ 6,500
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) | United Kingdom, Pounds
Long-term Debt, Fiscal Year Maturity [Abstract]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (UK) | £																£ 4,500
Revolving Credit Facility | Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity													35,000,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Availability Reserve, Minimum													$ 3,000,000
Line of Credit Facility, Current Borrowing Capacity	15,288,000							15,288,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Line Of Credit Facility Gross Borrowing Base	29,817,000							29,817,000
Debt Instrument, Springing Maturity Date, days prior to maturity of Convertible Notes due 2024		191 days
Debt Instrument, Springing Maturity, days prior to maturity of secured term loans due 2026		100 days
Debt Instrument, Springing Maturity Date, days prior to maturity of Convertible Notes due 2024		191 days
Debt Instrument, Springing Maturity, days prior to maturity of secured term loans due 2026		100 days
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Prior Credit Agreement)
Debt Instrument [Line Items]
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Additional Long-Lived Asset Amount	0							$ 0
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Trade Receivables, Foreign, Percent								85%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Inventories, Foreign, Percent								70%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Inventories, Foreign, Liquidation Value, Percent								85%
Borrowing capacity	60,000,000							$ 60,000,000
Line of Credit Facility, Additional Borrowing Capacity	25,000,000							$ 25,000,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Trade Receivables, Domestic, Percent								85%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Inventories, Domestic, Percent								70%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Inventories, Liquidation Value, Percent								85%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Inventories, Liquidation Value, Amount	4,000,000							$ 4,000,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Property, Plant and Equipment, Liquidation Value, Percent								80%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Availability Reserve, Minimum	$ 3,000,000							$ 3,000,000
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent	11.25%							11.25%
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (North America Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Covenant Feature, Dominion Trigger	$ 7,500,000							$ 7,500,000
Line of Credit, Covenant Compliance, Interruption of Manufacturing Facilities Period								10 days
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent	12.50%							12.50%
Line of Credit, Covenant Compliance, Consecutive Business Days for Undrawn_Balance								5 days
Swing Line Loans | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity	$ 2,000,000							$ 2,000,000
Amount Available to Invacare Limited and Invacare Poirier SAS | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity	$ 15,000,000							$ 15,000,000
Base Rate | Secured Debt | Secured Term Loans due July 2026 | First year of loan period
Debt Instrument [Line Items]
Basis spread on variable rate | Rate		6%
Base Rate | Secured Debt | Secured Term Loans due July 2026 | Year 2 and on
Debt Instrument [Line Items]
Basis spread on variable rate | Rate		7.75%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Secured Debt | Secured Term Loans due July 2026 | First year of loan period
Debt Instrument [Line Items]
Basis spread on variable rate | Rate		7%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Secured Debt | Secured Term Loans due July 2026 | Year 2 and on
Debt Instrument [Line Items]
Basis spread on variable rate | Rate		8.75%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility | Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate | Rate								3.25%
Prime Rate | Revolving Credit Facility | Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate | Rate								2.25%
Maximum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage								0.375%
Maximum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Prior Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage								0.375%
Maximum | Adjusted LIBOR | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								3%
Maximum | Adjusted LIBOR | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Prior Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								2.75%
Maximum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								3%
Maximum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Prior Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								1.75%
Minimum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage								0.25%
Minimum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Prior Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage								0.25%
Minimum | Adjusted LIBOR | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								2.50%
Minimum | Adjusted LIBOR | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Prior Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								2.25%
Minimum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								2.50%
Minimum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Prior Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								1.25%

Other Long-Term Obligations - (

Other Long-Term Obligations - (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Deferred income taxes	$ 18,771	$ 21,664
Product liability	10,438	11,342
Pension	1,019	7,814
Convertible Debt Derivative	85	0
Supplemental Executive Retirement Plan liability	4,383	5,106
Deferred compensation	4,970	6,174
Deferred gain on sale leaseback	4,834	5,174
Life Insurance Liability, Noncurrent	2,533	4,568
Uncertain tax obligation including interest	2,891	3,171
Other	478	1,783
Other Long-Term Obligations	$ 50,402	$ 66,796

Other Long-Term Obligations - N

Other Long-Term Obligations - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Apr. 23, 2015
Income Tax Examination [Line Items]
Deferred gain on sale leaseback				$ 7,414,000
Sale and Leaseback Transaction, Gain (Loss), Net	$ 328,000	$ 317,000	$ 305,000

Leases and Commitments - Narrat

Leases and Commitments - Narrative (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 01, 2020
Operating Leased Assets [Line Items]
Sale and Leaseback Transaction, Gain (Loss), Net		$ 328,000	$ 317,000	$ 305,000
Sale Leaseback Transaction, Annual Payments.		$ 2,275,000
Lease Obligation Incurred	$ 38,704,000
Lessee, Finance Lease, Term of Contract					19 years 9 months
Minimum
Operating Leased Assets [Line Items]
Lease term		1 year
Maximum
Operating Leased Assets [Line Items]
Lease term		20 years

Leases and Commitments - Lease

Leases and Commitments - Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lease, Cost [Abstract]
Operating Lease, Expense	$ 5,712	$ 7,394	$ 8,138
Short-term Lease, Cost	2,549	3,541	3,968
Operating Lease, Cost	8,261	10,935	12,106
Finance Lease, Interest Expense	4,256	4,601	2,544
Finance Lease, Right-of-Use Asset, Amortization	4,246	4,996	3,479
Financing Lease, Cost	$ 8,502	$ 9,597	$ 6,023

Leases and Commitments - Future

Leases and Commitments - Future Minimum Lease Commitments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finance Leases
Capital Leases - 2021	$ 6,828
Capital Leases - 2022	6,764
Capital Leases - 2023	6,667
Capital Leases - 2024	6,554
Capital Leases - 2025	6,441
Capital Leases - Thereafter	62,531
Total future minimum lease payments	95,785
Amounts representing interest	(34,685)
Operating Leases, Future Minimum Payments, Interest Included in Payments	(2,108)
Present value of minimum lease payments	61,100
Operating Leases
Operating Leases - 2021	4,181
Operating Leases - 2022	3,085
Operating Leases - 2023	2,482
Operating Leases - 2024	1,303
Operating Leases - 2025	395
Operating Leases - Thereafter	1,341
Total future minimum lease payments	12,787
Operating Leases, Future Minimum Payments, Present Value of Net Minimum Payments	10,679
Finance Lease, Liability, Current	(3,106)	$ (3,009)
Operating Lease, Liability, Current	(3,420)	(4,217)
Long-Term Obligations - Finance Leases	57,994
Long-Term Obligations - Operating Leases	$ 7,259	$ 8,234

Leases and Commitments - Sale L

Leases and Commitments - Sale Leaseback Transactions (Details) - USD ($)		3 Months Ended	12 Months Ended
	Apr. 23, 2015	Sep. 30, 2016	Dec. 31, 2022
Sale Leaseback Transaction [Line Items]
Sale Leaseback Transaction, Net Proceeds, Investing Activities		$ 23,000,000
Sale Leaseback Transaction, Lease Term			20 years
Sale Leaseback Transaction, Lease Terms			Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then- current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases.
Deferred gain on sale leaseback	$ 7,414,000
Sale Leaseback Transaction, Immediate Loss Recognized	257,000
Capital Lease Obligations	$ 32,339,000

Leases and Commitments - Schedu

Leases and Commitments - Schedule of Cash Flows Supplemental Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Cash Flows Supplemental Information [Abstract]
Operating Leases, Cash Paid in Measurement of Amounts for Lease Liabilities	$ 7,618	$ 11,089	$ 12,527
Financing Leases, Cash Paid in Measurement of Amounts for Lease Liabilities	7,260	8,166	5,316
Total Cash Paid in Measurement of Amounts for Lease Liabilities	14,878	19,255	17,843
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	4,652	7,491	6,155
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	969	6,572	40,078
Right-of-Use Asset Obtained in Exchange for Total Lease Liability	$ 5,621	$ 14,063	$ 46,233

Leases and Commitments - Weight

Leases and Commitments - Weighted-Average Remaining Lease Terms and Discount Rates (Details)	Dec. 31, 2022	Dec. 31, 2021
Weighted-Average Remaining Lease Terms and Discount Rates [Abstract]
Finance Lease, Weighted Average Remaining Lease Term	14 years 9 months 18 days	15 years 9 months 18 days
Operating Lease, Weighted Average Remaining Lease Term	4 years 7 months 6 days	5 years
Finance Lease, Weighted Average Discount Rate, Percent	3.74%	6.43%
Operating Lease, Weighted Average Discount Rate, Percent	9.36%	7.10%

Retirement and Benefit Plans -

Retirement and Benefit Plans - (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) yr	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Retirement Benefits [Abstract]
Company matching employee contributions	66.70%
Maximum percentage of matching contribution for total compensation	3%
Contribution expense	$ 845,000	$ 1,022,000	$ 1,214,000
Supplemental Executive Retirement Plan
Defined Benefit Plan Disclosure [Line Items]
Interest credited for active participants (as a percent)	0%
Accumulated benefit obligation	$ 4,774,000	$ 5,497,000
Assumption, future salary increase rate	3.25%
Assumed discount rate	5.02%	2.83%
Retirement age | yr	67
Projected benefit obligation	$ 4,774,000	$ 5,497,000
Interest (benefit) cost	(541,000)	(4,000)	(213,000)
Net periodic benefit (income) costs	(332,000)	129,000	326,000
Defined Benefit Plan, Benefit Obligation, Benefits Paid	391,000
Domestic Plan
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit (income) costs	(1,099,000)	30,000	640,000
Service cost and accrual adjustments	(1,274,000)	(68,000)	569,000
Foreign Plan | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Amounts recognized in other comprehensive income (loss)	$ (633,000)	$ (823,000)	$ 1,678,000

Revenues (Details)

Revenues (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues	$ 181,320,000	$ 170,408,000	$ 189,017,000	$ 200,988,000	$ 226,191,000	$ 224,200,000	$ 225,864,000	$ 196,202,000	$ 741,733,000	$ 872,457,000	$ 850,689,000
Net Revenue									100%	100%
Deferred Revenue	$ 2,279,000				$ 4,156,000				$ 2,279,000	$ 4,156,000
Europe
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									434,372,000	499,118,000	468,041,000
North America
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									276,891,000	340,980,000	348,307,000
All Other
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									30,470,000	32,359,000	$ 34,341,000
Product [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									$ 723,540,000	$ 853,680,000
Net Revenue									98%	98%
Product [Member] | Europe
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									$ 422,440,000	$ 486,190,000
Product [Member] | North America
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									275,508,000	340,269,000
Product [Member] | All Other
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									25,592,000	27,221,000
Service [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									$ 18,193,000	$ 18,777,000
Net Revenue									2%	2%
Service [Member] | Europe
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									$ 11,932,000	$ 12,928,000
Service [Member] | North America
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									1,383,000	711,000
Service [Member] | All Other
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenues									$ 4,878,000	$ 5,138,000
General Terms and Conditions [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split									25%
Large National Customers [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split									20%
Government Tenders [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split									23%
Other Customers [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split									32%

Equity Compensation - Narrative

Equity Compensation - Narrative (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) votes $ / shares shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock par value (in dollars per share) | $ / shares	$ 0.25
Number of shares authorized	5,285,644
Stock option related treasury stock, shares acquired	139,000	213,000	231,000
Payments for Repurchase of Common Stock | $	$ 151,000	$ 1,754,000	$ 1,707,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments for Repurchase of Common Stock | $	$ 151,000	$ 1,754,000	$ 1,707,000
Expiration period	10 years
Performance shares and performance share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	3 years
Performance achievement level, lower range	0%
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Performance Award Target Acheivement, Upper Range, Percentage	150%
Performance achievement level, target range	100%
Restricted Stock and Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized		3,475,496	3,540,534
Weighted Average | Performance shares and performance share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense, period for recognition	3 years
Class B Common Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ratio of votes per share of Class B common stock to common stock | votes	10
Common Stock, Shares, Outstanding	3,667
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Holders Percentage of Total Outstanding	99.90%

Equity Compensation - Share-bas

Equity Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ (844)	$ (1,795)	$ 2,190
Selling, general and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	2,080	4,323	8,645
Selling, general and administrative expense | Restricted stock and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	2,924	5,450	5,332
Selling, general and administrative expense | Performance shares and performance share units
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ (844)	$ (1,127)	$ 3,313

Equity Compensation - Unrecogni

Equity Compensation - Unrecognized Compensation Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 2,221	$ 8,612	$ 14,749
Restricted stock and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	2,146	6,866	7,489
Performance shares and performance share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 75	$ 1,746	$ 7,260

Equity Compensation - Options A

Equity Compensation - Options Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	189,689	750,159	1,081,804	1,441,202
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 13.43	$ 12.69	$ 16.07	$ 18.26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(560,470)	(331,645)	(359,398)
Canceled - Weighted Average Exercise Price (in dollars per share)	$ 12.44	$ 23.71	$ 24.84
Options exercisable at end of period (in shares)	189,689	750,159	1,081,804
Number of shares authorized	5,285,644
$12.15 – $20.00 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, upper limit (in dollars per shares)	$ 12.15	$ 12.15	$ 12.15
$12.15 – $20.00 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, upper limit (in dollars per shares)	20
$12.15 – $20.00 | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	13.43
$30.01 – $33.36 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, upper limit (in dollars per shares)	$ 14.49	$ 17.47	$ 33.36
2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized		3,475,496	3,540,534

Equity Compensation - Stock Opt

Equity Compensation - Stock Options Outstanding by Exercise Price (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 13.43	$ 12.69	$ 16.07	$ 18.26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	189,689	750,159	1,081,804	1,441,202
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(560,470)	(331,645)	(359,398)
Canceled - Weighted Average Exercise Price (in dollars per share)	$ 12.44	$ 23.71	$ 24.84
Options exercisable at end of period (in shares)	189,689	750,159	1,081,804
Number of shares authorized	5,285,644
2013 Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized		3,475,496	3,540,534
$12.15 – $20.00 | Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per shares)	$ 12.15	$ 12.15	$ 12.15
$12.15 – $20.00 | Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per shares)	20
$30.01 – $33.36 | Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per shares)	$ 14.49	$ 17.47	$ 33.36
Stock Options | $12.15 – $20.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Number Outstanding at end of period (in shares)	189,689
Options Outstanding - Weighted Average Remaining Contractual Life	2 years
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 13.43
Options Exercisable - Number Exercisable at end of period (in shares)	189,689
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 13.43

Equity Compensation - Restricte

Equity Compensation - Restricted Stock Activity (Details) - Restricted stock and restricted stock units - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock / Units unvested at beginning of period (in shares)	1,160,847	1,145,058	965,085
Granted (in shares)	1,341,019	652,743	764,012
Vested (in shares)	(803,550)	(558,424)	(475,113)
Canceled (in shares)	(636,449)	(78,530)	(108,926)
Stock / Units unvested at end of period (in shares)	1,061,867	1,160,847	1,145,058
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock / Units unvested at beginning of period - Weighted Average Fair Value (in dollars per share)	$ 8.17	$ 8.62	$ 11.32
Granted - Weighted Average Fair Value (in dollars per share)	1.22	8.42	7.11
Vested - Weighted Average Fair Value (in dollars per share)	5.94	9.33	11.39
Canceled - Weighted Average Fair Value (in dollars per share)	4.40	8.44	9.90
Stock / Units unvested at end of period - Weighted Average Fair Value (in dollars per share)	$ 2.75	$ 8.17	$ 8.62

Equity Compensation - Performan

Equity Compensation - Performance Share Activity (Details) - Performance shares and performance share units - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock / Units unvested at beginning of period (in shares)	972,288	1,026,785	753,272
Granted (in shares)	460,187	471,819	523,329
Vested (in shares)	0	0	(183,840)
Canceled (in shares)	(1,114,404)	(526,316)	(65,976)
Stock / Units unvested at end of period (in shares)	318,071	972,288	1,026,785
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock / Units unvested at beginning of period - Weighted Average Fair Value (in dollars per share)	$ 7.76	$ 8.55	$ 11.82
Granted - Weighted Average Fair Value (in dollars per share)	1.48	8.49	7.82
Vested - Weighted Average Fair Value (in dollars per share)	0	0	17.48
Canceled - Weighted Average Fair Value (in dollars per share)	5.92	9.25	9.48
Stock / Units unvested at end of period - Weighted Average Fair Value (in dollars per share)	$ 5.15	$ 7.76	$ 8.55

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) by Component - Changes in Accumulated Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	$ 16,988	$ 45,436
OCI before reclassifications	(37,761)	(29,738)
Amount reclassified from accumulated OCI	(3,950)	1,290
Other Comprehensive Income (Loss)	(41,711)	(28,448)	$ 42,308
Ending balance	(24,723)	16,988	45,436
Foreign Currency
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	18,961	50,329
OCI before reclassifications	(42,840)	(31,368)
Amount reclassified from accumulated OCI	0	0
Other Comprehensive Income (Loss)	(42,840)	(31,368)
Ending balance	(23,879)	18,961	50,329
Long-Term Notes
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	2,127	(517)
OCI before reclassifications	(5,357)	2,644
Amount reclassified from accumulated OCI	0	0
Other Comprehensive Income (Loss)	(5,357)	2,644
Ending balance	(3,230)	2,127	(517)
Defined Benefit Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(4,101)	(3,674)
OCI before reclassifications	6,953	(457)
Amount reclassified from accumulated OCI	(466)	30
Other Comprehensive Income (Loss)	6,487	(427)
Ending balance	2,386	(4,101)	(3,674)
Derivatives
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	1	(702)
OCI before reclassifications	3,483	(557)
Amount reclassified from accumulated OCI	(3,484)	1,260
Other Comprehensive Income (Loss)	(1)	703
Ending balance	$ 0	$ 1	$ (702)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Income (Loss) by Component - Reclassifications out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Cost of products sold									$ (566,340)	$ (633,351)	$ (605,437)
Selling, general and administrative expenses									(226,780)	(232,242)	(236,357)
Income taxes									(3,070)	(6,445)	(3,841)
Revenues	$ 181,320	$ 170,408	$ 189,017	$ 200,988	$ 226,191	$ 224,200	$ 225,864	$ 196,202	741,733	872,457	$ 850,689
Defined Benefit Plans | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Selling, general and administrative expenses									(466)	30
Income taxes									0	0
Loss from Continuing Operations									(466)	30
Derivatives | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Earnings (loss) before income taxes									(3,747)	1,486
Income taxes									263	(226)
Loss from Continuing Operations									(3,484)	1,260
Derivatives | Reclassification out of Accumulated Other Comprehensive Income | Foreign exchange forward
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Cost of products sold									(3,610)	428
Revenues									$ 137	$ 1,058

Capital Stock - (Details)

Capital Stock - (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Capital Stock [Roll Forward]
Treasury Stock, Common, Shares	4,536,000	4,397,000	4,184,000
Number of stock awards canceled	636,449	78,530	108,926
Debt Conversion, Converted Instrument, Shares Issued	2,700,000
Common Stock
Capital Stock [Roll Forward]
Common Stock, Beginning Balance	39,416,000	38,613,000
Restricted stock awards	424,000	803,000
Common Stock, Ending Balance	42,540,000	39,416,000	38,613,000
Class B Common Shares
Capital Stock [Roll Forward]
Common Stock, Beginning Balance	4,000	4,000
Restricted stock awards	0	0
Common Stock, Ending Balance	4,000	4,000	4,000
Treasury Stock, Common
Capital Stock [Roll Forward]
Restricted stock awards	(139,000)	(213,000)

Charges Related To Restructur_3

Charges Related To Restructuring Activities - (Details) - USD ($)	3 Months Ended							12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Reserve [Roll Forward]
Beginning Balance				$ 482,000			$ 6,253,000	$ 482,000	$ 6,253,000	$ 7,027,000
Charges	$ (9,437,000)	$ (8,440,000)	$ (4,153,000)	(3,790,000)	$ (377,000)	$ (547,000)	(1,552,000)	(25,820,000)	(2,534,000)	(7,358,000)
Payments								(18,311,000)	(8,305,000)	(8,132,000)
Ending Balance	7,991,000							7,991,000	482,000	6,253,000
Severance
Restructuring Reserve [Roll Forward]
Beginning Balance				482,000			6,249,000	482,000	6,249,000	7,023,000
Charges								(9,087,000)	(1,860,000)	(7,012,000)
Payments								(6,097,000)	(7,627,000)	(7,786,000)
Ending Balance	3,472,000							3,472,000	482,000	6,249,000
Contract Terminations
Restructuring Reserve [Roll Forward]
Beginning Balance				0			4,000	0	4,000	4,000
Charges								(16,733,000)	(674,000)	(346,000)
Payments								(12,214,000)	(678,000)	(346,000)
Ending Balance	4,519,000							4,519,000	0	4,000
North America
Restructuring Reserve [Roll Forward]
Beginning Balance				482,000			179,000	482,000	179,000	211,000
Charges								(10,646,000)	(964,000)	(1,306,000)
Payments								(7,135,000)	(661,000)	(1,338,000)
Ending Balance	3,993,000							3,993,000	482,000	179,000
North America | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance				482,000			179,000	482,000	179,000	211,000
Charges								(2,472,000)	(964,000)	(1,306,000)
Payments								(1,987,000)	(661,000)	(1,338,000)
Ending Balance	967,000							967,000	482,000	179,000
North America | Contract Terminations
Restructuring Reserve [Roll Forward]
Beginning Balance				$ 0			0	0	0	0
Charges								(8,174,000)	0	0
Payments								(5,148,000)	0	0
Ending Balance	3,026,000							3,026,000	0	0
Europe
Restructuring Reserve [Roll Forward]
Beginning Balance							5,908,000		5,908,000	6,410,000
Charges								(13,918,000)	(1,560,000)	(5,934,000)
Payments								(11,111,000)	(7,468,000)	(6,436,000)
Ending Balance	2,807,000							2,807,000		5,908,000
Europe | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance							5,904,000		5,904,000	6,406,000
Charges								(5,359,000)	(886,000)	(5,588,000)
Payments								(4,045,000)	(6,790,000)	(6,090,000)
Ending Balance	1,314,000							1,314,000		5,904,000
Europe | Contract Terminations
Restructuring Reserve [Roll Forward]
Beginning Balance							4,000		4,000	4,000
Charges								(8,559,000)	(674,000)	(346,000)
Payments								(7,066,000)	(678,000)	(346,000)
Ending Balance	1,493,000							1,493,000		4,000
All Other
Restructuring Reserve [Roll Forward]
Beginning Balance							166,000		166,000	406,000
Charges								(1,256,000)	(10,000)	(118,000)
Payments								(65,000)	(176,000)	(358,000)
Ending Balance	1,191,000							1,191,000		166,000
All Other | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance							166,000		166,000	406,000
Charges								(1,256,000)	(10,000)	(118,000)
Payments								(65,000)	(176,000)	(358,000)
Ending Balance	1,191,000							1,191,000		166,000
All Other | Contract Terminations
Restructuring Reserve [Roll Forward]
Beginning Balance							$ 0		0	0
Charges								0	0	0
Payments								0	$ 0	0
Ending Balance	$ 0							$ 0		$ 0

Charges Related To Restructur_4

Charges Related To Restructuring Activities - Narrative (Details) - USD ($)	3 Months Ended							12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Charges	$ (9,437,000)	$ (8,440,000)	$ (4,153,000)	$ (3,790,000)	$ (377,000)	$ (547,000)	$ (1,552,000)	$ (25,820,000)	$ (2,534,000)	$ (7,358,000)
Payments								(18,311,000)	(8,305,000)	(8,132,000)
Severance
Restructuring Cost and Reserve [Line Items]
Charges								(9,087,000)	(1,860,000)	(7,012,000)
Payments								(6,097,000)	(7,627,000)	(7,786,000)
Contract Terminations
Restructuring Cost and Reserve [Line Items]
Charges								(16,733,000)	(674,000)	(346,000)
Payments								(12,214,000)	(678,000)	(346,000)
North America
Restructuring Cost and Reserve [Line Items]
Charges								(10,646,000)	(964,000)	(1,306,000)
Payments								(7,135,000)	(661,000)	(1,338,000)
North America | Severance
Restructuring Cost and Reserve [Line Items]
Charges								(2,472,000)	(964,000)	(1,306,000)
Payments								(1,987,000)	(661,000)	(1,338,000)
North America | Contract Terminations
Restructuring Cost and Reserve [Line Items]
Charges								(8,174,000)	0	0
Payments								(5,148,000)	0	0
Europe
Restructuring Cost and Reserve [Line Items]
Charges								(13,918,000)	(1,560,000)	(5,934,000)
Payments								(11,111,000)	(7,468,000)	(6,436,000)
Europe | Severance
Restructuring Cost and Reserve [Line Items]
Charges								(5,359,000)	(886,000)	(5,588,000)
Payments								(4,045,000)	(6,790,000)	(6,090,000)
Europe | Contract Terminations
Restructuring Cost and Reserve [Line Items]
Charges								(8,559,000)	(674,000)	(346,000)
Payments								(7,066,000)	(678,000)	(346,000)
All Other
Restructuring Cost and Reserve [Line Items]
Charges								(1,256,000)	(10,000)	(118,000)
Payments								(65,000)	(176,000)	(358,000)
All Other | Severance
Restructuring Cost and Reserve [Line Items]
Charges								(1,256,000)	(10,000)	(118,000)
Payments								(65,000)	(176,000)	(358,000)
All Other | Contract Terminations
Restructuring Cost and Reserve [Line Items]
Charges								0	0	0
Payments								$ 0	$ 0	$ 0

Income Taxes - Income Before In

Income Taxes - Income Before Income Tax (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Domestic									$ (95,070)	$ (53,916)	$ (42,213)
Foreign									(2,931)	14,798	17,774
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (20,667)	$ (33,434)	$ (21,023)	$ (22,877)	$ 3,553	$ (20,919)	$ (9,578)	$ (12,174)	$ (98,001)	$ (39,118)	$ (24,439)

Income Taxes - Income Tax Expen

Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Federal	$ 362	$ 85	$ 45
State	(105)	(12)	(180)
Foreign	3,054	6,596	6,168
Current Income Tax Expense (Benefit)	3,311	6,669	6,033
Deferred:
Federal	0	(662)	(26)
State	0	0	0
Foreign	(241)	438	(2,166)
Deferred Income Tax Expense (Benefit)	(241)	(224)	(2,192)
Income tax provision	$ 3,070	$ 6,445	$ 3,841

Income Taxes - Rate Reconciliat

Income Taxes - Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit), Intraperiod Tax Allocation	0%	5.40%	0%
Foreign goodwill write-off	0%	9%	0%
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Statutory federal income tax rate (benefit)	(21.00%)	(21.00%)	(21.00%)
State and local income taxes, net of federal income tax benefit	(0.10%)	0%	(0.60%)
Effective Income Tax Rate Reconciliation, Disposition of Business, Percent	0%	0%	(11.20%)
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent	0.20%	(1.70%)	(16.50%)
Foreign taxes at other than the federal statutory rate	1%	3.90%	8.80%
Federal and foreign valuation allowances	21.30%	20.40%	(4.30%)
Withholding taxes	0%	0.10%	0.10%
Unremitted earnings	0%	0%	(4.00%)
Debt repurchase	0%	0%	3.20%
Foreign branch activity	1%	4%	19.30%
Uncertain tax positions	0%	0.60%	2.90%
Other, net	0.70%	(3.20%)	(6.00%)
Effective Income Tax Rate, Continuing Operations	3.10%	16.50%	15.70%

Income Taxes - Components of De

Income Taxes - Components of Deferred Income Tax (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Long-term deferred income tax assets (liabilities), net:
Bad debt	$ 483,000	$ 387,000
Warranty	1,011,000	1,426,000
Other accrued expenses and reserves	398,000	484,000
Inventory	4,625,000	3,624,000
Goodwill and intangibles	(17,556,000)	(19,910,000)
Convertible debt	3,327,000	5,193,000
Fixed assets	(22,494,000)	(24,026,000)
Compensation and benefits	3,432,000	4,271,000
Loss and credit carryforwards	149,853,000	127,397,000
Product liability	870,000	1,596,000
State and local taxes	37,584,000	34,794,000
Valuation allowances	(198,797,000)	(176,230,000)
Deferred Tax Liabilities, Leasing Arrangements	17,496,000	19,649,000
Other, net	2,099,000	1,221,000
Net Deferred Income Taxes	$ 17,669,000	$ 20,124,000

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 3,149	$ 3,262
Additions to:
Positions taken during the current year	13	238
Positions taken during a prior year	0	3
Exchange rate impact	0	0
Deductions due to:
Positions taken during a prior year	(11)	(76)
Lapse of statute of limitations	(216)	(212)
Balance at end of year	2,796	3,149
Tax Credit Carryforward [Line Items]
Exchange rate impact	$ (139)	$ (66)

Income Taxes - (Narrative) (Det

Income Taxes - (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Tax Credit Carryforward [Line Items]
Income taxes (benefit)	$ 3,070,000	$ 6,445,000	$ 3,841,000
Deferred tax assets, gross	221,178,000	200,042,000
Deferred tax liabilities	40,050,000	43,936,000
Deferred tax assets, valuation allowance	198,797,000	176,230,000
Income Taxes Paid, Net	3,999,000	6,877,000	4,377,000
Domestic state and local tax loss carryforwards	690,125,000
Tax credit carryforwards	11,028,000
Unrecognized tax benefits, excluding interest and penalties	2,368,000	2,646,000
Unrecognized tax benefits that would impact effective tax rate	2,368,000	2,646,000
Income tax penalties and interest expense	(2,000)	(15,000)	$ (20,000)
Income tax penalties and interest accrued	523,000	525,000
Reversal of Withholding Taxes		988,000
Undistributed Profits of Non-U.S. Subsidiaries, indefinitely reinvested	38,702,000
Goodwill Impairment Deferred Tax Benefit		$ 662,000
Domestic tax authority
Tax Credit Carryforward [Line Items]
Federal tax credit carryforwards	465,473,000
Deferred Tax Assets, Tax Credit Carryforwards, Other	133,697,000
Foreign Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	60,463,000
Tax Year 2014 to 2017 | Foreign Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	12,899,000
Tax Year 2014 to 2017 | State and Local Jurisdiction [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	124,958,000
Tax year 2018 to 2027 | State and Local Jurisdiction [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	361,184,000
Tax Year 2019 to 2022 | Domestic tax authority
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	9,071,000
Tax Year 2028 and Thereafter | State and Local Jurisdiction [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	156,384,000
Unlimited Carryover [Member] | Foreign Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	2,511,000
Unlimited Carryover [Member] | State and Local Jurisdiction [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	47,599,000
Tax Year 2034 to 2036 [Member] | Domestic tax authority
Tax Credit Carryforward [Line Items]
Federal tax credit carryforwards	276,315,000
Tax Year 2031 | Domestic tax authority
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	1,957,000
Tax Year after 2027 | Foreign Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	18,376,000
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$ 20,080,000

Net Earnings (Loss) Per Commo_2

Net Earnings (Loss) Per Common Share - Computation of Basic and Diluted Net Earnings Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net Earnings (Loss) per Share—Basic:
Average common shares outstanding									36,517	34,875	34,266
Net Loss	$ (20,577)	$ (34,354)	$ (21,943)	$ (24,197)	$ 1,938	$ (22,759)	$ (10,698)	$ (14,044)	$ (101,071)	$ (45,563)	$ (28,280)
Net earnings per common share	$ (0.54)	$ (0.92)	$ (0.62)	$ (0.69)	$ 0.06	$ (0.65)	$ (0.31)	$ (0.41)	$ (2.77)	$ (1.31)	$ (0.83)
Diluted
Average common shares outstanding									36,517	34,875	34,266
Stock options and awards									112	399	109
Average common shares assuming dilution									36,629	35,274	34,375
Net Loss	$ (20,577)	$ (34,354)	$ (21,943)	$ (24,197)	$ 1,938	$ (22,759)	$ (10,698)	$ (14,044)	$ (101,071)	$ (45,563)	$ (28,280)
Net Earnings (loss) per Share - Assuming Dilution (in dollars per share)	$ (0.54)	$ (0.92)	$ (0.62)	$ (0.69)	$ 0.05	$ (0.65)	$ (0.31)	$ (0.41)	$ (2.77)	$ (1.31)	$ (0.83)

Net Earnings (Loss) Per Commo_3

Net Earnings (Loss) Per Common Share - Narrative (Details) - Stock Options - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	817,295	1,414,155	2,275,832
Average exercise price	$ 12.14	$ 12.14	$ 12.14
Fair value stock price	$ 1.26	$ 7.13	$ 7.42

Concentration Of Credit Risk -

Concentration Of Credit Risk - (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) Customer
Net Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Number of Customers Used For Concentration Risk Disclosure | Customer	10
Maximum percent of revenue from single customer	6.60%
Net Sales | Customer Concentration Risk | Credit Risk
Concentration Risk [Line Items]
Concentration risk, percentage	21.60%
Payment Guarantee
Concentration Risk [Line Items]
Retained recourse obligation	$ 2,573,000
Total contracts	$ 8,074,000

Derivatives - Notional Amounts

Derivatives - Notional Amounts - Designated as Hedges (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount, Derivative	$ 60,964	$ 120,242
Gain (Loss)	980	(1,553)
Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount, Derivative	0	23
Unrealized Gain (Loss)	0	1
Foreign exchange forward | Not Designated as Hedging Instrument
Derivative [Line Items]
Gain (Loss)	980	(1,553)
USD / MXN | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount, Derivative	0	23
Unrealized Gain (Loss)	$ 0	$ 1

Derivatives - Notional Amount_2

Derivatives - Notional Amounts - Not Designated as Hedges (Details) - Not Designated as Hedging Instrument - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Derivative [Line Items]
Notional Amount, Derivative	$ 60,964	$ 120,242
Gain (Loss)	980	(1,553)
Foreign exchange forward
Derivative [Line Items]
Gain (Loss)	980	(1,553)
USD / AUD
Derivative [Line Items]
Notional Amount, Derivative	0	3,792
Gain (Loss)	0	(57)
USD / CAD
Derivative [Line Items]
Notional Amount, Derivative	0	14,556
Gain (Loss)	0	(24)
USD / EUR
Derivative [Line Items]
Notional Amount, Derivative	60,964	70,454
Gain (Loss)	980	(1,104)
USD / DKK
Derivative [Line Items]
Notional Amount, Derivative	0	10,850
Gain (Loss)	0	(257)
USD / GBP
Derivative [Line Items]
Notional Amount, Derivative	0	4,028
Gain (Loss)	0	32
AUD / NZD
Derivative [Line Items]
Notional Amount, Derivative	0	7,366
Gain (Loss)	0	(17)
USD / NOK
Derivative [Line Items]
Notional Amount, Derivative	0	2,352
Gain (Loss)	0	(81)
Foreign Exchange Forward SEK / USD
Derivative [Line Items]
Notional Amount, Derivative	0	2,344
Gain (Loss)	0	(131)
Foreign Exchange Forward THB / USD
Derivative [Line Items]
Notional Amount, Derivative	0	4,500
Gain (Loss)	$ 0	$ 86

Derivatives - Balance Sheet Loc

Derivatives - Balance Sheet Location (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other Current Assets
Derivatives, Fair Value [Line Items]
Assets	$ 1,117	$ 386
Other Current Assets | Foreign exchange forward | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets	0	1
Other Current Assets | Foreign exchange forward | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets	1,117	385
Accrued Expenses
Derivatives, Fair Value [Line Items]
Liabilities	137	1,938
Accrued Expenses | Foreign exchange forward | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Liabilities	0	0
Accrued Expenses | Foreign exchange forward | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Liabilities	$ 137	$ 1,938

Derivatives - Gain (Loss) in St

Derivatives - Gain (Loss) in Statement of Finacial Position (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income on Derivatives	$ 3,747,000	$ (1,486,000)	$ (1,467,000)
Foreign exchange forward
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative expenses	Selling, general and administrative expenses	Selling, general and administrative expenses
Foreign exchange forward | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)	$ 3,483,000	$ (557,000)
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	3,484,000	(1,260,000)
Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)	0	0
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income on Derivatives	980,000	(1,553,000)
Not Designated as Hedging Instrument | Foreign exchange forward
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income on Derivatives	$ 980,000	$ (1,553,000)

Derivatives - Narrative (Detail

Derivatives - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2022	Jul. 26, 2022
Derivative [Line Items]
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 1,595,000
Minimum
Derivative [Line Items]
Percentage of forcasted transactions with currency rate exposure	50%
Maximum
Derivative [Line Items]
Percentage of forcasted transactions with currency rate exposure	90%
Foreign exchange forward
Derivative [Line Items]
Notional amount of derivatives, matured during period	$ 95,160,000	$ 122,624,000
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative expenses	Selling, general and administrative expenses	Selling, general and administrative expenses
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative expenses	Selling, general and administrative expenses	Selling, general and administrative expenses
Cash Flow Hedging
Derivative [Line Items]
Gain (Loss)	$ (3,747,000)	$ 1,486,000	$ 1,467,000
Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]	Revenues	Revenues	Revenues
Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of products sold	Cost of products sold	Cost of products sold
Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of products sold	Cost of products sold	Cost of products sold
Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]	Revenues	Revenues	Revenues
Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026
Derivative [Line Items]
Debt Instrument, Face Amount	$ 41,475,000			$ 31,106,000
Interest rate (as a percent)					5.68%

Derivatives - Fair Value of Con

Derivatives - Fair Value of Convertible Debt Hedges (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Loss (gain) on Convertible Debt Derivatives	$ (560)	$ (950)	$ 1,510	$ 0	$ 0
Convertible Debt Derivative	$ 85		$ 85	$ 0

Fair Values of Financial Inst_2

Fair Values of Financial Instruments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Foreign exchange forward | Quoted Prices in Active Markets for Identical Assets / (Liabilities) - Level I
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	$ 0	$ 0
Foreign exchange forward | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	980	(1,552)
Foreign exchange forward | Significant Other Unobservable Inputs - Level III
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	0	$ 0
Convertible Debt Derivative | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	$ (85)

Fair Values of Financial Inst_3

Fair Values of Financial Instruments - Details of Book Value and Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 58,792	$ 83,745
Long-term debt (including current maturities of long-term debt)	$ (354,241)	$ (308,129)
Carrying Value | Foreign exchange forward
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Accrued expenses	Accrued expenses
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets	Other current assets
Carrying Value | Convertible Senior Notes at 4.25% March 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	$ (67,665)	$ (119,036)
Carrying Value | Convertible Senior Notes at 4.50% February 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	0	(2,642)
Carrying Value | Convertible Senior Notes at 5.00% February 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(72,408)	(72,140)
Carrying Value | Series II Convertible Senior Notes at 5.00% November 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(76,719)	(78,251)
Carrying Value | Convertible Senior Secured Notes at 5.68% July 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(37,240)	0
Carrying Value | Secured Term Loans due July 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(82,808)	0
Carrying Value | Other obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(17,401)	(36,060)
Carrying Value | Convertible Subordinated Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(85)	0
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	58,792	83,745
Long-term debt (including current maturities of long-term debt)	$ (278,027)	$ (259,472)
Fair Value | Foreign exchange forward
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Accrued expenses	Accrued expenses
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets	Other current assets
Fair Value | Convertible Senior Notes at 4.25% March 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	$ (32,276)	$ (81,718)
Fair Value | Convertible Senior Notes at 4.50% February 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	0	(2,632)
Fair Value | Convertible Senior Notes at 5.00% February 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(62,460)	(64,897)
Fair Value | Series II Convertible Senior Notes at 5.00% November 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(64,678)	(74,165)
Fair Value | Convertible Senior Secured Notes at 5.68% July 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(34,341)	0
Fair Value | Secured Term Loans due July 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(66,871)	0
Fair Value | Other obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	(17,401)	(36,060)
Fair Value | Convertible Subordinated Debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt (including current maturities of long-term debt)	$ (85)	$ 0

Fair Values of Financial Inst_4

Fair Values of Financial Instruments - Narrative (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discounted cash flow, discount rate	14.51%	11.19%	11.27%

Business Segments - (Narrative)

Business Segments - (Narrative) (Details)	Dec. 31, 2022
Customer Concentration Risk | Net Sales
Segment Reporting Information [Line Items]
Maximum percent of revenue from single customer	6.60%

Business Segments - (Informatio

Business Segments - (Information by Segment) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Revenues	$ 181,320,000	$ 170,408,000	$ 189,017,000	$ 200,988,000	$ 226,191,000	$ 224,200,000	$ 225,864,000	$ 196,202,000	$ 741,733,000	$ 872,457,000	$ 850,689,000
Charges	9,437,000	8,440,000	4,153,000	3,790,000		377,000	547,000	1,552,000	25,820,000	2,534,000	7,358,000
Depreciation and amortization									15,491,000	16,821,000	14,317,000
Net interest expense (income)									28,464,000	24,306,000	28,406,000
Operating Income (Loss)									(80,466,000)	(24,234,000)	11,327,000
Restructuring Charges, Net of Inventory Adjustments									(25,820,000)	(2,534,000)	(7,358,000)
Asset write-downs to intangible assets									(3,259,000)	0	0
Loss (gain) on Convertible Debt Derivatives	(560,000)	(950,000)							1,510,000	0	0
Loss (gain) on debt extinguishment including debt finance charges and associated fees	3,021,000	6,398,000				10,131,000		709,000	9,419,000	9,422,000	(7,360,000)
Interest Revenue (Expense), Net									(28,464,000)	(24,306,000)	(28,406,000)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(20,667,000)	(33,434,000)	$ (21,023,000)	$ (22,877,000)	3,553,000	(20,919,000)	$ (9,578,000)	$ (12,174,000)	(98,001,000)	(39,118,000)	(24,439,000)
Assets	770,969,000				909,531,000				770,969,000	909,531,000	945,981,000
Long-lived assets	471,651,000				524,143,000				471,651,000	524,143,000	571,515,000
Expenditures for assets									3,778,000	17,698,000	22,304,000
Gain on sale of business									0	0	9,790,000
Goodwill, Impairment Loss						$ (28,564,000)			0	(28,564,000)	0
Europe
Segment Reporting Information [Line Items]
Revenues									434,372,000	499,118,000	468,041,000
Charges									13,918,000	1,560,000	5,934,000
Depreciation and amortization									6,513,000	8,557,000	7,615,000
Net interest expense (income)									483,000	2,790,000	1,884,000
Operating Income (Loss)									13,413,000	33,769,000	22,682,000
Asset write-downs to intangible assets	(2,247,000)								(2,247,000)
Assets	575,632,000				675,051,000				575,632,000	675,051,000	705,314,000
Long-lived assets	404,433,000				450,026,000				404,433,000	450,026,000	472,599,000
Expenditures for assets									727,000	2,419,000	5,221,000
North America
Segment Reporting Information [Line Items]
Revenues									276,891,000	340,980,000	348,307,000
Charges									10,646,000	964,000	1,306,000
Depreciation and amortization									8,427,000	7,623,000	6,013,000
Net interest expense (income)									27,773,000	21,764,000	26,510,000
Operating Income (Loss)									(34,197,000)	(1,928,000)	9,449,000
Asset write-downs to intangible assets		$ (1,012,000)							(1,012,000)
Assets	170,997,000				205,998,000				170,997,000	205,998,000	207,347,000
Long-lived assets	61,738,000				68,240,000				61,738,000	68,240,000	92,195,000
Expenditures for assets									2,530,000	14,055,000	16,473,000
All Other
Segment Reporting Information [Line Items]
Revenues									30,470,000	32,359,000	34,341,000
Charges									1,256,000	10,000	118,000
Depreciation and amortization									551,000	641,000	689,000
Net interest expense (income)									208,000	(248,000)	12,000
Operating Income (Loss)									(30,603,000)	(24,977,000)	(23,236,000)
Assets	24,340,000				28,482,000				24,340,000	28,482,000	33,320,000
Long-lived assets	$ 5,480,000				$ 5,877,000				5,480,000	5,877,000	6,721,000
Expenditures for assets									521,000	1,224,000	610,000
Operating Segments | Europe
Segment Reporting Information [Line Items]
Revenues									434,372,000	499,118,000	468,041,000
Operating Segments | North America
Segment Reporting Information [Line Items]
Revenues									276,891,000	340,980,000	348,307,000
Operating Segments | All Other
Segment Reporting Information [Line Items]
Revenues									30,470,000	32,359,000	34,341,000
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues									46,937,000	78,545,000	100,660,000
Intersegment Eliminations | Europe
Segment Reporting Information [Line Items]
Revenues									14,708,000	21,864,000	17,384,000
Intersegment Eliminations | North America
Segment Reporting Information [Line Items]
Revenues									32,229,000	56,681,000	80,748,000
Intersegment Eliminations | All Other
Segment Reporting Information [Line Items]
Revenues									$ 0	$ 0	$ 2,528,000

Business Segments - (Net Sales

Business Segments - (Net Sales by Product) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue from External Customer [Line Items]
Revenues	$ 181,320	$ 170,408	$ 189,017	$ 200,988	$ 226,191	$ 224,200	$ 225,864	$ 196,202	$ 741,733	$ 872,457	$ 850,689
Europe
Revenue from External Customer [Line Items]
Revenues									434,372	499,118	468,041
North America
Revenue from External Customer [Line Items]
Revenues									276,891	340,980	348,307
All Other
Revenue from External Customer [Line Items]
Revenues									30,470	32,359	34,341
Operating Segments | Europe
Revenue from External Customer [Line Items]
Revenues									434,372	499,118	468,041
Operating Segments | Europe | Lifestyle Products
Revenue from External Customer [Line Items]
Revenues									216,325	248,325	222,668
Operating Segments | Europe | Mobility and Seating
Revenue from External Customer [Line Items]
Revenues									186,153	214,398	200,687
Operating Segments | Europe | Respiratory Therapy
Revenue from External Customer [Line Items]
Revenues									14,003	19,348	24,786
Operating Segments | Europe | Other Products and Services
Revenue from External Customer [Line Items]
Revenues									17,891	17,047	19,900
Operating Segments | North America
Revenue from External Customer [Line Items]
Revenues									276,891	340,980	348,307
Operating Segments | North America | Lifestyle Products
Revenue from External Customer [Line Items]
Revenues									135,615	148,369	165,267
Operating Segments | North America | Mobility and Seating
Revenue from External Customer [Line Items]
Revenues									99,116	110,998	109,923
Operating Segments | North America | Respiratory Therapy
Revenue from External Customer [Line Items]
Revenues									41,083	80,903	72,285
Operating Segments | North America | Other Products and Services
Revenue from External Customer [Line Items]
Revenues									1,077	710	832
Operating Segments | All Other
Revenue from External Customer [Line Items]
Revenues									30,470	32,359	34,341
Operating Segments | All Other | Lifestyle Products
Revenue from External Customer [Line Items]
Revenues									11,221	11,438	13,503
Operating Segments | All Other | Mobility and Seating
Revenue from External Customer [Line Items]
Revenues									11,917	12,112	14,150
Operating Segments | All Other | Respiratory Therapy
Revenue from External Customer [Line Items]
Revenues									2,049	3,101	1,383
Operating Segments | All Other | Other Products and Services
Revenue from External Customer [Line Items]
Revenues									$ 5,283	$ 5,708	$ 5,305

Interim Financial Information -

Interim Financial Information - (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 181,320	$ 170,408	$ 189,017	$ 200,988	$ 226,191	$ 224,200	$ 225,864	$ 196,202	$ 741,733	$ 872,457	$ 850,689
Gross profit	48,303	31,379	47,982	47,729	63,340	60,310	60,818	54,638	175,393	239,106	245,252
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(20,667)	(33,434)	(21,023)	(22,877)	3,553	(20,919)	(9,578)	(12,174)	(98,001)	(39,118)	(24,439)
Net loss	$ (20,577)	$ (34,354)	$ (21,943)	$ (24,197)	$ 1,938	$ (22,759)	$ (10,698)	$ (14,044)	$ (101,071)	$ (45,563)	$ (28,280)
Net earnings (loss) per share - basic	$ (0.54)	$ (0.92)	$ (0.62)	$ (0.69)	$ 0.06	$ (0.65)	$ (0.31)	$ (0.41)	$ (2.77)	$ (1.31)	$ (0.83)
Net Earnings (loss) per Share - Assuming Dilution (in dollars per share)	$ (0.54)	$ (0.92)	$ (0.62)	$ (0.69)	$ 0.05	$ (0.65)	$ (0.31)	$ (0.41)	$ (2.77)	$ (1.31)	$ (0.83)
Impairment of intangible assets									$ 3,259	$ 0	$ 0

Interim Financial Information_2

Interim Financial Information - Narrative (Details) - USD ($)	3 Months Ended							12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gain (Loss) on Extinguishment of Debt, Net of Tax Per Diluted Share	$ 0.08	$ 0.17			$ 0.29
Gain on sale of business								$ 0	$ 0	$ 9,790,000
Gain (Loss) on Sale of Business, Net of Tax, Per Diluted Share							$ 0.02
Loss (gain) on debt extinguishment including debt finance charges and associated fees	$ 3,021,000	$ 6,398,000			$ 10,131,000		$ 709,000	9,419,000	9,422,000	(7,360,000)
Gain (Loss) on Extinguishment of Debt, Net of tax	3,021,000	6,398,000			10,131,000		709,000
Goodwill, Impairment Loss, Net of Tax					$ 27,903,000
Goodwill, Impairment Loss, Net of Tax, Per Diluted Share					$ 0.80
Impairment of goodwill					$ 28,564,000			0	28,564,000	0
Impairment of Intangible Assets (Excluding Goodwill), Net of Tax		0.02
Loss (gain) on Convertible Debt Derivatives, Net of Tax	$ 560,000	$ 950,000
Loss (gain) on Convertible Debt Derivatives, Per Diluted Share	$ (0.01)	$ (0.03)
Charges	$ 9,437,000	$ 8,440,000	$ 4,153,000	$ 3,790,000	377,000	$ 547,000	1,552,000	25,820,000	2,534,000	7,358,000
Restructuring charges, net of tax	$ 9,129,000	$ 8,383,000	$ 3,889,000	$ 3,525,000	$ 277,000	$ 413,000	$ 1,376,000
Restructuring charges, net of tax, per diluted share	$ 0.24	$ 0.22	$ 0.11	$ 0.10	$ 0.01	$ 0.01	$ 0.04
Loss (gain) on debt extinguishment including debt finance charges and associated fees	$ 3,021,000	$ 6,398,000			$ 10,131,000		$ 709,000	9,419,000	9,422,000	(7,360,000)
Net gain on convertible debt derivatives	$ 560,000	950,000						(1,510,000)	0	0
Impairment of goodwill					$ 28,564,000			0	28,564,000	0
Impairment of Intangible Assets (Excluding Goodwill), Net of Tax		0.02
Impairment of intangible assets								3,259,000	0	0
North America
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets (Excluding Goodwill), Net of Tax		729,000
Charges								10,646,000	964,000	1,306,000
Impairment of Intangible Assets (Excluding Goodwill), Net of Tax		729,000
Impairment of intangible assets		$ 1,012,000						1,012,000
Europe
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets (Excluding Goodwill), Net of Tax Per Diluted Share	$ 0.04
Impairment of Intangible Assets (Excluding Goodwill), Net of Tax	$ 1,605,000
Impairment of Intangible Assets (Excluding Goodwill), Net of Tax Per Diluted Share	$ 0.04
Charges								13,918,000	$ 1,560,000	$ 5,934,000
Impairment of Intangible Assets (Excluding Goodwill), Net of Tax	$ 1,605,000
Impairment of intangible assets	$ 2,247,000							$ 2,247,000

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts - (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Allowance for doubtful accounts [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance At Beginning of Period	$ 3,642	$ 4,518	$ 6,318
Charged To Cost And Expenses	(862)	(16)	(427)
Additions (Deductions) Describe	(1,225)	(860)	(2,227)
Balance At End of Period	3,279	3,642	4,518
Inventory obsolescense reserve [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance At Beginning of Period	19,201	20,665	18,178
Charged To Cost And Expenses	(7,574)	(2,389)	(3,304)
Additions (Deductions) Describe	(2,202)	(3,853)	(817)
Balance At End of Period	24,573	19,201	20,665
Tax valuation allowances [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance At Beginning of Period	176,230	163,298	162,790
Charged To Cost And Expenses	(21,025)	(10,311)	(701)
Additions (Deductions) Describe	1,542	2,621	1,209
Balance At End of Period	198,797	176,230	163,298
Accrued warranty cost [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance At Beginning of Period	11,198	10,991	11,626
Charged To Cost And Expenses	(2,360)	(6,925)	(7,408)
Additions (Deductions) Describe	(5,577)	(6,718)	(8,043)
Balance At End of Period	7,981	11,198	10,991
Accrued product liability [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance At Beginning of Period	13,704	14,757	16,150
Charged To Cost And Expenses	(1,478)	(1,084)	(1,139)
Additions (Deductions) Describe	(2,619)	(2,137)	(2,532)
Balance At End of Period	$ 12,563	$ 13,704	$ 14,757

Subsequent Events (Details)

Subsequent Events (Details)	1 Months Ended	3 Months Ended								12 Months Ended
	Jan. 31, 2023 USD ($)	Apr. 14, 2023 USD ($) numberOfEmployees	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Subsequent Event [Line Items]
Proceeds from sale of business										$ 0	$ 0	$ 14,563,000
Charges			$ 9,437,000	$ 8,440,000	$ 4,153,000	$ 3,790,000	$ 377,000	$ 547,000	$ 1,552,000	25,820,000	2,534,000	7,358,000
Charges			$ 9,437,000	$ 8,440,000	$ 4,153,000	$ 3,790,000	$ 377,000	$ 547,000	$ 1,552,000	25,820,000	2,534,000	7,358,000
Severance
Subsequent Event [Line Items]
Charges										9,087,000	1,860,000	7,012,000
Charges										9,087,000	1,860,000	7,012,000
Contract Terminations
Subsequent Event [Line Items]
Charges										16,733,000	674,000	346,000
Charges										$ 16,733,000	$ 674,000	$ 346,000
Subsequent Event
Subsequent Event [Line Items]
Proceeds from sale of business	$ 11,925,644
Debtor-in-Possession Financing, Amount Arranged	70,000,000
Debtor in Possession, Line of Credit Facility	$ 17,400,000
Charges		$ 1,700,000
Restructuring and Related Cost, Expected Number of Positions Eliminated | numberOfEmployees		90
Charges		$ 1,700,000
Restructuring and Related Cost, Expected Number of Positions Eliminated | numberOfEmployees		90
Subsequent Event | Severance
Subsequent Event [Line Items]
Charges		$ 900,000
Charges		900,000
Subsequent Event | Contract Terminations
Subsequent Event [Line Items]
Charges		800,000
Charges		$ 800,000

Uncategorized Items - ivc-20221

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 80,063,000